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Abstract
Exposing the position of dairy products on health in the context of obesity and gut
health: implications for research and practice
The position of any food in the diet is the focus of much debate, yet food is central to
health. As obesity and its related co-morbidities continue to compromise health status,
there is a need to evaluate the position of core foods consumed by affected populations.
Dairy products are a core food group which may have an important role in terms of
obesity. New research suggests a significant role for gut function in the aetiology of
obesity, so there may also be some value in considering the effect of dairy foods on gut
health. From a negative perspective, it has been suggested that dairy products are
associated with adverse metabolic health effects and can cause symptom exacerbation in
gut related problems such as Crohn’s disease (CD). Both overweight and CD are
increasingly prevalent and share an underlying inflammatory pathogenesis which may
be related to gut health. From a dietetic practice perspective, the setting for this thesis,
gaining knowledge on the position of dairy foods in these disease contexts may help to
ensure that affected individuals do not unnecessarily avoid an important core food
group delivering key nutrients in the diet. With this in mind, the thesis hypothesises that
the position of dairy foods in the diet is complex, defined by health-disease contexts and
subject to consumer behaviour.
To address the central hypothesis this research aimed to study the impact of dairy
products from two health perspectives: overweight and CD. Specific objectives were to
(1) evaluate associations between participants’ intake of dairy products and metabolic
profiles/dietary outcomes in a 12 month weight loss trial (2) identify the association
between CD patients’ intake of dairy products on CD symptoms and pathogenesis, and
23

(3) explore the impact of dietetic education on consumer’s perceptions of dairy
products. In this way some of the perceptions of diary food consumption in this context
could the examined and ways to integrate dairy foods appropriately in the diet could be
considered.
For analysis of dietary intake patterns, data were made available from a 12 month
dietary

randomized

controlled

weight

loss

trial

[the

‘Smart’

study;

ACTRN12608000425392]. Participants had received diet advice that included reduced
fat dairy foods. Mean baseline and 3 month dairy product intake was calculated.

A

systematic approach to estimating dairy food intake was developed to measure dietary
outcomes related to consumption of this food group. The association between milk fat
consumption and adverse baseline metabolic profiles was assessed using values for
validated biomarkers of milk fat intake and metabolic outcome measures. When
instructed to consume reduced fat dairy products, male RCT participants reduced their
overall intake of dairy products from 377.63±62.3g to 357.3±46.7g/day. In contrast
females increased their consumption of carbohydrate from dairy products to the extent
that a significant reduction in kilojoule intake from dairy products was no longer
evident (p=0.054). Both sexes failed to meet recommended dairy product intakes (of 2-3
servings per day). Biomarkers of milk fat intake were not associated with adverse
metabolic profiles and may be associated with favorable effects in the case of umbilicus
circumference (r=-.291, p=.018), hip circumference (r=-.285, p=-.021) and body mass
index (r=-.287, p=.018) after controlling for potential confounders. This study found
that recommending reduced fat dairy products in the weight loss context may be
problematic, especially for men, and indeed the need to change to these products may be
questionable.
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To examine the impact of dairy food consumption on Crohn’s disease, clinical data
from an Auckland CD cohort were made available. Associations between self-reported
effects of dairy product consumption on CD symptoms were evaluated. A nutrigenomic
case-control study was also conducted to assess the influence of genetically determined
lactase persistence on CD risk. Dairy product intake was found to have little influence
on self-reported CD symptoms in an Auckland population. The nutrigenomic casecontrol study indicated that genetically determined lactase persistence increased the risk
of CD in this population (OR=1.61, 95% CI=1.03-2.51), highlighting another potential
issue for providing advice on dairy food consumption.

To examine consumer perceptions, six semi-structured focus groups were conducted
with the RCT participants and compared to a control group of non-RCT University of
Wollongong staff to evaluate consumer perceptions of dairy products and the impact of
dietetic intervention on shaping these perceptions using the theory of planned behaviour
as an interpretive framework. Non-RCT participants perceived dairy foods as weight
inducing and were sceptical of functional dairy products. A lack of time/ability to
decipher dairy food labels was also discussed. In contrast trial participants discussed
several health benefits related to dairy foods, practised label reading and were confident
to incorporate dairy foods into their diet. Nutrition education provided as a result of
weight loss trial participation, influenced behavioural and control beliefs but not
normative beliefs relating to dairy products. This has significant implications for
practice in terms of approaches to providing guidance on dairy food consumption.
Put together these studies challenged previously held beliefs that dairy foods may be
detrimental to metabolic health (in overweight people) and in CD, specifically. The
results point to the need to take care when making statements for the general public and
25

to consider particular disease and behavioural aspects when advising individuals. The
importance of nutrition education to influence current beliefs/dietary outcomes in
relation to this food group was illustrated, in addition to the need to consider
nutrigenomic effects to gain a complete understanding of the complex and varied role of
dairy foods in these disease contexts.
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Chapter 1. Introduction: Dairy products in the diet: the case of obesity and Crohn’s
disease
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1.1 Introduction
This chapter addresses the current evidence regarding the position of dairy products as a
key core food group. Given the significance of obesity as a public health issue and the
emerging theoretical position linking obesity with deleterious effects on gut health, the
position of dairy foods will be explored from two disease perspectives: Crohn’s disease
(CD) and obesity. The review concludes with the overall thesis hypothesis and a
summary of the key aims and objectives of individual studies completed to this end.
From a practice perspective, deciding whether to support restriction or advise inclusion
of dairy foods is important for nutritional reasons, so understanding the impact of dairy
foods in these disease contexts is important.
1.2 Obesity
Obesity involves an excess of adipose tissue. It is a significant global health problem
resulting in considerable morbidity for affected individuals and a significant economic
burden for nations where obesity is highly prevalent. Globally the World Health
Organization estimates that over 300 million individuals are obese, with 1 billion
classified as overweight (World Health Organization, 2003). In Australia, 25% of adults
aged over 18 years participating in the 2007-08 National Health Survey were classified
as obese, according to their measured body mass index (BMI), whilst a further 37%
were considered overweight (Australian Bureau of Statistics, 2010). Alarmingly, it has
been projected that the prevalence of obesity in Australian adults will increase by 65%
in 2025 (Walls et al., 2011). Direct costs associated with both obesity and overweight
in Australia have been estimated to be as high as $21 billion in 2005 alone (Colagiuri,
2010). Anthropometric measures of body fatness are generally applied to determine
whether an individual is obese.
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In population studies BMI is the primary method for assessing obesity. An individual’s
BMI is calculated by dividing one’s weight in kilograms by their height (in metres
squared). Although there are variations according to age category and ethnicity (LopezJimenez, 2010), in general, individuals with a BMI of 20-24.9kg/m² are categorised as
being within the healthy weight range, whilst a BMI from 25-29.9kg/m² indicates that
an individual may be overweight. An individual is categorised as obese if they have a
BMI >30kg/m² (Alpert, 2009). There are some limitations to using BMI as a marker for
obesity/overweight, particularly for athletes (Nevill et al., 2006), and thus this simple
calculation can only provide an estimation of obesity within the general adult
population. Despite these limitations a higher BMI has been demonstrated to be a
strong predictor of mortality risk (Prospective Studies Collaboration, 2009), so it
remains a key diagnostic tool when evaluating obesity at a population level.
The excess adiposity observed in obesity has been associated with an increase in
systemic inflammation, as detected by several biomarkers of inflammation including
tumour necrosis factor-α (TNF-α), interleukin 6 (IL-6), C-reactive protein (CRP) and
leukocyte count (Lee & Pratley, 2005). In particular, elevated CRP and leukocyte
counts were identified in 74.4% and 15.6% of a sample (n=640) of morbidly obese
patients respectively (Lee & Pratley, 2005). Similarly, Visser et al. (1999) report that
obese men and women were more likely to have clinically elevated CRP levels in
comparison to their lean counterparts (OR 2.13 [95% CI 1.56-2.91] for obese men and
6.21[95% CI 4.94-7.81] for obese women respectively). Adiposity-related inflammation
has also been observed in overweight children. Results from a United States National
health survey revealed that obesity in children (aged 8-16 years) was associated with an
elevation in the inflammatory marker CRP (Visser et al., 2001).
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This systemic inflammation seen with obesity can be attributed to fat cells, or
adipoctyes. Previously thought to be a simple deposition site for excess energy,
adipocytes are now understood to have an important functional role in terms of the
secretion of proteins termed adipokines. Adipokines may be involved in the regulation
of a variety of processes including lipid homeostasis, immune function and insulin
sensitivity (John et al., 2006). However, the systemic inflammation observed in obesity
suggests that in conditions of excess adiposity or adipocyte hypertrophy, secretion of
pro-inflammatory adipokines such as TNF-α is increased, resulting in the expression of
inflammatory genes (Lam et al., 2011).
Obesity and its associated inflammation are thus particularly important from a health
perspective as key mediating factors in the development of chronic disease such as
atherosclerosis (Lyon, Law, Hsueh, 2003) and the metabolic syndrome (Eckel, Grundy
& Zimmet, 2005). The International Diabetes Federation defines the metabolic
syndrome as having central obesity (waist circumference greater than defined limits set
according to ethnicity) in addition to any two of the following: raised fasting plasma
glucose (≥5.6mmol/L), elevated blood pressure (≥130mmHg for systolic blood pressure,
≥85mmHg for diastolic blood pressure), reduced high density lipoprotein (HDL)
cholesterol (<1.03mmol/l males, <1.29mmol/l females) or elevated triglycerides
(≥1.7mmol/l) (Alberti, Zimmet & Shaw, 2006). Individuals with the metabolic
syndrome are at a greatly increased risk of developing cardiovascular disease and type 2
diabetes mellitus (Wilson et al., 2005), thus factors that may reduce the prevalence of
both obesity and the metabolic syndrome are key research priorities.
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1.3 Obesity and the gut
Fat deposited around the gut area is being recognised as a key mediating factor
associated with obesity and the metabolic syndrome. Supporting the hypothesis that
central adiposity may contribute significantly to adverse health effects, Janssen et al.
(2004) suggested that waist circumference may better predict obesity related health
risks than measures of BMI using data from a large national health survey involving
n=14924 adults. Pischon et al. (2008) report findings from the nine country European
Prospective Investigation into Cancer and Nutrition study, whereby risk of death was
strongly and positively correlated with both waist circumference and waist to hip ratio,
even after adjusting for BMI. In this large study, a 5cm increase in waist circumference
was associated with an increased risk of death by a factor of 1.17 (95% CI 1.15-1.20)
for males and 1.13 (95% CI 1.11-1.15) for females.
Measurements of an individual’s waist to hip ratio or waist circumference are therefore
considered valid indicators of abdominal obesity (Chan et al., 2003) that are easy to
obtain in clinical practice. Whilst general adiposity has been associated with adverse
health outcomes such as hypertension, coronary artery disease, stroke, infertility issues
and liver disease (Kopelman, 2007), abdominal obesity is proposed to be far more
insidious than gluteofemoral or peripheral adiposity in terms of its adverse effects on
metabolic health. Visceral fat, the term use to describe adipose tissue that is located
around the viscera of the abdomen including the mesentery and omentum, differs
greatly from subcutaneous fat in terms of its endocrine function, adipocytes and insulin
response (Ibrahim, 2010). In particular, visceral adipose tissue is more highly infiltrated
with cells that mediate inflammation in comparison to subcutaneous adipose tissue
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(Weisberg et al., 2003) which may explain the elevation of markers of inflammation
within this region.
The increased health risks observed with visceral fat in comparison to its subcutaneous
counterpart may also relate to its anatomical position. Visceral fat is located in close
proximity to the liver and thus venous blood from this region is drained through the
hepatic portal vein (Ibrahim, 2010). Therefore, free fatty acids and adipokines may
infiltrate the liver directly, activating pro-inflammatory pathways resulting in nonalcoholic fatty liver disease, hepatic insulin resistance and the cascade of metabolic
dysfunction associated with visceral obesity (Lam et al., 2011).
From the perspective of the gut, visceral adipose tissue has also been associated with an
increased infiltration of adipose tissue macrophages (ATMs), which are responsible for
adipose cell death or necrosis (Lam et al., 2011). This may be explained by the
observation that the adipoctye size required to stimulate this programmed cell death is
smaller in visceral adipoctyes than those in subcutaneous tissue (Murano et al., 2008).
As a key source of pro-inflammatory cytokines, an influx of ATMs may result in
inflammation of the gut by increasing the permeability of tight junctions maintaining
intestinal and gut barrier function, a phenomenon termed ‘leaky gut’ (Lam et al., 2011).
Disruption to gut barrier function may result in an influx of microbial antigens and
endotoxins from gut bacteria, a phenomenon which has been observed in patients with
inflammatory bowel disease (Pastor Rojo et al., 2007).
1.4 Inflammatory bowel disease
Inflammatory bowel disease (IBD) is the collective term given to a group of chronic
conditions of systemic inflammation that primarily affect the gastrointestinal tract,
although may result in some extra-gastrointestinal complications (Walsh, Mabee &
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Trivedi, 2011). Patients suffering from IBD are most commonly diagnosed with having
either Ulcerative Colitis (UC) or Crohn’s disease (CD). Patients presenting with both
forms of IBD may report similar symptoms of chronic and intermittent abdominal pain,
diarrhoea, irregular bowel movements or fatigue (Walsh, Mabee & Trivedi, 2011).
However the histological pathogenesis of UC and CD are quite distinct. CD can result
in intermittent inflammatory regions (known as ‘skip lesions’) throughout any area of
the gastrointestinal tract from the mouth to the anus which may result in stricturing or
fistula formation in affected regions (Veloso et al., 2001). In contrast, UC primarily
affects only the mucosal layer of the colon and presents as a continuous site of
inflammation/ulcerations, lacking the ‘skip lesions’ characteristic of CD (Szigethy,
McLafferty & Goyal, 2011).
The prevalence of IBD is increasing worldwide (Munkholm et al., 1992), (Phavichitr,
Cameron & Catto-Smith, 2003), (Leong, Lau & Sung, 2004). Whilst there is
considerable variation, estimated prevalence rates include 26-199 per 100,000 and 37246 per 100,000 in North America for CD and UC, respectively (Loftus, 2004). New
Zealand data suggests a point prevalence of 155.2 per 100,000 for CD and 145 per
100,000 of UC (Gearry et al., 2006). In the Australian context, crude annual incidence
rates of 17.4 cases per 100,000 for CD and 11.2 cases per 100,000 for UC have been
reported (Wilson et al., 2010).

Thus, IBD contributes a significant health care burden, with sufferers often requiring
ongoing pharmaceutical support to induce remission or lesson inflammatory symptoms
during stages of acute IBD (Harris et al., 2009). In addition IBD patients are at an
increased risk for the development of some cancers (Bernstein et al., 2001) and may
require surgical resection of affected regions of the gastrointestinal tract.
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1.5 Obesity, central adiposity and Crohn’s disease
As previously discussed, obesity is associated with an increase in inflammation and
may compromise gut barrier function. Thus, there is an emerging body of evidence to
suggest that obesity may have detrimental consequences for individuals with, or at risk
of developing conditions of chronic gastrointestinal inflammation, particularly CD.
In one of the first human studies to explore this issue, Mendall et al. (2011) observed a
significantly greater risk of CD in obese individuals in comparison to both controls [OR
3.22 (95%CI 1.59-6.52), p = 0.001] and UC patients [OR 2.02 (95% CI 1.18-3.43), p =
0.0096], in a case control study involving n=524 IBD patients and n=480 controls aged
50-70 years. This study reported a dose response, with CD risk increasing with
increased BMI. The potential for body weight to influence CD progression was reported
by Hass et al. (2006), whereby overweight CD patients (BMI ≥ 25kg/m²) had a shorter
time to first gastrointestinal surgery (an indication of CD severity) in comparison to
underweight (BMI<19.5kg/m²) CD patients (P=.043). Similarly, obese CD patients
(defined in this instance as BMI >25kg/m² at disease diagnosis and BMI>30kg/m²
during the course of the diagnosis) had a higher risk of developing active CD on a
yearly basis in comparison to CD patients of a healthy BMI (OR 1.50, 95% CI 1.072.11) and were more likely to require hospitalisation as a result of their disease (OR
2.35, 95% CI 1.56-3.52) (Blain et al., 2002).
1.6 Dairy products: a core food group within many Western cuisine contexts
As scientific research identifies new aetiological factors underpinning the development
of chronic inflammatory conditions such as obesity and CD, nutrition research seeking
to re-evaluate the position of core food groups in these disease contexts is required.
Exploration of the health outcomes associated with intake of core foods is extremely
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important from a clinical practice perspective to ensure that dietetic advice reflects the
best available evidence.
Dairy products, such as milk, cheese and yoghurt, are an important core food group in
many cuisine contexts, contributing a complex array of nutrients to the diet and thus are
an important candidate for evaluation. In the period from 2009-2010, per capita
consumption of major dairy products in Australia was 192.4L milk, 12.9kg cheese,
3.8kg butter and butter blends and 7.1kg of yoghurt (Dairy Manufacturers & Dairy
Australia, 2010). Dairy products are a major dietary source of calcium for many
Western countries, contributing 50-66% and 51% of dietary calcium for Australian and
American adults, respectively (McLennan & Podger,1998b, & Weinberg et al., 2004).
In addition to dietary calcium, dairy products contribute protein, vitamins, minerals and
other bioactive components to the total diet (Australian Bureau of statistics, 1997 &
Russel et al., 1999). As such, consumption of this food group is encouraged to ensure
optimal nutritional status across many Western nations.
1.7 Dairy products may infer health benefits for both obesity and CD
New research indicates that dairy products may infer advantageous effects for obese
individuals in terms of reducing visceral adiposity and decreasing inflammation. Given
the aforementioned association between obesity, inflammation and CD, such products
may also be helpful to CD patients.
1.7.1 Dairy products may augment central adiposity
Diets containing dairy products may help to reduce central adiposity in overweight
individuals. Zemel et al. (2004) reported findings from a 24 week randomised, placebo
controlled trial whereby n=32 obese adults were prescribed a 500kcal/d energy deficit
35

of a standard diet (400-500mg dietary calcium/day), a high calcium diet (800mg
calcium/day) or a high dairy diet (providing 1200-1300mg calcium a day from dairy
products). After 24 weeks, significantly more abdominal fat was lost on the high dairy
diet at 14.0±2.3%, in comparison to the high-calcium and low-calcium diets at
12.9±2.2% and 5.3±2.3% respectively (p<0.025). A greater reduction in central
adiposity, as indicated by waist circumference, was also reported by the same research
group for obese individuals (n=18) consuming three serves of yoghurt/day participating
in a 12 week randomised controlled trial with a 500kcal energy deficit, in comparison to
a control group (n=16) prescribed 0-1 serves dairy products/day (-3.99±0.48 cm vs.
-0.58±1.04cm, p<0.001) (Zemel et al., 2005a).
Wennersberg et al. (2009) also reported a significant treatment effect of 3-5 servings of
dairy products/day on both waist circumference and sagittal abdominal diameter (p=
0.003 and p=0.034 respectively) during a six month intervention study in overweight
adults with a low baseline calcium intake (<700mg/day) in comparison to a control
group. In contrast to these findings, van Loan et al. (2011) failed to find any difference
in intra-abdominal fat loss between a sample of overweight and obese adults (n=71)
assigned to either a low dairy (<one dairy product serving/day) or adequate dairy (≥four
dairy product servings/day) dietary protocol, during a 15 week controlled feeding study
with a 500kcal energy deficit. Thus, the role of dairy products in the augmentation of
central adiposity remains an important target for more conclusive research seeking to
identify foods that may be advantageous in terms of both metabolic and gut health.
1.7.2 Dairy products may decrease inflammation
Dairy products may have an additional functional role that is relevant to both CD and
obesity. Recent research suggests that dairy products may be associated with an
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attenuation of inflammation in obese individuals. In a 20 subject cross-over study, three
servings of supplemented dairy products per day (contributing 1200-1400mg calcium)
were found to decrease circulating levels of the inflammatory markers TNF-α and IL-6
by 15% and 13% respectively (p<0.01 for both) in comparison to a eucaloric soy based
diet (Zemel et al., 2010). Similar findings were reported in a cross-sectional Greek
study involving over n=3000 healthy participants. Analysis of food frequency data and
fasted blood samples revealed that individuals consuming >14 servings of dairy foods
per week had a significant reduction (p<0.01) in CRP, IL-6 and TNF-α by 29%, 9% and
20% respectively in comparison to individuals consuming <8 servings per week after
controlling for potential confounders (Panagiotakos et al., 2010).
Decreases in markers of inflammation were also reported by Stancliffe, Thorpe &
Zemel (2011) following a 12 week randomised parallel–group weight maintenance
study involving 30 overweight and obese participants, whereby participants were
required to consume either an adequate dairy (3.5 serves/day) or a low dairy (0.5
serve/day) diet. A significant and progressive reduction in inflammatory markers was
seen with time for individuals in the adequate dairy group, with a 47% reduction in
CRP, 35% reduction in TNF- α (P,0.05) and 21% reduction in IL-6 (p<0.02) reported
following twelve months of participation.
Thus, in addition to their potential role in augmenting central adiposity and reducing
inflammation, there are additional reasons to justify exploring the position of dairy
products in obesity and CD. These factors will be discussed separately for each disease
state.
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1.8 Dairy products, obesity and the metabolic syndrome
Dairy products have been suggested to have a favourable role in the diet with respect to
metabolic health, including weight loss. This is thought to occur particularly through
improvements in hypertension, body composition, insulin resistance and energy
expenditure (Azadbakht et al., 2005). Evidence from both epidemiological and
intervention studies exploring the effect of diets inclusive of dairy products on
metabolic health will now be discussed.
1.8.1 Epidemiological evidence regarding dairy products, obesity and the metabolic
syndrome
Epidemiological evidence largely supports the theory that the intake of dairy products
may benefit individuals with some aspect of the metabolic syndrome. French data from
the Epidemiological Study on the Insulin Resistance Syndrome cohort reported that in a
large sample (n=3435) intakes of dairy products were inversely associated with risk of
developing the metabolic syndrome and hyperglycaemia, in a nine year follow up study
(Fumeron et al., 2011). Similarly, a meta-analysis of 15 prospective cohort studies
identified a reduced risk of both stroke (OR 0.84, 95% CI 0.76-0.93) and heart disease
OR 0.79, 95% CI 0.75-0.82) for individuals reporting high milk product intakes relative
to individuals reporting limited intake (Elwood et al., 2008). These favourable
associations between dairy product intake and aspects of the metabolic syndrome
contribute evidence to support the inclusion of dairy products as a core food group in
many dietary guidelines. This may be particularly pertinent when considering
epidemiological evidence to suggest that dairy products may also be advantageous in
terms of improving insulin resistance and the associated risk of developing type 2
diabetes mellitus.
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In particular, an inverse relationship between the intake of dairy products and insulin
resistance in overweight young adults (aged 18-25 years, BMI ≥25kg/m²) was reported
by Pereira et al. (2002), in a large prospective study with ten years of follow up. A
reduction in the relative risk of type 2 diabetes mellitus for women within the highest
quintile of dairy product intake (relative risk: 0.79, 95% CI 0.67-0.94, p =0.007)
compared to those reporting minimal dairy food intake in a large prospective study
(n=37183) with ten years of follow up was also reported by Liu et al. (2006). A similar
result was reported for males, with a reduction in relative risk of type 2 diabetes
mellitus also attributed to individuals within the highest quintile of dairy product intake
(relative risk: 0.77, 95% CI 0.62-0.95, p=0.003) in a prospective study (n=41254) with
12 years of follow up. Within this study the relative risk of developing type 2 diabetes
mellitus was decreased by nine percent for every additional serving of dairy products
reportedly consumed per day (Choi et al., 2005). Should intervention studies support
these observations, dairy products may be an important adjunct to the dietary
management of conditions relating to both insulin resistance and hyperglycaemia.
In addition to improvements in the aforementioned aspects of the metabolic syndrome,
epidemiological evidence has repeatedly suggested an inverse association with dairy
product intake and hypertension in adults (Wang et al., 2008, Engberink et al., 2009),
potentially as a result of the beneficial effects of calcium and potassium contained
within these foods (Appel et al., 1997). Another potential explanation for this
association relates to the presence of milk protein derived peptides which have
demonstrated effects in reducing hypertension, arterial stiffness and LDL cholesterol in
both human and animal studies (Turpeinen et al., 2009). As a core food group that is
widely consumed by many Western populations, dairy products may thus have an
important role to play in ameliorating hypertension for at risk populations. Before any
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definitive conclusions can be drawn regarding the effects of dairy products on the
metabolic syndrome however, it is important to consider the limitations of
epidemiological evidence.
Epidemiological and longitudinal studies are advantageous in terms of their ability to
study health outcomes over a long period of time, which may be preferable when
attempting to discern dietary factors which may influence chronic and multi-factorial
conditions such as obesity and the metabolic syndrome. However, such studies cannot
infer direct causality when seeking to determine associations between dairy product
intake and aspects of the metabolic syndrome. Thus, controlled intervention studies may
provide insight into the short term effect of dairy products on metabolic health and
generate hypotheses relating to mechanistic factors that may account for any association
observed.
1.8.2 Intervention studies regarding dairy products, obesity and the metabolic
syndrome
Intervention studies seeking to expose the role of dairy products in ameliorating obesity
and adverse metabolic profiles have yielded inconclusive results, with some supporting
the idea that dairy may improve metabolic health (Josse et al., 2011, Zemel et al., 2009)
and others opposing this idea (Wennersberg et al., 2009, Weaver et al., 2011, Palacios
et al., 2011). These conflicting results observed in the clinical trial setting highlight the
difficulty in attributing health effects to any one component of the diet.
In particular, support for the favourable position of dairy products on metabolic health
was provided by Zemel et al. (2005b), reporting results from a 24 week randomised
controlled trial involving obese African-American adults (n=34). Individuals consuming
a high dairy diet (three servings of dairy products/day) were observed to have a decrease
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in total body fat (p<0.01), insulin (p<0.04) and blood pressure (p<0.01 for both systolic
and diastolic blood pressure) in comparison to individuals consuming a low dairy diet
(<one dairy product serving/day), despite both groups not having a change in total
energy or macronutrient intake for the study duration (Zemel et al., 2005b). When
considering this study, it must be noted that African-Americans have been suggested to
have increased calcium absorption and renal calcium conservation in comparison to
their white counterparts (Aloia 2008). Thus care must be taken when extrapolating the
results from Zemel et al. (2005b) to the broader population. It is possible that the high
calcium content of dairy products may be processed differently in vivo for AfricanAmerican, potentially influencing the effects reported. However, in a study of
Caucasian adults, Shahar et al. (2007) reported an enhancement in weight loss for
individuals consuming reduced fat dairy products as part of an energy restricted diet in a
six month randomised clinical trial (n=259) of patients with type 2 diabetes mellitus.
In contrast to these findings, dietary intervention trials whereby the calcium content of
dairy products prescribed was compared to an equivalent amount of calcium via a
calcium supplement (an exploration of the idea that it may be the high calcium content
of dairy products that is responsible for some of the favourable results reported,
discussed in more detail in 1.9.1) failed to induce weight loss or improve aspects of the
metabolic syndrome. In particular, supplementation with 500mg calcium/day from
either dairy origin or a supplement (calcium carbonate) did not significantly increase
weight loss compared to a placebo in a study of overweight females (n=67) assigned to
an energy intake of 4.5MJ/day for three weeks. However, a significant decline in fat
free mass (-1.46±3.36kg, p=0.006) that was observed in the placebo group was not
evident for either of the intervention groups, potentially indicating that dairy or calcium
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may preserve metabolically active tissue during conditions of energy deficit (KabrnováHlavatá et al., 2008).
More recently, no improvements in weight loss, body composition or waist
circumference were identified for overweight adults consuming 3-4 serves of dairy
products/day in comparison to a calcium supplemented (900mg calcium) or placebo
group during a 12 week clinical trial with a 500kcal/day energy deficit (Smilowitz et al.,
2011).
Similarly, a meta-analysis by Trowman et al. (2006) assessed whether there was a
relationship between higher calcium intakes, from either supplements or dairy products,
and weight loss. Of the eleven studies included in this analysis, four investigated the
effect of higher calcium intakes from dairy products on body weight. Analysis of these
studies using a random effects statistical model, indicated that there was no significant
difference in weight between individuals with high intakes of dairy products and
controls (P = 0.75).
The conflicting literature in this area suggest that there is a clear need for further
research to determine whether dairy products may influence weight loss and aspects of
the metabolic syndrome, particularly in overweight individuals.
1.9 Possible mechanisms to explain proposed dairy mediated improvements in
weight loss/metabolic health
The complex composition of milk and dairy products ensure that it is difficult to
identify one single mechanism that may explain their proposed effect on metabolic
health. Thus several hypotheses have been generated in recent years.
1.9.1 Dairy products have a high calcium content
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One of the proposed mechanisms relates to the large amount of calcium contained
within dairy products. Zemel et al. (2004) hypothesised that intakes of large amounts of
calcium (such as that contained within many dairy products) may depress the action of
the bioactive form of vitamin D (1, 23-dihydroxyvitamin D3) which promotes adipocyte
uptake of calcium and stimulates lipogenesis. Thus, calcium intake may decrease
lipogenesis and increase lipolysis through depressing this bioactive form of vitamin D
and, therefore, inhibit the influx of calcium into adipoctyes, with the net result being a
reduction in the accumulation of lipids into fat cells within the body. This calciummediated stimulation of lipolysis hypothesis has been challenged by Bortolotti et al.
(2008) following a placebo-controlled cross-over study of obese adults (n=10) with low
habitual dietary calcium intakes (<800mg calcium/day). It was observed that dietary
calcium supplementation (800mg calcium/day) did not influence glycerol turnover or
circulating plasma free fatty acid concentrations in these individuals as would be
expected with a stimulation of lipolyisis.
1.9.2 Dairy product intakes may increase faecal fat excretion
Despite evidence refuting the idea that calcium may stimulate lipolysis, further roles for
dairy calcium in metabolic health have been reported. High intakes of dietary calcium
from dairy products (1800mg/day) were found to increase both faecal fat excretion and
faecal energy content in comparison to a low calcium diet (500mg/day) with the same
protein content (14.2g vs. 6.0g p<0.05 for faecal fat and 1045kj vs. 684kj, p<0.05, for
faecal energy) in a one week randomised cross-over trial involving overweight adults
(Jacobsen et al., 2005). Similarly, Bendsen et al. (2008) reported a similar finding in a
small sample (n=11) of overweight adults following a one week randomised cross over
trial whereby faecal fat excretion was compared following intake of a high calcium diet
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from reduced fat dairy products (2300mg calcium from dairy products/day) and a low
calcium (700mg calcium/day) diet. A significant increase in faecal fat excretion was
observed in the high calcium from dairy products diet in comparison to the low calcium
diet (11.5±1.4g/day fat excreted in faeces vs. 5.4±0.5g/day, p<0.001), estimated to
result in a daily energy loss of 230kj.
Increases in faecal fat excretion have been suggested to result from the formation of
insoluble calcium fatty acid soaps following intake of calcium in conjunction with a
source of fat, such as that found in dairy foods (Lorenzen et al., 2006). As yet, it is
unclear whether dairy mediated increases in faecal fat excretion remain in individuals
consuming dairy products over a long period of time. This is an area which requires
further investigation to determine whether any physiological adaptations may occur
following chronically high dairy food intakes that may reduce the size of the effect
observed. However such small but significant increases in faecal energy may still have
important implications in terms of body mass and suggest that dairy products may be an
important dietary component for individuals seeking to reduce the risk of incremental
weight gain that may occur during the course of a lifetime.
1.9.3 Dairy product intake may increase energy expenditure and fat oxidation
A further proposed mechanism for dairy mediated improvements in metabolic health is
that dietary calcium and dairy products may increase energy expenditure and reduce an
individual’s respiratory quotient, reflecting preferential fat oxidation above other
macronutrients including protein and carbohydrates. Finding dietary factors that may
increase fat oxidation may be particularly advantageous for overweight individuals as
their capacity to utilise fat as a source of fuel may be reduced (Blaak et al., 2006).
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Acute calcium intakes from both supplements and dairy foods were positively
correlated with 24 hour fat oxidation (r=0.38, p=0.03) in a small sample (n=35) of
healthy weight adults (Melanson et al., 2003). Similar results were reported for
overweight adult subjects (n=10) whereby post-prandial fat oxidation was least
suppressed following intake of a high calcium from dairy food meal in comparison to a
low calcium control meal and one with equivalent calcium from non dairy sources
(Cummings et al., 2006).
In one of few studies examining the effect of chronic intakes of dairy products on fat
oxidation, healthy women randomly assigned to a high dairy product diet (10001400mg calcium from dairy products/day) over a one year time period, had a
significantly higher mean change in fat oxidation following two meal challenges
(conducted at baseline and at the conclusion of the trial), in comparison to a control
group with a habitually low intake of dairy products (<800mg calcium from dairy
products/day) (Gunther et al., 2005).
Thus, it appears that at least acutely, dairy products may assist in increasing fat
oxidation, which will be particularly beneficial to overweight individuals. Whether
chronic intake of dairy products will increase long term fat oxidation warrants further
investigation. Should future studies confirm the observations reported by Gunther et al.
(2005), the inclusion of dairy products as a key dietary component for overweight
individuals may be imperative.
1.9.4 Dairy product intake may improve satiety
Finally, dairy products have been hypothesised to be more satiating than other core
foods. Schneeman, Burton-Freeman & Davis (2003) observed an increase in total
concentration of the satiety hormone Cholecystokinin following consumption of test
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meals, matched for macronutrients, containing two thirds of energy from dairy products
in comparison to non-dairy test meals in a cross-over feeding study involving n=24
adults in the healthy-overweight BMI range. This study is limited by the small sample
size which may restrict the generalisability of these results, thus further research
exploring the potential for dairy products to increase satiation, particularly in the
overweight population may be informative.
Whilst the aforementioned mechanistic studies provide theoretical evidence to support a
potential favourable role of dairy products in terms of obesity and the metabolic
syndrome, it is likely that a complex interplay between these and many other unknown
factors exists. The possibility that individuals with higher dairy product intakes may
have healthier total diets must also be considered. Individuals reporting the highest
quartile of dairy product intakes were found to consume a total diet that may be
considered of higher quality, inclusive of whole grains, fibre, fruit and vegetables in
comparison to low dairy food consumers in a Tehranian study (Azadbakht et al., 2005).
Similarly, in a prospective study of n=41254 male health professionals from the United
States, higher dairy product intake was associated with a lower intake of alcohol and a
higher intake of fruit and vegetables (Choi et al., 2005).
1.10 Dairy fat and the metabolic syndrome
The impact of fat from dairy products is of particular interest when exploring the
position of this core food group in relation to obesity and the metabolic syndrome.
Dairy products are an important source of total and saturated fat, with the fat content of
bovine milk estimated at 33g per litre (German et al., 2009). Thus Australian data
indicates that dairy fat contributed 30% of saturated fat to the Australian diet
(McLennan & Podger, 1997b). In the United States, dairy products have been reported
46

to contribute 19% of total fat and 32% of saturated fat to the diet of Americans
(Weinberg et al., 2004). This is of particular interest when considering potential
metabolic effects of this food group as dietary fat intake, particularly saturated fat, has
been traditionally associated with an increased risk of developing cardiovascular disease
(Artaud-Wild et al., 1993).
Dietary saturated fat intakes have been associated with a reduction in favourable high
density lipoprotein (HDL) cholesterol levels (Knuiman et al., 1987) and an increase in
potentially atherogenic low density lipoprotein (LDL) cholesterol levels (Sacks &
Katan, 2002). Thus, consumption of reduced fat dairy products as opposed to their full
fat counterparts is encouraged by National Health bodies (National Health & Medical
Research Council 2003, United States Department of Agriculture, 2010 & Health
Canada, 2007). However, the dietary outcomes resulting from such recommendations
have not been thoroughly evaluated. This is particularly problematic in the current
nutrition research climate as questions surround the detrimental health impact of dairy
fat intake (Griffin, 2011).
Saturated fatty acids contributed from dairy foods have been associated with either a
neutral effect on total cholesterol levels, an increase in HDL-cholesterol or a reduction
in the number of very low density lipoprotein (VLDL) cholesterol particles in a Swedish
cross-sectional study involving healthy men (Sjogren et al., 2004). A reduction in the
number of VLDL-cholesterol particles is important, as these are now understood to be
more detrimental to cardiovascular health in comparison to larger more buoyant LDLcholesterol particles (German et al., 2009).
Data from observational studies suggest that full fat dairy products are not associated
with adverse metabolic health outcomes. The Caerphilly study was a large prospective
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cohort study involving n=2375 males from the Caerphilly region of the United
Kingdom (Elwood, Pickering & Fehily, 2007). This study commenced between 1979
and 1983, well before the widespread use of reduced fat dairy products in the United
Kingdom in 2000 (Elwood et al., 2008). However, favourable health outcomes were
still associated with both milk and dairy product intake in this sample suggesting that
whole fat dairy products may be advantageous. In particular, study participants
reporting intakes of a pint (473ml using metric measurements) or more of milk per day
and the highest quartile of total dairy product intake were associated with a reduced risk
of developing the metabolic syndrome (adjusted ORs 038, 95% CI 0.18-0.78) and 0.44
,95% CI 0.21-0.91) respectively) (Elwood, Pickering & Fehily, 2007).
In the Australian context, full fat but not reduced fat dairy products were inversely
associated with mortality from cardiovascular disease in a 16 year prospective study
(n=1529). After adjusting for dietary calcium, individuals reporting the highest intake of
full fat dairy products (excluding butter) had a reduced risk of cardiovascular mortality
(Hazard Ratio 0.31, 95% CI 0.12-0.79, p=0.04). When butter (a food product that is
often discouraged as a result of its high saturated fat content) was included in the
analysis as part of the full fat dairy product categorisation, a similar inverse association
in cardiovascular mortality was still seen (Hazard Ratio 0.33, 95% CI 0.14-0.82,
p=0.06) (Bonthuis et al., 2010). The authors of this study acknowledge that individuals
consuming the highest amount of full fat dairy products were younger, with a lower
BMI and less likely to report having a medical condition (p<0.01). Thus, it is possible
that the associations observed may be due to chance or residual confounding. However,
this study did control for both age and BMI as potential confounding factors and
outcomes support a growing body of literature that questions the positioning of dairy fat
as a dietary component likely to induce cardiovascular events.
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In addition, biomarker studies suggest that milk fat intake is not associated with an
increased risk of myocardial infarction (Aslibekyan, Campos & Baylin, 2011) and may
be inversely associated with risk of stroke (Warensjö et al., 2009) and first myocardial
infarction in women (Warensjö et al., 2010b).
Reports suggesting a neutral or even favourable role of milk and dairy fat on metabolic
heath may have two possible explanations to account for these observations:

1. Milk fat is delivered as part of a complex matrix of nutrients contained within
whole dairy products that may ameliorate the harmful effects

For example, Lorenzen & Astrup (2011) reported results from a small (n=9) randomised
cross-over study, whereby the observed increase in total and LDL-cholesterol from a fat
rich diet (49% energy from fat), was partially counteracted by a high calcium intake
(2800mg/day), potentially by an increase in faecal fat excretion (p<0.0001). In addition
to calcium, dairy products contain conjugated linoleic acid (CLA), which is a naturally
occurring fatty acid derived from the isomerisation of linoleic acid by bacteria within
the ruminant gut (Rainer & Heiss, 2004). Animal studies have demonstrated that CLA
may reduce insulin resistance, increase fat oxidation (Nagao et al., 2003) and improve
body composition (DeLany et al., 1999), however conclusive evidence for this in
humans is lacking.

2. The structural composition of milk fat may differ from other dietary sources of
saturated fat, to the extent that is metabolized differently in vivo, with differing
health effects.

The saturated fatty acids found within milk products are predominantly shorter in chain
length when compared to other saturated fatty acids. These shorter chain fatty acid
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chains more readily undergo β- oxidation within the liver for energy utilisation in
comparison to longer-chain length fatty acids found in other types of fat. Longer-chain
fatty acids do not readily undergo this oxidation and are instead packaged into
chylomicrons where they may be distributed throughout the blood, with potential
implications for cardiovascular health (Parodi, 2006). Dairy products are one of the few
dietary sources of short chain fatty acids (Iggman & Risérus, 2011).When considering
the health effects of these fatty acids in the dairy context, propionic acid, a short chain
fatty acid found in milk, cheese and yoghurt has recently been suggested to improve
insulin sensitivity and satiety in humans (Al-Lahham et al., 2010).
Overall, it is likely that a combination of the two explanations is in effect. However,
there is a clear need for further research to determine the position of dairy fat on health
and also to examine the dietary outcomes that may arise from widespread
recommendations to consume reduced fat dairy products. It may be that generalised
reduced fat advice is not appropriate in the dairy food context, and that individualised
food based advice, taking into consideration the wide variety of components within this
food group is preferable.
1.11 Dairy products and Crohn’s disease
When there is a disease condition, the impact of dairy food may need to be considered
differently. The importance of evaluating dairy products as they relate to CD
specifically will now be discussed.
The potential need for intensive surgical and pharmaceutical intervention coupled with
the severe adverse gastrointestinal symptoms associated with active IBD may increase
the risk of nutritional deficiencies within this clinical population. This is particularly of
concern for CD patients. It has been reported that CD patients are more likely to
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develop protein energy malnutrition and chronic nutritional deficiencies than their UC
counterparts (Han et al., 1999). This is likely because a high proportion of individuals
with CD have small intestinal involvement (Oshitani et al., 2006) as this is a key site of
nutrient absorption, chronic inflammation or surgical resection of this region may
severely compromise the nutritional status of the CD patient (Han et al., 1999).
1.11.1 Decreased bone mineral density in Crohn’s disease
One of the key nutrients of concern for CD patients is dietary calcium. CD patients are
often prescribed corticosteroids to decrease inflammation and maintain remission of
their symptoms. A side effect of corticosteroid usage results in increased urinary
calcium excretion and suppression of its absorption in the small bowel (Caniggia et al.,
1981) and (Han et al., 1999). Thus, prolonged corticosteroid use has been reported to
reduce bone mineral density in CD patients (Bernstein et al., 1995). CD patients are
therefore at high risk for developing osteoporosis or osteopenia (Klaus et al., 2002),
which may have significant implications in terms of future morbidity.
As previously discussed, dairy products are the largest contributors of dietary calcium in
many Western cuisine contexts (McLennan & Podger, 1998a, Russell et al., 1999,
Gerrior & Zizza, 1994). A comprehensive review by Heaney (2000) concluded that
higher intakes of dairy products are associated with a reduced risk of osteoporosis and
increased bone mineral density. Von Tirpitz et al. (2002) reported a significant
reduction in the spinal bone mineral density of CD patients self reporting milk
intolerance (z-score -1.33±0.92 vs. -0.19±0.95 respectively, p= 0.0002) in comparison
to those tolerating milk products. Thus ensuring appropriate advice relating to this core
food group may be particularly important for CD patients.
1.11.2 Milk allergies and lactose intolerance in Crohn’s disease
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Despite the potential for adverse effects, CD patients may intentionally avoid
consuming adequate amounts of dairy products for several reasons. Allergies to major
milk proteins have been reported in a small sample of CD patients, with elevated serum
antibodies of Immunoglobulin G and M associated with intakes of milk proteins in CD
patients in comparison to age-matched controls (Knoflach et al., 1987).
The most frequently reported reason for dairy product avoidance in CD patients relates
to issues with lactose intolerance. Lactose intolerance results from an inability to break
down lactose (β-galactose-1,4-glucose), the sugar found in milk, into its constituent
glucose and galactose (Harrington & Mayberry, 2008). Lactose requires LactasePhlorizin Hydrolase (lactase), an enzyme that lines the small intestinal villi epithelium,
to undergo this digestive process (Heyman, 2006). Individuals lacking sufficient
quantities of this enzyme are thus said to be lactose intolerant (Harrington & Mayberry,
2008). Undigested lactose passes into the colon where it is fermented by bacteria
resulting in an increased production of hydrogen, methane and carbon dioxide.
Undigested lactose also attracts fluid into the bowel via osmosis (Harrington &
Mayberry, 2008). The clinical symptoms associated with lactose maldigestion include
abdominal distension, flatus, diarrhoea and gastrointestinal pain (Heyman, 2006).
Systemic symptoms associated with lactose intolerance have also been described,
including headaches, muscle pain, lethargy, joint pain and asthma (Matthews et al.,
2005).
There are three main types of lactase deficiency:

1. Primary lactase deficiency, or lactase non persistence, is genetically determined
and results from a continual decline in lactase levels during the early years of
life post weaning (Harrington & Mayberry, 2008). This is the most common
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form of lactase deficiency and its prevalence is largely dictated by geographical
area. Areas with a traditionally rich Pastoralist heritage have been reported to
have a higher prevalence of lactose tolerance (known as lactase persistence in
this context) in comparison to individuals in other regions (Tishkoff et al.,
2007). Primary lactase deficiency prevalence may be as high as 95-100% in
some Asian regions, or as low as 2-15% in Northern European populations
(Harrington & Mayberry, 2008).
2. Secondary lactase deficiency may occur as a result of damage to the small
intestinal mucosa following gastritis or another infection that may increase
gastrointestinal transit time and decrease the opportunity for lactase to exert its
digestive function (Lomer, Parkes & Sandersen, 2008).
3. Congenital lactase deficiency is a rare condition whereby lactase activity in the
small intestinal epithelium is reduced from birth. This condition can have severe
implications for new born infants and medical nutrition therapy is required to
reduce the risk of malnutrition in affected individuals (Torniainen, 2009).

CD patients are most likely to have issues with dairy products relating to either primary
or secondary lactase deficiencies. Intermittent or secondary lactose intolerance may be
experienced by individuals with small intestinal involvement during periods of
gastrointestinal inflammation characteristic of some forms of CD, as this is the site of
lactose digestion (Swallow, 2003). CD involving the small bowel (in particular the
duodenum and jejunum) was associated with a higher prevalence of lactose intolerance
in comparison to CD affecting distal regions of the gastrointestinal tract such as the
terminal ileum and the colon in a sample of n=121 CD patients (Mishkin,Yalovsky &
Mishkin, 1997). Furthermore, decreased levels of lactase within the duodenum have
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been identified in individuals with active CD, but not in those with quiescent CD (von
Tirpitz et al., 2002).
It is difficult to ascertain whether lactase deficiency in CD patients results from
gastrointestinal inflammation during the active disease state or as a result of underlying
genetic differences between CD patients and controls.
Whilst there is limited data in this area, lactose intolerance in CD patients has
traditionally been diagnosed using hydrogen breath testing. Hydrogen breath testing
requires participants to consume a specified amount of lactose dissolved in water.
Following ingestion of this test amount of lactose (approximately 25-50 grams) the
hydrogen concentration of expired air is quantified repeatedly for several hours (Simrén
& Stotzer, 2006). Theoretically, increased breath concentrations of hydrogen gas
following this test indicate that lactose is not being adequately digested in the small
intestine and is thus being fermented by colonic bacteria (Suarez, Savaiano & Levitt,
1995). Lactose intolerance, diagnosed using this method, was reported in 16.9% of CD
patients in a sample of n=124 (Hüppe et al., 1992). A higher prevalence of lactose
maldigestion in CD patients categorised as having a low ethnic risk for lactose
intolerance in comparison to matched controls (40% vs. 29.2%, p<0.025) was also
reported by Mishkin, Yalovsky & Mishkin (1997).
Despite its frequent utility in the diagnosis of lactose intolerance, hydrogen breath
testing may be subject to limitations. The need for hydrogen producing bacteria in the
large bowel to cause an increase in breath hydrogen following lactose fermentation may
result in a false negative result in individuals with predominantly non hydrogen
producing bacteria (Simrén & Stotzer, 2006). In addition, individuals with delayed
gastric emptying or increased gastrointestinal transit time may receive either false
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negative or false positive results respectively using this system (Simrén & Stotzer,
2006).
1.11.3 Genetic lactase non persistence
Advances in scientific understanding of the human genome, and the role of single
nucleotide polymorphisms (SNPs) on a variety of health related conditions have led to
the identification of a genetic polymorphism that is associated with lactase non
persistence in European populations (Enattah et al., 2002). Utility of this polymorphism
as an adjunct to widely utilised hydrogen breath testing may contribute to understanding
whether lactose intolerance in CD is related to inflammatory symptoms or a genetic
predisposition.
Enattah et al. (2002) identified a DNA polymorphism, rs4988235 (c.1993+327C>T,
previously termed C/T-13910) that demonstrated complete agreement with adult lactase
non persistence, as identified by intestinal biopsy samples in a Finnish population. This
polymorphism is located 14kb upstream from the LCT gene locus, which encodes the
lactase enzyme. Homozygotes for the C allele of rs4988235 were found to be lactasenon persistent or to have primary lactase deficiency, whilst those heterozygous or
homozygous for the T allele were determined to be lactase persistent, that is they
continued to produce lactase throughout adulthood.
There was a strong association between rs4988235 and lactase non persistence in a
Swedish study involving n=51 participants (Ridefelt & Håkansson, 2005). Similarly, in
a sample of n=120 Austrian outpatients with irritable bowel syndrome, the rs4988235
SNP correlated almost perfectly (97.4%) with individuals diagnosed with lactose
intolerance according to hydrogen breath testing (Kerber et al., 2007). This finding was
in agreement with Högenauer et al. (2005) who reported that of n=37 individuals
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homozygous for the C genotype of rs4988235 encoding lactase non-persistence, n=36
(97%) had a positive hydrogen breath test indicating lactase intolerance. Strong
agreement between the CC genotype of rs4988235 and lactase non persistence was also
reported in a German study (Buening et al., 2005). Thus, rs4988235 is now seen as a
valid marker for the identification of lactase non persistence in European populations.
To date few studies have been conducted to determine whether genetic lactase non
persistence occurs more frequently in CD populations. In one of the few studies
completed to date to test this theory, Büning et al. (2003) found no difference in the
frequency of the rs4988235 SNP encoding lactase non-persistence when comparing 166
CD patients to n=187 healthy controls. More recently Eadala et al. (2011) reported that
there was no difference in genetic lactase persistence between CD patients and controls.
However, this study was based on a small sample, (n=70 CD patients, n=30 controls)
which may have limited the interpretation of these results. There is a clear need for a
large case control study with sufficient statistical power to determine whether genetic
lactase persistence truly differs between CD patients and healthy controls.
1.11.4 Self-reported dairy product intolerance in Crohn’s disease
Whilst examining the importance of lactase deficiency and lactose intolerance in CD is
important, dairy products are composed of a range of nutrients and potential bioactive
components in addition to lactose. Thus, exploring self-reported dairy product tolerance
in this clinical population may provide important insights to guide clinical practice in
relation to this food group.
Intolerance to dairy products was self-reported in a small number of CD patients in a
multicentre trial (Riordan et al., 1993). Von Tirpitz et al. (2002) reported a prevalence
of perceived milk intolerance in 46.9% of CD patients, compared with 16.6% of a
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control group. Overall, however, there is a paucity of more recent data with appropriate
sample sizes to estimate the true incidence of self-reported intolerance to dairy foods in
this clinical population. As a result of these reports and other anecdotal evidence, newly
diagnosed CD patients were historically instructed to avoid dairy products. Whether this
is still the case remains uncertain (Mishkin, Yalovsky & Mishkin, 1997) and warrants
further investigation.
There is another theory, relating to the presence of an infective agent in dairy products
that has been hypothesised to increase the risk of developing CD which is worthwhile
considering when exploring the position of this core food group in the context of this
disease.
1.11.5 Mycobacterium avium subspecies paratuberculosis and Crohn’s disease
Mycobacterium avium subspecies paratubercuosis (MAP) is an infective agent that
largely affects ruminants, resulting in a chronic gastrointestinal inflammatory condition
known as Johne’s disease (Harris & Barletta, 2001). Ruminants suffering from Johne’s
disease may experience diarrhoea, emaciation, granuloma, reduced milk production and
eventual death (Ellingson et al. 2005). MAP infection resulting in Johne’s disease
shares many clinical similarities with CD symptoms and can replicate in the
gastrointestinal tract in vivo (Chiodini, 1989). Ruminants infected with MAP secrete
this live infective agent into their milk (Ellingson et al. 2005), potentially increasing the
risk of its contamination into the food supply.
MAP contained within milk products is resistant to current pasteurisation methods, and
viable MAP has been identified in commercially available dairy products across several
countries including the United Kingdom (Grant, Ball & Rowe, 2002) and the Czech
Republic (Ayele et al., 2005). In an American study involving 702 commercially
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available pasteurized whole milk samples, viable MAP was identified in 2.8% of the
samples, indicating that public exposure to this pathogen is occurring (Ellingson et al.
2005). The presence of this pathogen in the milk supply may be a significant public
health risk. However, Grant, Ball & Rowe (1999) reported that MAP species
contaminated within samples of raw bovine milk were able to be eradicated by heating
to 72°C and holding for 25 seconds. Therefore, changes to milk processing methods
may dramatically reduce the exposure to this pathogen for the general public. However,
these changes are yet to be adopted by the dairy industry.
Recent technological advances have meant that MAP has resurfaced within the
literature as a potential etiological factor in the pathogenesis of CD in particular. Using
reverse transcription polymerase chain reaction (RT-PCR) methods (described in more
detail in chapter 2), MAP DNA was identified in a larger proportion of CD patients
compared to controls (33.8% vs. 21.5% OR 1.86, 95% CI 1.25-2.78, p= 0.002) in a New
Zealand study (Bentley et al., 2008). MAP DNA was also identified in both CD patients
and controls (n=13 vs. n=3 respectively), however viable MAP cultured in the blood of
50% of a sample of n=28 CD patients was not seen in controls (n=15) (Naser et al.
2004). It may be that individuals without CD are able to kill this pathogen prior to its
destructive colonisation, or that MAP is treated differently in vivo in those with a
genetic predisposition to CD. Support for the latter of these theories has recently been
provided by Elliott et al. (2011), who observed that monoctyes infected with MAP
triggered differing cytokine responses between CD cells and controls. For cells that
elicited a cytokine response to MAP, an increased IL-6 response was observed in CD
cells in comparison to controls. Similarly, the peripheral blood mononuclear cells of CD
patients incubated with the MAP pathogen resulted in a significantly increased
production of the cytokines TNF-α and Interleukin-10 (p<0.05) and an increased
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proliferation of T-cells (p<0.0001) in comparison to UC patients and healthy controls
(Sibartie et al., 2010). Furthermore, most MAP survived within both groups of
monocytes, with no difference in the proportion destroyed between CD patients and
controls, suggesting that proposed differences in MAP effects are not the result of
improved destruction of this pathogen by healthy controls in comparison to CD patients
(Elliott et al., 2011).
Lactase non persistence was inversely correlated with intake of dairy products (r²=.59),
in a study involving annual per capita population intake data from 26 countries (Shrier,
Szilagyi & Correa, 2008). This indicates that one’s ability to digest lactose will have a
profound impact of eventual intake of dairy products, likely as a result of adverse
symptoms experienced when consuming lactose containing foods. Thus lactase
deficiency status is also used as a marker for dairy product intake in epidemiological
studies exploring the MAP and CD hypothesis. Lactase non persistence was associated
with a 60% risk reduction in CD (OR 0.41, 95% CI 0.27-0.61), in a study utilising CD
incidence per 100,000 data from 15 countries (Shrier, Szilagyi & Correa, 2008). A
strong negative correlation between CD incidence and lactase persistence (r=-0.655,
p=0.0017) was also estimated using data from 20 countries (Juste, 2010). This
epidemiological data requires further investigation to substantiate these observations.
Should evidence confirm the link between MAP contained within dairy products and
CD pathogenesis, ensuring its irradiation from the food supply will be imperative from
a public health perspective. However, it will also be imperative to distinguish between
dairy products per se as a potential aetiological factor for CD and the MAP species that
may be found within them. Should such a situation arise, nutrition education and
dietetic counselling for CD patients will be a valuable resource to communicate this
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message in order to protect them from unnecessary avoidance of pathogen free dairy
foods.
To ensure that advice relating to dairy product intake reflects the best available evidence
for CD patients, there is a need to explore these issues in more detail. The possibility
remains that dairy products may need to be avoided by a small proportion of CD
patients; however, it is likely that these individuals represent a minority of this clinical
population and evidence to discourage widespread avoidance of this important food
group may have significant implications from a nutritional perspective.
1.12 Summary
The position of dairy foods in the diet for health promotion remains somewhat
problematic despite the ever increasing scientific publications on health benefits and
with a wide focus on obesity. An exploration of the position of dairy products in
specific metabolic areas may be informative as there is now evidence to suggest that
obesity and Crohn’s disease are two conditions that share an underlying inflammatory
pathogenesis. From a practice perspective there is an urgent need to evaluate the
position of dairy products in the context of these conditions to ensure that individuals
are not unnecessarily avoiding them, as a potential factor that may ameliorate
inflammation and adverse health outcomes associated with both conditions. Should
outcomes from this thesis provide supportive evidence to suggest that the position of
dairy foods in these disease contexts requires reassessment, the role of nutrition
education in changing attitudes towards dairy products will need to be explored.
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1.13 Central thesis hypothesis, aims and objectives
The above literature review highlights the need to explore the position of dairy products
in the contexts of both obesity and gut health (more specifically CD). To this end the
central hypothesis of this thesis is that:
The position of dairy foods in the diet is complex, defined by health-disease context and
subject to consumer behaviour.
To address the central thesis hypothesis, five studies were completed. The first two
studies were conducted on data and additional laboratory analyses made available from
a weight loss trial conducted in Wollongong, Australia, whilst the final study drew some
of its participants from this study group. Studies three and four utilised population
survey data from Auckland, New Zealand. A conceptual framework of these studies is
listed in chapter 2 (figure 2.1). The objectives of each study were as follows:
Study 1:

1.

To compare the amount, type and dietary contribution of dairy products
consumed by overweight adults at baseline and following three months of
participation in a clinical weight loss trial whereby advice to consume reduced
fat dairy products was given.

2. To determine whether individuals complied with dietetic advice to consume a
minimum of two to three serves of reduced fat dairy products per day based on
their individual dietary requirement.
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Study 2:

1. To determine whether dairy fat intake, as measured by both diet history
interview and validated whole blood biomarkers, is associated with adverse
metabolic profiles in a sample of overweight adults participating in a weight loss
trial.

Study 3:

1. To evaluate the self-reported effects of dairy products on CD symptoms
2. To determine whether these effects differed between types of dairy products
consumed and disease state or location

Study 4:
1. To determine whether genetic adult lactase persistence is associated with CD
risk in a New Zealand population

Study 5:

1. To explore the salient beliefs of adult weight loss trial participants regarding
dairy products and to compare these with a control group not exposed to
nutrition education.

1.14 Thesis structure and significance
To set the research scene, chapter 2 summarises the key methodological considerations
surrounding each study in the thesis.
Chapter 3 begins with the practice context and presents a simple observational study
that describes the dietary consequences of recommending reduced fat dairy products. It
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highlights gender differences in the adoption of advice to replace whole dairy products
with their reduced fat counterparts and illustrates the difficulty in meeting
recommended intakes during periods of energy restriction. Thus, while encouraging
reduced fat dairy foods is often standard practice, it may not result in desired consumer
behaviour. The next chapter addresses the question of whether it is even necessary.
Chapter 4 explores the association between dairy fat intake and adverse metabolic
profiles in overweight individuals. Validated biomarkers of milk fat intake, coupled
with diet history interview data are utilised to determine potential associations between
clinical data reflective of metabolic syndrome risk in overweight individuals. Bearing in
mind the limitations of this analysis, no adverse associations between milk fat intake
and adverse metabolic profiles are found; in contrast some desirable associations are
identified. This study challenges widely held beliefs that dairy fat may be associated
with exacerbations of the metabolic syndrome in overweight individuals. Furthermore,
it supports a growing body of evidence which suggests that dairy fat may have
favourable health effects and may be included as part of the total diet for individuals
unable or unwilling to consume reduced fat dairy foods.
A key component of the central thesis hypothesis is that the position of dairy foods in
the diet is defined by the health-disease context. Chapter 5 moves the investigation to
the context of gut health, and describes the third study, whereby self-reported effects of
dairy products on CD symptoms are evaluated in a New Zealand cohort. Outcomes
from this research reveal that overall; consumption of dairy products has little effect on
self-reported CD symptoms. However, for those reporting a perceived worsening of CD
symptoms associated with dairy product intake, foods with a higher fat content are
reported to be most problematic. In addition, the lactose content of dairy products does
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not appear to influence self-reported symptoms, whilst individuals with colonic CD
involvement more frequently reported experiencing a worsening of CD symptoms
following intake of a milk product in comparison to those with ileal disease. This
research illustrates the complex and highly individual nature of dairy product tolerance
in a clinical population and challenged the need to encourage widespread dairy product
avoidance for all CD patients.
Despite these results, it has been suggested that contamination of dairy products with an
infective agent (MAP) leading to an inflammatory condition in ruminants may increase
CD risk. Thus a further study involving novel nutrigenomics research was completed to
determine whether genetic lactase persistence is associated with an increased risk of
CD. Findings from this large case control study indicate that the ability to digest lactose
is associated with an increase in CD risk, particularly with the risk of developing CD of
an inflammatory nature. This study contributes evidence to support this idea and
identifies a potential public health issue that warrants further investigation as to whether
the milk supply may be contaminated with this infective agent. Such actions may be
necessary to ensure that the benefits from dairy products can be appreciated by all CD
patients (that can tolerate them), and those that may be genetically susceptible to the
condition with minimal risk of harm.
The studies presented in chapters 3-6 provide evidence to challenge widely held beliefs
that dairy products may have a negative impact in the context of both obesity and CD.
From a practice perspective, there remains the issue of influencing consumer beliefs
surrounding this core food group. Chapter 7 outlines the fifth and final study completed
within this thesis. This study explores consumer perceptions of dairy products and
evaluates the impact of dietetic education in shaping these perceptions. Outcomes from
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this study illustrate the potential of nutrition education in shaping control and
behavioural beliefs surrounding dairy foods in a sample of overweight individuals. This
‘proof of concept’ study illustrates that nutrition education may change beliefs relating
to dairy products and is thus vital when seeking to change consumer behaviour in
relation to this food group based on emerging evidence.
The thesis concludes with a summary of the main findings from the five studies and
identifies the significance of these findings in the context of the thesis aims. Overall the
body of work illustrates the many contingencies associated with the incorporation of
dairy products within the diet. The issue of context is highly relevant, considering both
the obesity and CD contexts, where certain beliefs may appear unsupported. Directions
for future research are also presented in this concluding chapter.
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Chapter 2. Methodology
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2.1 Introduction
This thesis explores the central hypothesis that the position of dairy foods in the diet is
complex, defined by health-disease context and subject to consumer behaviour.
Establishment of an evidence base surrounding the position of a core food group such as
dairy in the context of chronic disease is a difficult task given the complexities
associated with nutrition research. There is a need to consider the impact of
psychological, physiological and genetic influences that may be driving food choice and
eventual health outcomes. As such exploration of the position of dairy products in the
context of both obesity and CD will require a variety of study designs and methods to
ensure that each relevant influence is considered.

This chapter outlines the methodological framework underpinning this thesis and will
include a brief review of the literature surrounding each of the methods employed as
part of the five studies that make up this body of work. To this end, this chapter will
review the literature surrounding the utility of study designs in evidence based nutrition,
dietary methodology, dietary biomarkers and nutrigenomics as they relate to the central
thesis hypothesis. Finally, an exploration of the utility of social research will be
included as an important methodological tool to translate research outcomes to practice.
A conceptual framework of the studies included within this thesis and the methods
utilised within them is included as Figure 2.1.
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Study 5. What do consumers think about dairy foods? Can
nutrition education influence perceptions relating to dairy
foods?




Social research
Focus group interviews
Theory of planned behaviour theoretical framework

Obesity

Study 1. What happens when people
are advised to consume reduced fat
dairy foods?



Secondary analysis of data from
randomised controlled trial
Dietary methodology –diet
history interview

Dietary position of dairy foods is
complex, defined by health-disease
context and subject to consumer
behaviour




Fatty acid biomarkers
Diet history interview

Crohn’s Disease

Study 3. Does intake of dairy products
result in adverse Crohn’s disease
symptoms?


Study 2. Does dairy fat intake lead
to adverse metabolic parameters?

Secondary analysis of survey data

Study 4. Can a genetic factor mediating dairy
product intake increase Crohn’s disease risk?



Nutrigenomics research
Genetic case control study

Figure 2.1. Conceptual framework of thesis and the studies contained within it.
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2.2 Study designs in evidence based nutrition
Practice is based on evidence based nutrition and different study designs are referred to
in constructing the evidence base. One of the most important study designs in evidence
based nutrition is the randomised controlled trial (RCT). While an RCT was not
specifically designed for this thesis, data from an RCT was utilised to address some of
the questions.

2.2.1 Randomised controlled trials
The Australian National Health and Medical Research has categorised the RCT
amongst the highest level of evidence in their hierarchical ranking, second only to
systematic literature reviews inclusive of such RCTs (National Health & Medical
Research Council, 2009). Such trials are advantageous in that they involve the random
allocation of participants to receive a particular treatment or intervention and thus may
eliminate bias between treatment groups by controlling for potential confounding
variables, minimising the potential for between group differences (Jadad, 1998). The
inclusion of a control group in RCTs may also reduce the likelihood that results
observed stem from familiarity of the treatment/study design or other potential
confounding factors such as seasonality of response to a study protocol (Margetts &
Nelson, 1997). These factors, specific to the study design of an RCT, ensure that the
identification of outcomes that may have occurred as a direct result of an intervention is
possible (Stolberg, Norman & Trop, 2004).

As a result of their strengths, RCTs have a wide range of research applications. This
methodology has been applied across the pharmaceutical discipline (Melander et al.,
2003) and is considered a core component underpinning evidence based medicine
(Stolberg, Norman & Trop, 2004). In the nutrition science domain, RCTs are important
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when seeking to test the effect of a particular food or nutrient on health outcomes. RCTs
in nutrition science have provided insight into a variety of diet disease relationships
including the potential role of dietary fibre in reducing blood pressure (Whelton et al.,
2005) and the role of polyunsaturated fatty acids in the reduction of cardiovascular
disease risk (Bucher et al., 2002).

However, the utility of RCTs in nutrition research is not always practical due to the
large financial commitment and significant number of personnel required to complete
such a trial with sufficient statistical power to observe the effect of a particular food or
nutrient on a health outcome (Neuman, 2011). In addition, RCTs seeking to explore the
position of dairy foods on chronic disease such as obesity and the metabolic syndrome
must be of sufficient duration to ensure that any changes in the biological parameters
associated with the disease in question can be identified (Elwood et al., 2005).

The use of RCTs in nutrition research in further compounded by the difficulties
associated with accurately measuring nutrient intake data (Margetts & Nelson, 1997),
controlling the background diet and the issues associated with attributing health effects
to a single nutrient, considering the complexity of foods in terms of their differing
physiological effects based on genetic and environmental factors (Jacobs et al., 2009).
Despite these limitations, RCTs are still an extremely important tool for nutrition
research.

For the reasons outlined previously it is seldom practical to conduct RCTs that address
specific nutrition questions relating to core foods and chronic disease. In light of this
fact, research involving the secondary analysis of data collected from larger studies is
becoming increasingly prevalent (Neuman, 2011). Such secondary analyses add value to
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these larger studies by extracting available data to ask additional questions that may be
informative to both clinical practice and future nutrition research.

Recently, secondary analyses of large nutrition studies have made significant
contributions to the knowledge base surrounding core foods on health outcomes (Lin et
al., 2000, Thomson et al., 2011). In particular, a secondary analysis of dietary intake
data from a large number (n=3080) of breast cancer survivors participating in the
Women’s Healthy Eating and Living study, revealed that individuals in the highest
tertile of vegetable consumption had a reduced risk of breast cancer reoccurrence in
comparison to individuals reporting the lowest intakes of vegetables (HR 0.69, 95% CI
0.55-0.97) (Thomson et al., 2011). In an earlier study, Albert et al. (1998) reported a
significantly reduced risk of sudden cardiac death (OR 0.48, 95% CI 0.24-0.97, p=.04)
in males consuming fish at least once a week in comparison to those consuming it less
than monthly, in a secondary analysis of food frequency data from the United States
Physicians Health Study (n=20551). Thus, secondary analyses offer an important
opportunity to add value to RCTs by asking additional research questions which may be
of value to researchers seeking to explore the relationship between core foods and
chronic diseases in a cost-effective way.

A large proportion of this thesis was derived from the secondary analysis of a
randomised controlled trial that was completed at the University of Wollongong from
2008-2010 (National Health and Medical Research Council project grant (# 514631,
Tapsell, Batterham and Charlton), project name: Is a higher intake of omega 3 fatty
acids advantageous for weight loss? [ACTRN12608000425392]). The ‘Smart’ study
was a 12 month randomised controlled trial whereby participants were randomised to
one of three groups and advised to consume either:
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180g of fish per week in addition to a placebo capsule



180g of fish per week in addition to a 630mg long chain omega-3
polyunsaturated fatty acid capsule



A control diet in addition to a placebo capsule

All participants were prescribed a 2000kJ deficit background diet that was matched for
macronutrient intakes and based on individual energy requirements. Further details on
the RCT from which dietary data from studies 1 and 2 (chapters 3 and 4 respectively)
and the participants from study 5 (chapter 7) were drawn can be found as appendix 1
and will be discussed within each study chapter as appropriate.

2.2.2 Survey research
Survey research is an important methodological tool in evidence based nutrition
research that may be utilised to explore a broad range of topics ranging from
demographic data to attitudinal and behavioural information (Kiecolt & Nathan, 1985).
As in RCTs, conducting survey research can also be expensive and labour intensive.

A secondary analysis of survey data may be defined as the re-analysis of an existing
survey data set that may have been obtained by an individual or organization for a
purpose that is specific to the subsequent researcher (Gilbert, 2001). Secondary analyses
of survey data offer many advantages to the nutrition researcher in situations where
resources may be limited. In particular they are economical, can be completed in a
timely manner and provide a unique opportunity to explore existing data to generate
new hypotheses and insights to stimulate further research (Kiecolt & Nathan, 1985).
The potential for secondary analyses of survey data to add value to existing theoretical
concepts or to generate additional hypotheses for exploration is evident from the utility
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of large survey data sets for this purpose in recent years. For example, anthropometric
survey data from the 1999 National Food Consumption Survey of South Africa were
reassessed using updated reference standards for estimating stunting, wasting,
overweight and obesity. This secondary analysis reported a higher prevalence of
stunting and obesity/overweight in children (at 20.1% and 30.0% respectively) assessed
using the updated 2006 World Health Organization reference standards in comparison
to previous results found using the 1977 National Centre for Health Statistics reference
standards. Such a re-analysis will assist health authorities to create more targeted health
strategies to address the issues identified (Bosman et al., 2011).
From a nutrition perspective, a recent secondary analysis of the 2006-2007 Pakistan
Demographic and Health Survey involving n=941 Pakistani infants, revealed that a
large proportion (60.8%) did not receive complementary solid foods at recommended
ages. Such information may be extremely valuable to future health programs involving
pregnant women in this region to ensure that education regarding the appropriate time to
introduce complementary foods is prioritised (Hazir et al., 2012).
Despite their strengths, secondary analyses of survey data may be limited in that the
survey was not originally designed to assess a research question subsequently
developed. This may have implications in terms of the ability to both acquire pertinent
information and to appropriately interpret results obtained (Kiecolt & Nathan, 1985). As
such, survey questions designed to explore a particular theoretical hypothesis, may not
provide sufficient detail for a subsequent researcher to make meaningful observations
from the survey data being utilised (Gilbert, 2001).

Whilst it is important to take the aforementioned limitations into consideration when
interpreting results, secondary analysis of survey data provides a unique opportunity to
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maximise research outcomes that may be of benefit to those participating without any
additional burden. This method of research may be particularly pertinent when
involving groups of individuals with chronic and debilitating conditions. In the case of
IBD, access to an appropriate number of patients may not be possible without the
cooperation of a large and established research initiative, with close relationships with
physicians treating such patients.

In this thesis, dietary and clinical survey data from a large New Zealand study involving
individuals with IBD was analysed to explore the position of dairy products in this
disease context. Further details on the study from which this survey data was drawn can
be found in chapter 5 (section 5.2).

2.3 Dietary methodology
Nutrition research relies heavily on the quality of the dietary intake data obtained.
Currently, doubly labelled water is the gold standard for measuring energy expenditure,
which is considered equivalent to energy intake in individuals that are relatively weight
stable (Johnson, 2002). The high cost and equipment burden required to use doubly
labelled water for estimating dietary intake means that its use is limited to the laboratory
setting (Johnson, 2002). As such, appropriate alternatives to estimate energy and
nutrient intakes have been developed. Some of these methodological tools include food
records, food frequency questionnaires (FFQ), diet history interviews and 24 hour
dietary recalls. Each of these tools has their own inherent strengths and limitations but
all are reliant on participants to self report dietary intakes (Johnson, 2002).

Briefly, FFQs require participants to state how often (daily, weekly, fortnightly,
monthly) and in what approximate quantity they consume a particular food item. Food
items are generally selected to estimate dietary intakes for a specific study purpose and
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rarely assess the totality of the diet (Cade et al., 2002). Twenty four hour dietary recalls
require participants to state all foods consumed in the preceding day. This method relies
heavily on participant memory to accurately list all foods eaten and in what quantities
so that meaningful estimations of intake can be made. As the 24 hour dietary recall
method only assesses intake at one particular time point, it may be limited in terms of
assessing habitual dietary intakes (West Suitor, Yaktine & Oira, 2007).

Dietary intake information for the primary RCT from which data was sought was
acquired using both 3-day food records and a diet history interview. These methods of
assessing dietary intake will be discussed in more detail below.

2.3.1 Diet history interview
Diet history interviews are structured interviews completed by trained interviewers
whereby participants are asked to recall which foods are typically eaten during main
meals and snacks, and in what quantities using open ended questions (Whitney, et al.,
2009). Specifically to the studies presented, probing questions were used to clarify
recipes, ingredients and key brand names of foods commonly consumed. Food models
were also utilised to assist with portion size estimation. Following the initial interview,
further questions enquiring about the frequency of intake of food groups, were asked to
ensure that all items were captured and to reduce the possibility that foods consumed
outside of main meals were omitted.

One of the strengths of the diet history interview is its ability to capture habitual meal
pattern intakes and include data relating to the frequency of intake of core foods
(Trabulsi & Schoeller, 2001). In particular, the diet history interview data utilised
throughout this thesis has been reported to reflect intakes relating to the previous 30
days (Martin et al., 2002). Information about food preparation methods and the cuisine
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context in which items are consumed is also provided using this method, which may
have a significant impact on estimated nutrient intakes (Thompson & Byers, 1994).
This may be particularly important when seeking to evaluate the position of core foods
on chronic diseases. Information from diet history interviews relating to dairy product
intake have been widely used to explore potential relationships between this food group
and health outcomes (Pereira et al., 2002, Sonestedt et al., 2011).

A possible weakness of the diet history interview method may stem from participant
difficulties with accurately recalling usual dietary intake resulting in random error. In
addition, underreporting of usual intake during a diet history interview has been
reported, particularly in overweight populations (Heitmann & Lissner, 1995, Waling &
Larsson, 2009). Over-reporting of usual intake may also occur, with either introducing
a potential systematic error in data collected (Trabulsi & Schoeller, 2001).

2.3.2 Food records
Food records are a prospective method of quantifying dietary intake whereby
participants are required to record all food items and drinks that have been consumed
daily during the measurement period (Trabulsi & Schoeller, 2001). In the case of the
primary RCT described, participants were required to complete the food record over a
3-day period, inclusive of one weekend day. Food records may be advantageous over
retrospective dietary assessment tools such as 24 hour dietary recalls as they reduce
participant reliance on memory to accurately recall past dietary intakes and are helpful
for capturing more detailed quantitative information as participants are encouraged to
weigh/measure items consumed to increase accuracy (Trabulsi & Schoeller, 2001).
However, as this is a prospective method of capturing food intake for a given period of
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time, it is subject to several limitations which may reduce its accuracy in capturing
habitual intakes of core foods such as dairy products.

In particular, food records may be subject to reporting bias, whereby individuals may
alter usual dietary intake during the study period (Trabulsi & Schoeller, 2001). Goris et
al. (2000) reported that completion of a 7-day food record was associated with a
1.0±1.3kg loss of body mass in a sample of obese men (n=30). This differed
significantly (p<0.05) from body mass measured over a non recording week indicating
that the participants reduced energy intake during the reporting period. Food records
also rely heavily on the ability of participants to accurately follow the instructions
provided to ensure that dietary data recorded is comprehensive enough for meaningful
assessments to be made (Thompson & Byers, 1994). Incomplete or inaccurate food
records may further limit the utility of this form of dietary assessment when seeking to
acquire accurate data regarding the intake of core foods. Finally, food records are
completed for a relatively short time period (3 days in the case of the RCT from which
data was drawn), thus this dietary assessment tool may not capture intakes of foods that
fall outside of the reporting period or seasonal variation in food intake. This is of
concern when seeking to draw meaningful conclusions regarding the positioning of
dairy products on health (Margetts & Nelson, 1997).

Upon careful consideration of the aforementioned strengths and limitations associated
with each of the methods of estimating dietary intake and an examination of data
acquired, it was considered preferable to utilise nutrient intake data acquired using the
diet history interview over the 3-day food records. Studies 1 and 3 (chapters 3 and 4,
respectively) presented within this thesis utilised nutrient intake data obtained from diet
history interviews conducted by trained Accredited Practising Dietitians. The diet
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history interview utilised for this study has demonstrated good relative validity against a
3-day food record in an overweight population (BMI 31.3± 5.0) from a similar
geographic region (Martin et al., 2003) and its use may ensure that a better estimation of
habitual dairy product intake is possible. This is particularly pertinent given that some
dairy products have a relatively high fat content and a systematic underreporting of
dietary fat has previously been observed in a study of overweight men completing food
records (Goris et al., 2000).

2.4 Dietary biomarkers
The term biomarker has a range of applications and may mark the risk of adverse
clinical endpoints. For instance elevated oxidized plasma LDL-cholesterol may reflect
an increased risk of cardiovascular disease in a particular individual (Fraley &
Tsimikas, 2006). Nutritional biomarkers are a specific type of biomarker that may be
defined as a biological specimen that reflects nutritional status as a result of the intake
of a particular dietary component (Potischman & Freudenheim, 2003). As outlined
previously standard methods of estimating dietary intakes are subject to a range of
limitations which may reduce the reliability of diet disease relationships observed. The
use of dietary biomarkers as an objective measure of nutrient intakes are thus becoming
an increasingly important adjunct to traditional dietary assessment tools (Jenab et al.,
2009).

Dietary biomarkers have a range of functions throughout the nutrition research domain
including:
1.

Validation of traditional nutrition assessment tools

2. Approximation of an individual’s nutritional status in relation to intake of a
particular nutrient
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3.

Objective assessment of the dietary intake of a specific food or nutrient
(Potischman & Freudenheim, 2003).

The last of these functions is of most relevance to the work presented within this thesis
so will be discussed in greater detail.

Dietary biomarkers have been widely utilised to estimate dietary intakes of particular
foods and nutrients. For example, Amiano et al. (2001) reported that the concentration
of very long chain omega three polyunsaturated fatty acids in the serum, phospholipids
and cholesterol esters of healthy volunteers (n=120) reflected habitual fish intake in a
cross-sectional study. More recently, a systematic review by Baldrick et al. (2011)
found that serum concentrations of vitamin C and carotenoids may reflect intakes of
fruit and vegetables, respectively.

In the case of dairy products, nutritional biomarkers to reflect milk fat intake have been
validated across several biological specimen types and in a range of individuals.
The observation that the odd numbered fatty acids Pentadecanoic acid (15:0) and
heptadecanoic acid (17:0) are not able to be synthesised endogenously by humans
(Wolk et al., 1998) and are instead synthesised by ruminant bacteria (Wu & Palmquist,
1991) led to the hypothesis that these fatty acids may be suitable candidates to reflect
intakes of ruminant fat. That is, they may reflect intakes of fat from milk products and
to a lesser extent, fat from ruminant meats. In the first study to test this hypothesis,
Wolk et al. (1998) reported that subcutaneous adipose tissue concentrations of 15:0 and
17:0 correlated well with intakes of milk fat assessed by four 1 week weighed food
records completed quarterly over a one year period (r=0.63 for 15:0 and r=0.42 for
17:0) in a sample of n=81 healthy Swedish women. Ruminant meat intake was not
found to influence this association, indicating that it may not confound estimates of
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milk fat intake in individuals with a high dairy intake. Similar findings were reported
for Swedish males, with adipose tissue concentrations of 15:0 and 15:0+17:0 displaying
significant correlations (r= 0.74, and r=0.56, p<0.001, respectively) with reported milk
fat intakes (Wolk, Furuheim & Vessby, 2001).

As the incorporation of fatty acids into adipose tissue takes a long period of time,
adipose tissue concentrations of 15:0 and 17:0 are advantageous in their ability to reflect
long term (yearly) dietary intakes (Baylin & Campos, 2006). However, the acquisition
of adipose tissue samples is often highly invasive, expensive and less tolerated by
participants. As a result, less invasive biological samples to reflect milk fat intake have
been validated. For example, in the study discussed previously, Wolk, Furuheim &
Vessby (2001) reported significant correlations between both serum cholesterol ester
and serum phospholipid concentrations of 15:0 and reported dairy fat intakes (r=0.45
and r=0.50 respectively, p<0.001 for both) and for the sum of 15:0 and 17:0 (r=056 and
r=0.50 respectively, p<0.001 for both). Similarly, Sun et al. (2007) reported that
concentrations of 15:0 in plasma and erythrocyte samples from women participating in
the Nurse’s Health Study correlated (r=0.36 and r=0.30 for plasma and erythrocytes
respectively) with average reported dairy fat intake (assessed using a FFQ), and may
thus be a suitable alternative to adipose tissue for estimating intakes of milk fat. This
study also failed to find a correlation between ruminant meat intake and concentrations
of 15:0 (Sun et al., 2007).

Whole blood samples may present a novel, cost-effective and less invasive method to
assess associations between milk fat intake and health that may be less prone to
measurement error than analyses that require plasma to be separated into its constituent
cholesterol ester, phospholipid and triacylglycerol fractions (Baylin et al., 2005).
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Baylin et al. (2005) reported that fasting whole blood samples were comparable to both
adipose tissue and plasma samples in terms of their correlation with intakes of milk fat
reported by n=200 Costa Rican men and women using a FFQ (for 15:0, r= 0.20 vs. 0.26
and 0.23 for adipose tissue, plasma and whole blood respectively). Further research
exploring the utility of whole blood samples as valid biomarkers of milk fat intake may
be informative for researchers seeking to use samples requiring minimal processing.
For this reason, whole blood samples were utilised to assess the concentrations of 15:0
and 17:0 as biomarkers of milk fat intake in this thesis. More detailed information on
the laboratory methods for the fatty acid analysis of whole blood utilised within this
study can be found in chapter 4 (section 4.2.1).

The inclusion of objective methods for estimating intakes of dairy fat is an important
component of this thesis when seeking to explore the effects of this food component on
metabolic parameters. In the CD context, inclusion of objective analyses that may
identify potential exposure to dairy products may also be informative.

2.5 Nutrigenomics
Such objective analyses may be found through the utility of nutrigenomics research.
Nutrigenomics or nutritional genomics is the field of science which seeks to explore the
role of diet on an individual’s genes (Kaput, 2005). It is an emerging field of nutrition
research that has significant potential in terms of identifying key dietary factors that
may influence the expression of genes involved in chronic diseases (Kaput, 2005).
Nutrigenomics is a growing area of research which seeks to contribute to the evidence
base surrounding individual dietary requirements with an end goal being the creation of
diets that have been personalised to best complement an individual’s genotype in terms
of the maintenance of health and prevention of disease (Joost et al., 2007). Recently,
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nutrigenomic research has uncovered that an individual’s blood pressure response to a
low sodium diet may relate to the presence of common variants of the α, β and γ
subunits of the epithelial sodium channel in a Chinese study involving n=1906
participants (Zhao et al., 2011).

Failure to consider the impact of genetic influences driving both food choice and the
expression of particular genes in response to a component of the diet may result in
erroneous conclusions in the field of nutrition research (Mutch, Wahli & Williamson,
2005). As such, the study presented in chapter six involves novel nutrigenomic research
whereby a genetic variant or SNP, associated with lactase persistence (described in
more detail in chapter 1) was evaluated in relation to CD risk.

A SNP is the term used to describe a variation in a DNA sequence as a result of a single
nucleotide within a genome (Syvanen, 2001). SNPs are extremely common throughout
the human genome and are estimated to be present once in every one thousand bases
(Sachidanandam et al., 2001). Whether or not a SNP has any role in the phenotypic
expression of a particular characteristic depends on their position within the genome.
SNPs present within coding regions of genes may influence the expression, structure or
function of a protein encoded by that gene, and have a critical role in terms of the
presence or absence of a particular disease or characteristic (Syvanen, 2001). One
common method for the genotyping of SNPs involves the use of RT-PCR technology
(Bustin, 2000). This method has been widely utilised in nutrigenomics research
(Huebner et al., 2010, Turcot et al., 2012). More details on the methods utilised to
genotype the lactase persistence SNP in the aforementioned study can be found in
section 6.2.2.
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Evaluation of a SNP which is considered a proxy for exposure to a particular food or
nutrient may be particularly advantageous for generating hypotheses relating to the
position of that food on chronic disease. Utilising this genetic information will provide
an objective measure of chronic dietary exposure and thus reduce reliance on methods
of dietary assessment which may are subject to several sources of bias (as described in
section 2.3) (Davey Smith, 2011).

2.5.1 Genetic case-control studies
The data reported in chapter 6 was derived from a population based genetic case-control
study. This study design involves a comparison between cases (a random group of
individuals who have a particular condition or disease) and controls (a group of
unrelated individuals lacking the disease or condition). All individuals were genotyped
for a particular candidate SNP/loci for a disease and statistical methods were applied to
determine whether there was a significant difference in the allelic frequencies between
cases and controls. Should statistical differences in allele frequencies between the
groups be observed, an association between the candidate SNP and a particular disease
or condition are inferred (Ghosh, 2007). In the study presented in chapter 6, individuals
with CD were compared with a control group to determine whether there were any
differences between the groups in terms of the presence of the lactase persistence SNP.
There are several factors that must be considered when using this study design for
nutrigenomic research.

Cases and controls must be matched for ethnicity to ensure that their allelic composition
is essentially homogenous to avoid making incorrect genetic associations. Thus care
must be taken, even with individuals from the same geographic location to ensure that
genetically diverse individuals within that location are not included in the analysis
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(Ghosh, 2007). Furthermore, the case control design relies on the assumption that
individuals within the control group do not have the condition under examination. It
may be possible that some controls are indeed affected by the condition being explored,
however, are unaware of this due to a lack of symptoms or a formal diagnosis. If such a
situation should occur, inaccurate conclusions may be drawn. Conversely, individuals
self-reporting the presence of a particular disease or condition without a formal
diagnosis may introduce a further source of error. In the case-control study presented in
chapter 6, participants were screened to determine their ethnicity, and only European
Caucasian individuals were included in the analyses, with ethnic sub-populations within
the study removed from the genetic analyses. Similarly, only individuals with a formal
CD diagnosis from a trained gastroenterologist were included in the analysis to reduce
the possibility of bias within the results.

The interaction between genetic variants and dietary intake is extremely complex given
that associations observed are largely influenced by environmental factors. Thus a need
for more complex nutrigenomic research involving combinations of relevant gene
variants in conjunction with human intervention trials to test observed associations with
chronic conditions has been discussed (Joost et al., 2007). Whilst this is a valid point,
the scientific understanding of all possible genetic combinations and environmental
factors that may influence chronic disease pathogenesis remains far from conclusive.
Thus nutrigenomic case control research involving genetic variants that may serve as a
proxy for chronic exposure to a core food, such as dairy, may contribute important
evidence to drive further research in this area.
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2.6 Social research
All of the aforementioned research methods have been utilised to extract important
information relating to the positioning of dairy foods as a core food within the context
of both CD and obesity. The translation of this new information to practice however
will require a consideration of consumer perceptions and beliefs that may influence
dietary behaviour in relation to this food group.

Social research seeks to understand and explain the nature of human beliefs and
behaviours in the context in which they are experienced. Social research is often
qualitative in nature, and is an important adjunct to quantitative research methods, as it
is concerned with understanding the reasons behind a particular phenomenon or
behaviour that may not be immediately apparent using traditional quantitative
approaches such as statistical analyses (Draper, 2004). This is particularly pertinent in
the domain of nutrition where it is well documented that food choice and dietary
behaviours are shaped by a range of factors including cultural, societal and social
influences (Patrick & Nicklas, 2005, Hetherington, 2007) that may be difficult to
identify if one is solely reliant on quantitative data.

2.6.1 Focus group interview
Social research may be driven by theoretical positions and the data collected using
qualitative methodologies may be used to generate hypotheses (Harris et al., 2009). One
method of collecting qualitative data is the focus group interview. Focus groups
interviews are a group based interview, involving a small group of individuals who have
been purposively sampled (due to a shared experience or commonality), to answer a
series of open ended questions related to a particular phenomenon or experience and
encouraged to speak freely until all their views have been expressed (Harris et al.,
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2009). Focus group interview sessions are typically 45-90 minutes long (Wong, 2008).
This type of qualitative methodology is advantageous in that it utilises group dynamics
to generate discussion relating to a particular topic that may be less accessible for an
individual participating in a one on one interview. Such interviews are also important
platforms to identify non verbal communication that may be informative to the research
topic such as voice deflections, facial gestures and body language that may help drive
hypotheses or contextualise the information supplied (Kitzinger, 1995). To capture this
information, focus group interviews are recorded using an audio or visual device (Harris
et al., 2009). In addition, a trained observer or note taker may be present to detect and
record such non verbal communications and transcribe audio data obtained (Wong,
2008).

Focus group interviews require a skilled moderator to facilitate the discussion and lead
the sessions. The moderator has an important role in terms of guiding the discussion
through the use of probing questions so that all relevant areas of interest are addressed
and any ambiguities clarified (Krueger & Casey, 2000). The moderator is also
responsible for establishing a group dynamic whereby individuals feel comfortable to
freely express their thoughts and experiences, and may prompt more reserved
individuals to answer questions to ensure a balanced representation of opinions from the
group are attained (Wong, 2008).

The number of participants present within each focus group interview may vary, with
preferable group sizes of four to eight people described by Kitzinger (1995). However,
smaller groups such as those involving four to six individuals may be preferable
(Krueger & Casey, 2000) to facilitate group cohesion and ensure that all participants are
actively sharing their experiences (Wong, 2008). The number of focus group interviews
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required should be influenced by the level of saturation that has occurred from the data
obtained (Cameron, 2005). In the context of focus group research, data saturation refers
to a situation whereby no new opinions are being expressed and new ideas are no longer
being generated from group members (Krueger & Casey, 2000).

Whilst there are many advantages to the use of focus group interviews in nutrition
research, such interviews may be subject to bias. This may result from the presence of
dominant group participants who may influence the opinions of others or reduce their
likelihood of expressing an opposing opinion (Krueger & Casey, 2000). To reduce the
potential for bias, standardised methodology including the use of a pre-developed
interview schedule and a systematic method of data analysis guided by a solid
theoretical framework may maintain objectivity.

The study presented in chapter 7 specifically involves the use of focus group interviews
to seek to understand both consumer perceptions of dairy products and the impact of
nutrition education in shaping attitudes relating to these perceptions. Each focus group
interview was facilitated by a trained moderator in the presence of an observer to record
non-verbal communication. In addition, each focus group was recorded using a digital
recording device. Data from focus group interviews completed as part of this thesis was
obtained using a pre-developed interview schedule that was standardised to suit each
group. This schedule involved the use of a list of fixed questions (as included in chapter
7, figure 7.1) to ensure that opinions expressed between the groups were comparable.
Probing questions and directed discussions tailored specifically to each group were then
applied to ensure that the standardised schedule was flexible enough to suit the two
group types involved (Morgan, 1997).
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In addition to the use of a pre-developed interview schedule, a systematic method of
data analysis was employed. Data from each focus group interview was initially
transcribed verbatim, with transcripts entered coded thematically using NVivo
qualitative software (QSR International Pty Ltd, Melbourne, Australia). NVivo is a
program that has been widely utilised in the field of qualitative nutrition science
(Skinner, Hanning & Tsuji, 2006, Schryver & Smith, 2006 & Kafka et al., 2011) to
assist with the analysis of focus group interviews by enabling researchers to code key
quotes, identify pertinent themes and manage the large amount of data generated from
focus group interview transcripts (Hoover & Koerber, 2011).

2.6.2 Theoretical positions for social research
Outcomes from the focus groups completed within this thesis were contextualised using
concepts from the theory of planned behaviour (TPB). This theoretical framework was
chosen as it has been widely utilised to predict an individual’s likelihood of adopting a
particular behaviour. In particular, it has previously been utilised to predict behaviour
related to food choice (Åstrøsm & Rise, 2001) and has been validated to predict
consumption of dairy products specifically (Kim, Reicks & Sjoberg, 2003).
The TPB is an extension of the theory of reasoned action, by taking into consideration
an individual’s perceived self efficacy or sense of control to allow the performance of a
particular behaviour (Ajzen, 1991). The TPB implies that an individual’s intention to
perform a behaviour is influenced by their attitude towards adopting the behaviour, an
evaluation of the subjective norms or social influence of others who may
encourage/discourage such behaviour and an individual’s perception of the level of
control in their ability to adopt the behaviour (Ajzen, 1991).
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Shaping these attitudes are salient beliefs including behavioural beliefs (reflecting
attitudes towards the behaviour), normative beliefs (reflecting the social influences of
others relevant to the behaviour and an individual’s motivation to comply with such an
influence) and control beliefs (reflecting those beliefs which underlie the perceived
level of ease or difficulty one might experience towards adopting the behaviour) (Ajzen,
1991). A visual illustration of the relationship between the TPB and dairy product
consumption intentions and behaviour has been adapted from Kim, Reicks & Sjoberg
(2003) and Park & Ureda (1999) (Figure 2.2).

Figure 2.2. Relationship between the theory of planned behaviour and dairy
product intake behaviour (Adapted from Kim, Reicks & Sjoberg and Park & Ureda)

This thesis has utilized focus group interviews to evaluate the current beliefs
surrounding the position of dairy foods on health. Contextualising focus group findings
using the TPB ensures that the effectiveness of nutrition education as a vehicle to
translate dairy related research to practice may be evaluated. As the central hypothesis
for this thesis theorizes, the position of dairy foods in the diet is subject to consumer
89

behaviour. Thus it is imperative to include such an exploration of factors pertaining to
this behaviour in any body of work seeking to translate research outcomes to practice.

2.7 Concluding remarks
This chapter has outlined each of the key research frameworks that have been utilised in
the methodology for this thesis. An overview of the strengths and limitations of many of
the methods selected for use has been discussed, with a justification for use of particular
methods selected provided based on their appropriateness to the aims of both the
individual studies and the central thesis hypothesis. Further details as they relate to each
individual study will be provided within each chapter where relevant.
Overall, it is clear that a range of methods including the secondary analysis of RCT
data, dietary biomarkers of milk fat intake, secondary analysis of survey data,
nutrigenomic case control evaluation and social research are necessary to explore the
position of dairy products on health in both the obesity and CD contexts. The inclusion
of research methods that broadly address the relevant physiological, psychological and
genetic domains in relation to this core food group provide a comprehensive body of
knowledge to address the central thesis hypothesis.

It is anticipated that research outcomes resulting from the methodology of this thesis,
will be informative in terms of exposing the dietary position of dairy products in both
the CD and obesity contexts. However, perhaps more importantly, the methodology of
this thesis highlights the need to consider novel aspects such as nutrigenomic factors as
an adjunct to traditional nutrition research when seeking to expose the complexity of the
dietary position of a core food group. Finally, the incorporation of social research in
relation to dairy products highlights the potential for nutrition education to translate
complex theoretical findings into practice.
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Chapter 3. Dietary consequences of recommending reduced fat dairy products in the
weight loss context: a secondary analysis with practical implications for dietitians1

1

The study reported in this chapter was based on a secondary analysis of a weight loss trial funded by the
National Health and Medical Research Council, Australia (project grant #514631, Tapsell, Batterham and
Charlton, project name: is a higher intake of omega 3 fatty acids advantageous for weight loss?). The
preliminary outcomes of this chapter were presented at a plenary session at a scientific conference and the
manuscript has been submitted for consideration in a nutrition journal.
Journal Article (submitted)
A significant portion of this chapter has been submitted to the Journal of the American Dietetic
Association : Nolan-Clark D, Mathers E, Probst Y, Charlton K, Batterham M, Tapsell LC ‘Dietary
consequences of recommending reduced fat dairy products in the weight loss context: A secondary
analysis with practical implications for dietitians’.
DNC was responsible for the design of the study, organization and conduct of the study, data collection
and analysis, critical discussion of the analysis and preparation of the manuscript. EM assisted with data
analysis, YP, KC, MB and LT were involved with the critical discussions of the study design, critical
discussion of the analysis and revision of the manuscript.
Conference Abstract (Published)
Nolan, D. Tapsell, L., Probst, Y., Charlton, K. and Batterham, M 2010 ‘Dietary outcomes and
consequences of recommending low fat dairy products to overweight adults participating in a weight loss
trial’, Nutrition and Dietetics, 67(Suppl. 1), pp. 16 (oral presentation at the ‘Best of the Best’ plenary
session Dietitians Association of Australia National Conference, 29 May 2010, Melbourne, Australia)
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3.1 Introduction
Dairy products form an integral component of a balanced diet within many cuisine
contexts. This core food group is highly nutrient dense, and the greatest contributor of
dietary calcium to the Australian diet (McLennan & Podger, 1998a). However, dairy
foods are also a significant source of saturated fat for many individuals, contributing
over 30% of total dietary saturated fat for Australian adults (McLennan & Podger,
1998b). This is particularly pertinent given that saturated fatty acids have been reported
to increase LDL-cholesterol (Howell et al., 1997), a risk factor for coronary heart
disease (Grundy et al., 2004). Whole dairy products also have a significantly higher
energy content than their reduced fat counterparts (Smit et al., 2004). Given that weight
loss is contingent on the creation of an overall energy deficit through the reduction of
total kilojoule content largely irrespective of the type of food consumed (Hall, 2007),
reduced fat dairy products are generally recommended for overweight individuals.
On a population level, reduced fat dairy products are encouraged for Australian adults
to maintain an appropriate body weight (National Health & Medical Research Council,
2003). The Australian Guide to Healthy Eating recommends consumption of at least
two serves of preferably reduced fat dairy products per day to meet calcium
requirements (Kellet, Smith & Schmerlaib, 1998). However, individuals largely fail to
meet the recommended dietary intakes for calcium (McLennan & Podger, 1998a)
indicating that these dairy product serving targets are not being reached. Thus there
appears to be a gap between best advice and practice.
There is a paucity of literature detailing the feasibility, level of compliance and dietary
outcomes of dietetic advice to consume recommended amounts of reduced fat dairy
products in the weight loss context. This is of concern for dietetics professionals, who
routinely recommend reduced fat dairy products as standard practice in counselling
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overweight individuals, in order to maintain nutritional adequacy whilst reducing total
kilojoule intake. The implications of this advice can be examined in detail through
secondary analysis of comprehensive dietary trials in which this advice was given.
Data on individuals who have participated in a weight loss trial, inclusive of advice to
consume an appropriate quantity of reduced fat dairy products, provide a valuable
opportunity to evaluate the impact and feasibility of dietary recommendations to
consume reduced fat dairy products in the context of weight loss. Outcomes from the
utility of such data will be informative to dietitians, who routinely counsel overweight
individuals to consume reduced fat dairy products.
The aim of this study was to compare the amount, type and dietary contribution of dairy
products consumed by overweight adults at baseline and three months during
participation in a weight loss trial whereby recommendations to consume dairy products
to meet dietary requirement were given. A secondary aim was to determine whether
individuals complied with dietetic advice to consume a minimum of two to three serves
of reduced fat dairy products per day based on their individual dietary requirement.
3.2 Methods
A secondary analysis was conducted on baseline and three month dietary data acquired
from a 12 month weight loss trial (The ‘Smart’ study, described in more detail in
chapter 2, section 2.2.2), which examined the effect of dietary omega 3 fatty acids on
weight loss and other metabolic outcomes. This time period was selected to maximise
the sample size available for generating meaningful results due to the high number of
participant withdrawals from the ‘Smart’ trial (n=54) throughout the 12 month time
period.
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During the weight loss trial, participants received intensive dietetic intervention (six
nutrition education sessions with qualified dietitians in addition to written education
resources), to manipulate intakes of fish, omega-3 fatty acids or reduce total
fat/kilojoule intake in the case of controls. All participants were encouraged to consume
a background diet that complied with the Australian Guide to Healthy Eating (Kellet,
Smith & Schmerlaib, 1998), with consumption of either two or three serves of reduced
fat dairy products per day prescribed depending on their individual energy requirement.
Participants were given specific instructions regarding what was considered a serving size of
milk (250ml), cheese (30g) and yoghurt (200g) and advised to minimise cheese intake due to

its high kilojoule and fat content. A written educational resource describing how target
dairy product intakes may be achieved was also provided. As cream and ice cream are not
core foods, participants were not given specific advice regarding serving sizes of these foods but
intake of these foods was discouraged as was intake of high energy and high fat items from
other food categories.

The original study was approved by the University of Wollongong Human Research
Ethics Committee and all participants provided written informed consent forms prior to
commencement. Access to the data for this secondary analysis met ethical approval and
all information utilised was coded to protect participant anonymity.
Diet history interview data from the weight loss trial collected by Accredited Practising
Dietitians using a validated tool (Martin et al., 2003), was entered into FoodWorks
nutrient analysis software (Version 5, Xyris Software, Highgate Hill, QLD, 2007), using
the ‘AUSNUT1999 All Foods’ and ‘AUSbrands 1999’ databases (Food Standards
Australia and New Zealand, 1999). Nutrients contributed from dairy foods that were
compared at baseline and after three months of dietary intervention included energy
(kJ), total fat (g), total saturated fat (g), available carbohydrate (g) and calcium (mg).
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The total amount (or weight in grams) of dairy products consumed was also estimated at
both time points. Nutrient data was exported into Microsoft Excel (Microsoft Office
Inc., 2007) and dairy product intake data used for analysis in this study was identified
visually by an Accredited Practising Dietitian and cross checked by another dietitian to
ensure no dairy product items reported in the diet history interviews were missed in the
categorisation. Anthropometric and demographic data from baseline was obtained from
the weight loss trial database including age (years) and BMI (kg/m²).
Dairy products were categorised into the following groups: ‘dairy milk’, ‘yoghurt’,
‘cream’, ‘cheese’, ‘frozen milk products’ and ‘other dishes where milk or a milk product
is the major component’ according to the food grouping hierarchy utilised in the
National Nutrition Survey (McLennan & Podger, 1998a). In contrast to the National
Nutrition Survey, data for milk substitutes such as soy products reported to be
consumed by participants in this study were excluded from analysis. Flavoured milk
was grouped with ‘dairy milk’ due to the limited consumption of items fitting within
this category. For milk and cheese, food intake was further sub-divided into full fat and
reduced fat categories.
The amount of dairy products in tea, coffee, pizza and cheeseburgers was included in
the analysis. As this involved extracting data from a combined food source, several
methods were used to estimate the amount of dairy products contributed by these
sources.
For tea and coffee the amount of milk in these beverages was estimated and added to the
‘dairy milk’’ category using the protocol outlined in Figure 3.1. It was assumed that all
of the calcium from tea/coffee was contributed from milk.
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1. Identify the type of milk added to tea and coffee for each case

2. Determine weight of a known volume of specified milk using FoodWorks
eg. 250ml skim milk weighs 260g

3. Calculate amount of calcium contained per gram of that milk using values
provided by FoodWorks
eg. 260g skim milk provides 319.8mg of calcium, thus there are 0.813g of skim milk
for every 1mg of calcium

4. Calculate amount of milk in hot beverage using the amount of calcium contained
within it as listed by FoodWorks
Eg. 200mg of calcium within a beverage x 0.813g milk/mg calcium = 162.g of skim
milk within that beverage
Figure 3.1. Method for estimating amount of milk contained within hot beverages

A similar process was utilised to determine the amount of cheese contained within
pizzas. The calcium content of three commonly reported pizza brands in the sample
(Domino’s, Pizza Hut and McCain frozen pizzas) was identified from the diet history
interview data using FoodWorks. The total amount of calcium contributed per gram of
cheese was calculated so that the amount of calcium in the pizza varieties was used to
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estimate the amount of cheese in the pizza. The total weight of cheese estimated to be
within a standard slice of pizza was then divided by the total weight of the slice to
determine the percentage contribution of the cheese to the weight of the pizza.
Following this method an analysis of three popular pizzas (Hawaiian, cheese lovers and
supreme) indicated that cheese contributed on average 20% of the total weight of a
pizza. This calculation was then applied to estimate the total weight of cheese
contributed by all pizzas reported to be consumed in the diet history interviews.
Cheeseburgers were also considered a contributor to dairy products in the study
sample. For commercial burgers of specified variety, nutrition information was sought
to ensure the correct amount and type of cheese was used. For cheeseburgers lacking
detailed nutritional information, 1 slice (or 21g) of full fat cheese was utilised to
approximate the amount added to a hamburger with cheese.
Mixed dishes containing small amounts of dairy products such as mashed potato made
with milk and bakery products were not included in the analysis due to their negligible
contribution to total dairy product intake and the difficulty in accurately quantifying this
amount.
3.2.1 Compliance with meeting prescribed number of serves of dairy products
To measure participants’ compliance with meeting the number of serves of dairy
products prescribed as part of the weight loss trial, a database with each individual’s
baseline estimated energy requirement was accessed. All estimated requirements were
calculated using the Mifflin St Jeor Equation, a widely validated formula for estimating
energy requirements in overweight populations (Mifflin et al., 1990). Dietary
prescriptions were modelled in 500kJ increments, with recommendations of either two
to three dairy product serves daily given to participants based on their energy
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requirements, e.g. individuals requiring >7.5MJ/day were generally three serves. The
prescribed amount of dairy food for each participant was identified and compared with
reported dairy product intake data from the diet history interviews. The number of dairy
product serves in each participant’s diet was estimated by dividing the total calcium
contributed from dairy products by a factor of 300, assuming one dairy product serving
contained 300mg of calcium. This method was utilised by Fulgoni et al. (2004) in a
study evaluating dairy food intake.
3.2.2 Statistical analysis
Total macronutrient and categorised dairy product intake data was exported from
Microsoft Excel to SPSS (V15.0 1989-2006, SPSS Inc., Chicago II, USA) for statistical
analyses. The Shapiro-Wilk test was performed to assess the normality of data, and log
transformations for all non-parametric data were performed. Based on the
transformation outcome either Paired t tests or Wilcoxon signed ranks tests were
employed to assess statistical differences between the amount and type of
macronutrients and dairy products consumed at baseline and three months. Data was
considered significant at the alpha <0.05 level.
3.3 Results
One hundred and eighteen participants were enrolled in the original weight loss trial at
baseline. Participants who withdrew from the trial prior to the completion of a diet
history interview at three months were excluded from the analysis, leaving a total of
n=86 participants remaining. Participants were on average, aged 45.2±8.8 years,
predominantly female (73.2%) and obese at baseline, with a mean BMI of
31.1±3.4kg/m². As expected, total dietary energy, fat and carbohydrate intake
significantly reduced following three months of the weight loss intervention (Table 3.1).
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Table 3.1. Total key macronutrients and dairy products consumed per day for all
participants at baseline and 3 months
Baseline
(Mean±SEM)
Group (n= 86)

3 Months
(Mean±SEM)

P Value

9707.9±320.5
90.1±3.7
238.3±8.6

6534.0±154.2
45.8±1.7
174.3±4.3

0.00*^
0.00*^
0.00*^

338.6±29.3
1185.2±84.2
14.1±1.2
22.6±1.5
17.3±1.3
553.9±42.9
Males (n= 23)

332.4±19.1
933.5±59.1
5.8±0.6
27.6±2.2
15.6±0.8
513.6±28.4

0.25^
0.00*^
0.00*^
0.04*^
0.91^
0.98^

Weight (g)
Energy (Kj)
Fat (g)
Carbohydrate (g)
Protein (g)
Calcium (mg)

377.6±62.3
1395.6±214.5
17.8±3.5
25.0±3.0
16.5±2.9
636.9±96.2
Females (n= 63)

357.3±46.8
902.6±122.5
4.6±0.9
25.9±3.9
17.2±2.2
576.9±75.0

0.00*†
0.01*†
0.00*^
0.79^
0.90^
0.00*^

Weight (g)
Energy (Kj)

324.3±33.1
1108.4±83.3

323.3±19.8
944.8±67.7

0.33^
0.05^

Total Macronutrient Intake
Energy (kJ)
Fat (g)
Carbohydrate (g)
Dairy Product Contribution
Weight (g)
Energy (Kj)
Fat (g)
Carbohydrate (g)
Protein (g)
Calcium (mg)
Dairy product Contribution

12.8±1.1
6.2±0.7
Fat (g)
21.8±1.8
28.2±2.7
Carbohydrate (g)
15.1±0.8
16.5±1.5
Protein (g)
523.6±46.8
490.5±27.4
Calcium (mg)
*p value <0.05, †Paired t test ^Wilcoxon signed ranks test

0.00*^
0.03*^
0.95^
0.99^
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3.3.1 Changes in dairy food intake
The total weight of dairy products consumed per day did not differ significantly from
baseline for the whole group following three months of dietetic intervention. However
total fat and kilojoules from dairy products were significantly lower at three months
compared to baseline intakes, whilst carbohydrates provided from dairy products
significantly increased (Table 3.1). At baseline, dairy products contributed 12.2%,
15.6% and 9.4% of total dietary intakes of energy, fat and carbohydrates, respectively.
Following the intervention, the relative contribution of dairy foods to total energy and
carbohydrate intake increased (at 14.3% and 15.8% for energy and carbohydrate,
respectively), whilst the amount of fat contributed by dairy foods decreased to
contribute 12.7% of total dietary fat intake.
When analysed by gender, males consumed significantly less dairy products per day
compared to baseline (p=0.00), and a reduced energy and calcium contribution from
dairy products was observed following the dietetic intervention. In contrast, there was
no significant difference in the amount of dairy products consumed per day by females
(p=0.33). Whilst the total fat consumed from dairy products for females was
significantly lower than baseline measures (p=0.00), energy contributed from dairy
foods did not change significantly (p=0.05) and carbohydrate from dairy products
increased from 21.8g±1.8g to 28.2g±2.7g (p=0.03).
3.3.2 Changes in types of dairy product consumed
Consumption of all cheese and full fat cheese decreased significantly from baseline at
the three month time period (Table 3.2), whilst yoghurt consumption increased
significantly (p=0.00). Total milk (p=0.00) and reduced fat milk (p=0.03) consumption
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increased significantly, whereas full fat milk (p=0.00) and frozen dairy (p=0.00)
consumption significantly decreased from baseline to three months.
Table 3.2. Dairy food categories consumed for all participants at baseline and
three months (n=86)
Baseline

3 Months

(Mean±SEM)

(Mean±SEM)

All Cheese (g)

23.1±2.5

8.9±1.7

0.00*^

Whole cheese (g)

17.1±2.0

4.8±1.6

0.00*^

Reduced fat cheese (g)

6.3±1.3

4.3±0.8

0.49^

Yoghurt (g)

40.9±5.2

103.4±9.3

0.00*^

All Milk (g)

106.5±23.3

204.7±16.3

0.00*^

Whole milk (g)

101.9±23.4

8.9±3.3

0.00*^

Reduced fat milk (g)

148.0±20.6

195.8±16.2

0.03*^

Frozen dairy (g)

19.1±3.4

7.0±1.9

0.00*^

Other milk dishes (g)

2.4±1.5

3.5±2.7

0.65^

Cream (g)

1.6±0.5

3.4±2.6

0.08^

P value

*p value <0.05 ^Wilcoxon signed ranks test.
3.3.3 Participant compliance with individualised dairy food prescription
From the n=86 participants in the study sample only n=17 (19.7%) were meeting or
exceeding the number of reference units of dairy products that they had been prescribed
according to their individual energy requirement at the three month time point (Figure
3.2). Twenty four participants (27.8% of the total sample) were prescribed a total of
three serves of dairy products per day of whom only four (16.7%) either met or
exceeded this recommendation. Of the remaining n=62 participants who were
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prescribed two serves of dairy products per day in accordance with their energy
requirements, only n=13 (20.9%) either met or exceeded this recommendation. This
decreased from the proportion of participants who were meeting their recommended
number of serves at baseline (n=26 or 30.2%).
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Number of Participants

70
60
50

Meeting Recommended
dairy product unit*
servings
Not meeting
recommended dairy
product unit* servings
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0

Baseline

3 Months
Time

Figure 3.2. Participants meeting the number of prescribed dairy product unit*
serves
*One unit serve = amount of dairy products that provides 300mg calcium
3.4 Discussion
This study demonstrated that recommending reduced fat dairy products effectively
decreased the consumption of fat contributed from these foods following three months
of intensive dietetic intervention. Men and women appeared to take on advice about
reduced fat dairy product consumption differently. Men tended to decrease their overall
intake of dairy foods when advised to choose low fat variants, whilst women replaced

102

whole fat dairy products with reduced fat alternatives with no net reduction in kilojoules
from this food group.
This data is consistent with findings by Collins et al., (2011) whereby men participating
in a weight loss trial decreased milk consumption overall rather than change to reduced
fat dairy products. Males have also been reported to have a greater frequency of
consumption of whole milk products in comparison to females (Fagerli & Wandel,
1999). This discrepancy may reflect differing motivations driving food choice between
the genders. In a 23 country study, Wardle et al. (2004) reported that males place less
importance on healthy eating in comparison to females and that they prioritise taste and
convenience over health aspects when making food choices. Whilst evidence is
conflicting, an overall reduction in dairy product intake observed for males may be
particularly problematic in the weight loss context, as a daily intake of 1000mg of
calcium from dairy products was demonstrated by Jacobsen et al. (2005) to increase
faecal energy excretion by 350Kj/day, which may have a significant effect on weight
loss over a long period of time.
The lack of a net reduction in energy consumed from dairy products in women may be
explained in part by the observed increase in carbohydrates contributed from these
foods. Data from this study suggest that some of the energy from dairy fat has been
replaced with carbohydrate, potentially through increased consumption of higher
carbohydrate dairy products such as yoghurt. Whilst the increase in carbohydrate from
dairy foods observed for women was relatively small, it is an important consideration in
the current nutrition climate whereby reduced fat replacements are recommended across
a range of food groups with potentially additive effects. This may be particularly
pertinent in the weight loss context as recent reviews have questioned the long held
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relationship between dietary fat consumption and both the metabolic syndrome
(Melanson, Astrup & Donahoo, 2009) and cardiovascular disease (Siri-Tarino et al.,
2010) and dietary substitution of saturated fat with carbohydrates has been reported to
increase the risk of ischemic heart disease in a pooled analysis of cohort studies
(Jakobsen et al., 2009). Overall, findings from this study reflect the need to consider
the impact of gender when providing dietetic advice to consume reduced fat dairy
products.
3.4.1 Changes in types of dairy products consumed
Of all the dairy products categorised, milk was consumed in the largest quantity at both
time periods, consistent with findings from the 1995 National Nutrition Survey
(McLeannan & Podger, 1998a). Intake of all milk, including reduced fat milk varieties,
increased significantly over the study duration which indicates the acceptability of this
dietary advice. Participants were compliant with advice to reduce consumption of
cheese and when data was further categorised into full fat and low fat cheese; low fat
cheese intake did not significantly increase for the group. It may be that cheese
consumed prior to the dietetic intervention was contributed from high fat products such
as pizza and cheeseburgers. Thus reduction in cheese without a concurrent increase in
reduced fat cheese intake may reflect adoption of overall dietetic advice to consume
meals low in fat rather than a conscious effort on the participant’s behalf to avoid
specific foods such as cheese. The increase in yoghurt consumption observed may have
contributed to the increase in carbohydrates from dairy products observed following the
intervention.
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3.4.2 Compliance with dairy product recommendations
Overall the majority of the study sample did not meet the minimum number of reference
units of dairy products that they were prescribed according to their individual energy
requirement. This is of particular concern as these prescriptions are quite low given that
dairy products are the greatest contributor of calcium to the Australian diet (McLennan
& Podger, 1998a) and Australian nutrient reference values recommend consumption of
at least 1000mg calcium per day for adults (Department of Health and Ageing/National
Health and Medical Research Council, 2005).
Unexpectedly, the number of unit serves of dairy products estimated to be consumed
per day by participants decreased following dietetic intervention. This may reflect the
difficulty experienced by many individuals in meeting nutritional requirements during
periods of energy restriction (Ashley et al., 2007). To ensure adequate intakes of
calcium, future weight loss trials may consider the incorporation of calcium fortified
dairy products. However, dairy products contribute an array of nutrients in addition to
calcium, thus encouraging adequate intake of this food group should remain the priority.
This may be particularly pertinent in a weight loss trial where dairy products may be
unnecessarily restricted due to their reported perception as being weight inducing
(Eddy, Brochetti & Duncan, 1999).
The failure of participants to meet recommended intakes of dairy products may also be
explained from a food pattern perspective, whereby individuals were consuming a
significant amount of dairy products through ingestion of high energy products such as
pizza, ice cream and cream based sauces. Participants consumed slightly more dairy
products at baseline; with a mean reported intake of 338.6±29.3g/day, in comparison to
the average Australian adult, at 290g/day (Australian Bureau of Statistics, 1997). Thus
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dietary advice to limit such foods during weight loss trial participation may have
inadvertently reduced dairy product intake. The contribution of these foods to total dairy
product intake may be an important consideration for dietitians when introducing a
weight loss dietary protocol to ensure optimal dairy product intake. Individualised
advice regarding cooking methods and brand names of appropriate dairy products
available may also assist to facilitate dietary change in this area (Kapur et al., 2008).
3.5 Limitations of Study
This study provided insight into the dietary consequences of recommending reduced fat
dairy foods within a weight loss context; however several limitations need to be
acknowledged in the interpretation of results. The weight loss trial from which the data
for this study was derived, was not designed to evaluate changes in the intake of dairy
foods specifically, however general advice to consume a minimum of 2-3 serves of
dairy products per day was provided. As this general advice is likely reflective of
dietetic advice that the general public may receive, this study provided a valuable
platform to assess behaviour in relation to dairy product intake in the weight loss
context. In addition, the results reflect only a sample population of individuals
participating in a weight loss trial and are thus not reflective of the general population.
However the findings reported may facilitate a greater understanding of the feasibility
of overweight individuals adopting dietary recommendations in relation to dairy food
during conditions of energy restriction.
The reliance on self-reported data via the diet history interview was a further limitation
of this study as the information provided by participants may be subject to social
desirability bias (Schoeller, 1995). Under-reporting of food intake is known to be
common in overweight individuals (Johansson et al., 1998). To overcome this potential
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bias in future studies, the use of validated fatty acid biomarkers of habitual dairy fat
intake, pentadecanoic acid (15:0) and heptadecanoic acid (17:0) (Wolk, Furuheim &
Vessby, 2001), may provide objective measures of intake and thereby reduce reliance
on self-reported dietary practices. Finally, this study calculated one serve of dairy food
as a 300mg calcium equivalent. This may have been too crude an estimation, as the
calcium content of dairy products may vary widely.
3.6 Conclusion
Individuals participating in a clinical weight loss trial successfully reduced total fat
intake from dairy products following three months of dietetic intervention inclusive of
advice to consume reduced fat dairy foods. A gender difference was identified in the
way in which dietary advice to substitute reduced fat dairy products for regular varieties
was applied. Men tended to reduce the total amount and energy contribution of dairy
products overall, whilst women increased the consumption of carbohydrate from dairy
products without a concurrent reduction in energy. Consumption of reduced fat milk
and yoghurt significantly increased, and cheese consumption decreased, but this was at
the expense of a greater proportion of participants being unable to meet their
recommended number of dairy product serves during the intervention.
From a behavioural perspective, this study indicated that men and women may respond
differently to advice to change from regular to reduced fat dairy products. Of more
concern however, is that in a weight loss context, both men and women may choose to
consume even less of this food category with significant nutritional implications.
Overall, outcomes from this study highlight the many complexities associated with
providing standardised advice with regard to dairy products in the weight loss context.
The efficacy of advice to consume reduced fat dairy products as part of a dietary
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strategy to facilitate weight loss depends largely on consumer behaviour and personal
preferences as theorised in the central hypothesis. Thus, it is prudent to evaluate the
positioning of dairy fat per se on metabolic parameters to determine whether full fat
dairy foods may be an appropriate alternative for individuals unwilling to select reduced
fat alternatives.
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Chapter 4. Biomarkers of milk fat intake are not associated with poorer metabolic
profiles in an overweight adult sample1

1

The dietary intake data reported in this chapter was based on a secondary analysis of a weight loss trial
funded by the National Health and Medical Research Council, Australia (project grant #514631, Tapsell,
Batterham and Charlton, project name: is a higher intake of omega 3 fatty acids advantageous for weight
loss?). Funding for the fatty acid analyses was provided by the small grants scheme, from the Smart
Foods Centre, University of Wollongong, Australia (Tapsell, Nolan, project name: analysis of baseline
dairy product intake from a sample of overweight adults participating in a weight loss trial using whole
blood fatty acid biomarkers). The preliminary outcomes of this study were presented as both an oral and
poster presentation at two national conferences
Conference Abstracts:
Nolan, D., Tapsell, L., Charlton, K. and Batterham, M 2009, ‘Baseline Dairy Food intake is associated
with more favourable metabolic profiles in overweight females but not males participating in a weight
loss trial’, Australian and New Zealand Obesity Society Conference Proceedings, 23-25th October 2009,
Melbourne, Australia (poster)
Nolan, DJ., Probst YC, Charlton KE, Batterham MJ, Tapsell, LC 2010 ‘Biomarkers of milk fat intake
and metabolic risk factors in overweight adults participating in a weight loss trial’, proceedings from
Nutrition Society of Australia, Annual Scientific Meeting, 1st December 2010, Perth, Western Australia
(oral presentation).
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4.1 Introduction
Full cream dairy products contribute a significant amount of saturated fat to the dietary
intakes of many Western cultures. Total dietary and saturated fat intake has
traditionally been implicated as a key factor associated with an increased risk of
developing aspects of the metabolic syndrome (Riccardi, Giacco & Rivellese, 2004, Hu
et al., 1997) – a term used to describe individuals possessing several cardiovascular risk
factors such as obesity, insulin resistance, hypertension and hyperlipidemia (Huang,
2009). In particular, substitution of whole milk with skim milk has been proposed to
reduce coronary heart disease risk by 14% in males, following results from a small
short-term cross-over dietary intervention (Steinmetz et al., 1994).
General acceptance of this hypothesis has resulted in widespread public health
recommendations to consume reduced fat dairy products (National Health & Medical
Research Council, 2003, United States Department of Agriculture, 2010 & Health
Canada, 2007) and has seen some full cream dairy products, particularly cheese,
positioned negatively in nutrition profiling systems adopted in the United States of
America (United States Department of Health and Human Services, 2002) and across a
range of other Western countries (Tritcherborn, Harzer & Kunz, 2011).
More recently however, the relationship between dairy fat intake and the metabolic
syndrome has been questioned. Higher dairy product intake (inclusive of full fat
varieties such as cheese) was associated with a reduced incidence of the metabolic
syndrome in a nine year follow up study involving data from the French
Epidemiological Study on the Insulin Resistance Syndrome (Fumeron et al., 2011). A
similar protective effect of dairy foods was observed by Lutsey, Steffen & Stevens
(2008), who reported a 13% metabolic syndrome risk reduction for individuals in the
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highest quintile of dairy food intake. In addition, Elwood et al. (2010) reports that
many of the observational studies suggesting a protective role for dairy foods in the
prevention of diabetes and vascular disease were completed prior to the widespread
introduction of reduced fat varieties, further suggesting that dairy fat may not be as
atherogenic as previously believed. Thus there appears to be an inconsistency between
evidence and public health advice.
A possible explanation for the lack of consensus in the dairy fat and metabolic
syndrome disease relationship may relate to the utilisation of self-reported dietary intake
data. An increase in awareness of healthy eating patterns as a result of advertising and
nutrition education may exacerbate bias associated with self-reported dietary intake
methodology such as diet history interviews (Johansson et al., 1998). Underreporting of
dietary intake is common (Rennie et al., 2006), particularly in overweight populations
(Bailey et al., 2007) and the FFQs widely used in large prospective studies are limited
by nature in their ability to capture all food varieties consumed (Rutishauser, 2005).
Valid objective measures of dairy intake are therefore vital to address issues associated
with self-reported dietary intake data such as memory bias, over and under reporting
and issues with methodological tools utilised to acquire dietary data (Trabulsi &
Schoeller, 2001). Such objective methods of estimating dietary intake may be found
through the use of nutritional biomarkers which have been validated to estimate intakes
of particular nutrients or food groups.
The fatty acids 15:0 and 17:0 are synthesized by ruminant bacteria (Wu & Palmquist,
1991) and are unable to be endogenously produced by humans (Wolk et al., 1998). In
light of these facts, concentrations of 15:0 and 17:0 have now been validated to reflect
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habitual milk fat intake in adipose tissue (Wolk et al., 1998), plasma, erythrocytes (Sun
et al., 2007) and whole blood samples (Baylin et al., 2005).
Evaluation of the association between milk fat intake and metabolic profiles using
validated biomarkers has not been conducted in the Australian context. This is of
concern, given the high prevalence of the metabolic syndrome within Australian adults,
coupled with a relatively high intake of milk fat. A recent study indicated that up to one
in three Australian adults, aged over 25 years may have the metabolic syndrome
(Cameron et al., 2007), whilst latest available National Nutrition Survey data indicates
that dairy fat contributed 30% of the total dietary saturated fat intake of Australian
adults (McLennan & Podger, 1997b). Exploring this phenomenon using both
biomarkers and self-reported dietary intake data will reduce possible sources of error
associated with using these tools in isolation.
Opportunities to analyse the relationship between biomarkers of milk fat intake and
disease profiles are likely to be limited, but they exist in smaller studies such as clinical
trials where accurate data on dietary intakes and blood fatty acid compositions are
available. Whilst utilising data from a clinical trial may limit the ability to extrapolate
study outcomes to the wider population, such a strategy will provide insight that may
guide future research in this important area. Thus, the aim of this study was to
determine whether dairy fat intake, as measured by both diet history interview and
whole blood concentrations of 15:0 and 17:0, is associated with adverse metabolic
profiles in a sample of overweight adults participating in a weight loss trial.
4.2 Methods
Data was made available from a twelve month clinical weight loss trial in Wollongong,
Australia, where participants were advised to consume defined amounts of dairy foods
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as part of a healthy diet. Further details on the clinical trial from which the participants
were drawn from can be found at www.anzctr.org.au, (ACTRN12608000425392).
The study reported here was a cross-sectional analysis of baseline whole blood fatty
acid concentrations, dietary intake data and clinical data. Baseline metabolic profile
data including weight, BMI , umbilicus circumference, hip circumference, waist to hip
ratio, fasting blood glucose, total cholesterol, serum triglycerides, HDL cholesterol,
LDL cholesterol, total cholesterol:HDL cholesterol ratio, fasting insulin, systolic blood
pressure, diastolic blood pressure and percentage body fat using dual-energy x-ray
absorbtiometry (DEXA) were acquired from the clinical trial database.

As participants had already consented to fatty acid analyses in the original trial,
additional ethical approval was not required. The original weight loss trial was approved
by University of Wollongong Human Research Ethics Committee.

4.2.1 Fatty acid analyses
Fatty acid analyses were completed in May 2010 at the laboratory of the Functional
Food Group, School of Agriculture, Food and Wine at the University of Adelaide.
Initially 0.5ml whole blood samples were mixed with 0.9% saline and 2ml of AR
Isopropanol. Samples were then centrifuged for 10 minutes at 3000rpm (using Heraeus
Sepatech Magafuge 1.0), and the organic phase removed. The samples were evaporated
to dryness using a vacuum concentrator and analysed using a gas chromatograph
(Hewlett Packard 6890 Gas Chromatograph with a SGE BPx70 column and a Flame
Ionisation Detector). Fatty acids were listed as the percentage concentrations of 15:0
and 17:0 of the whole blood samples.
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4.2.2 Analysis of dietary intake
Diet history interview data collected at baseline by Accredited Practising Dietitians
using a validated tool (Martin et al., 2003), was entered into FoodWorks nutrient
analysis software (Version 5, Xyris Software, Highgate Hill, QLD, 2007), using the
‘AUSNUT1999 All Foods’ and ‘AUSbrands 1999’ databases (Food Standards Australia
and New Zealand 1999). Dairy products including milk, yoghurt, cream, cheese, frozen
milk products and butter were identified and included in the analysis, with the methods
developed in chapter 3 utilised for estimating the milk contained within items such as
tea, coffee, cheeseburgers and pizzas. The total weight (g) of dairy products reported to
be consumed and the total fat (g) contributed by this food group was calculated for each
participant.

4.2.3 Statistical analyses
All statistical analyses were completed using SPSS statistical software package (V15.0
1989-2006, SPSS Inc., Chicago II, USA). The Shapiro-Wilk test was performed to
assess the normality of data, and log transformations for all non-parametric data were
performed. Descriptive statistics including mean ± standard deviation (SD) and inter
quartile range (IQR) for non parametric data, were calculated for metabolic variables,
and biomarker concentrations. Associations between metabolic profiles, dietary intake
of dairy fat and biomarkers were assessed using Pearson’s correlation coefficient.
Pearson’s parametric partial correlations (or its non-parametric equivalent) were
conducted to assess the association between metabolic profiles, dairy fat intake and
biomarkers controlling for BMI, age and smoking status. Data was considered
significant at the alpha <0.05 level. As this was an exploratory study corrections for
multiple testing were not applied.
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4.3 Results
Blood samples, metabolic profile data and dietary intake information were available for
n= 69 adults enrolled in the clinical weight loss trial. Participants were predominantly
female (n=56) and aged 45.3±7.7 years. Subject metabolic characteristics from this
sample are listed in Table 4.1.

Table 4.1. Baseline metabolic profiles of participants (n=69)
Metabolic Variable

Mean±SD/Median(IQR)

Weight (kg)

87.95±11.62

Body Mass Index (kg/m²)

31(28.7-34.8)

Umbilicus Circumference (cm)

103.3 (97.4-111.2)

Hip Circumference (cm)

109 (101-120)

Waist to hip ratio

.950 (.91-1.0)

Blood Glucose† (mmol/L)

5.1 (4.7-5.4)

Total Cholesterol† (mmol/L)

5.084±0.822

Triglycerides† (mmol/L)

1.4 (.99-1.93)

HDL Cholesterol (mmol/L)

1.35 (1.2-1.6)

Total Cholesterol: HDL Cholesterol†

3.818±1.13

LDL Cholesterol†(mmol/L)

2.97±0.833

Insulin †(m/uL)

10.7 (8.6-17.1)

Leptin†(ng/ml)

22.3 (13.5-30.9)

Systolic Blood Pressure (mm/Hg)

121.3 (112.7-131.7)

Diastolic Blood Pressure (mm/Hg)

71.77±8.91

DEXA (% body fat)

40 (31-43)

†

Indicates fasted sample
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Diet history interview data revealed that participants were consuming 360.8±234.9g/day
of total dairy products, with a total dairy fat intake of 16.2±9.9g/day. The amount of
15:0, 17:0 and 15:0+17:0 contained within the blood samples (expressed as a percentage
of the whole blood sample) were 0.27±0.43%, 0.31±.045% and 0.58±.080%
respectively. Biomarkers of milk fat intake were significantly correlated with total
intake of dairy products and consumption of fat from dairy food (Table 4.2), with
concentrations of 15:0+17:0 displaying the strongest association with reported milk fat
intake (Figure 4.1).

Table 4.2. Associations between reported intakes of dairy products/dairy fat with
biomarkers of milk fat intake (n=69).
15:0

17:0

15:0+17:0

Total intake of dairy

r = .357**

r = .386**

r = .415**

products

p = .003

p = .001

p = .000

Total fat from dairy

r = .378**

r = .378**

r = .421**

products

p = .001

p = .001

p= .000

**Significant at p<0.01, r = Pearson’s correlation coefficient

Correlations between concentrations of 15:0, 17:0 and 15:0+17:0 and self-reported
intakes of both dairy products and fat from dairy products indicated that there were no
associations between these biomarkers of milk fat and an adverse metabolic profile,
with some small favourable associations identified (Table 4.3).
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Figure 4.1 Scatter plot of correlation between self-reported intakes of dairy fat and
whole blood concentrations of 15:0+17:0 (using log transformed dietary data).
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Table 4.3. Associations between biomarkers of milk fat intake and self-reported
dairy product and dairy fat intakes with baseline metabolic profiles
Metabolic Variable
(n=69)

-.041
-.116

-.135
-.283*

-.103
-.226

Reported
dairy
product
intake
r
-.049
-.025

-.250*

-.247*

-.270*

-.069

.125

-.249*

-.199

-.245*

-.049

-.179

-.092
-.001

-.239*
-.093

-.167
-.056

-.045
-.149

.206
-.089

.226

.026

.132

.057

.106

-.111
.136

-.238*
.109

-.200
.136

-.083
.070

-.023
-.089

.001

-.079

-.047

-.025

.105

.186

.060

.132

.037

.161

.005
.010
.119

.060
-.061
-.107

.039
-.073
-.001

-.075
-.006
-.337**

.082
-.016
.141

.143

-.168

-.012

-.303

-.002

-.173
-.200
DEXA (% body fat)
†
Indicates fasted sample, *p <0.05, **p<0.01

-.219

-.163

-.109

Weight (kg)
Body Mass Index
(kg/m²)
Umbilicus
Circumference (cm)
Hip Circumference
(cm)
Waist to hip ratio
Blood Glucose†
(mmol/L)
Total Cholesterol†
(mmol/L)
Triglycerides† (mmol/L)
HDL Cholesterol
(mmol/L)
Total Cholesterol: HDL
Cholesterol†
LDL
Cholesterol†(mmol/L)
Insulin †(m/uL)
Leptin†(ng/ml)
Systolic Blood Pressure
(mm/Hg)
Diastolic Blood
Pressure (mm/Hg)

15:0
r

17:0
r

15:0+17:0
r

Reported
dairy fat
intake
r
.123
.056

After controlling for BMI, age and smoking status, some of the favourable associations
were attenuated, with the exception of 15:0 with umbilicus and hip circumference (r=.291, p =.018 and r=-.285, p=.021 respectively), and17:0 and BMI (r=-.287, p=.018)
and total dairy product intake and systolic blood pressure (r=-.355, p=.004).
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4.4 Discussion
This study aimed to explore whether adverse metabolic profiles were associated with
milk fat intake in an opportunistic sample of overweight adults. Self-reported intakes of
dairy products were higher than the latest reported intakes for Australian adults aged
≥19 years, which were 320g/day and 260g/day for males and females respectively
(Australian Bureau of Statistics, 1997). As the study sample consisted of overweight
individuals, intakes of major food groups such as dairy products may be higher than the
national average.

Significant correlations between self-reported intakes of both dairy products overall and
fat from dairy products with biomarkers of milk fat intake were observed, suggesting
that whole blood biomarkers may be a useful adjunct to traditional dietary assessment
tools seeking to estimate milk fat intake. Whole blood concentrations of 15:0+17:0
correlated most strongly with reported milk fat intakes in comparison to either 15:0 or
17:0 alone. This is in contrast to observations for serum and adipose tissue reported by
other studies (Wolk, Furuheim & Vessby, 2001, Sun et al., 2007), whereby
concentrations of 15:0 correlated most significantly to intakes of milk fat. This
discrepancy may reflect the utility of a validated diet history to acquire habitual dietary
intake in contrast to the use of the FFQ and 24 hour recall reported in the aforemetioned
studies (Wolk, Furuheim & Vessby, 2001, Sun et al., 2007).

Findings from this exploratory study indicate that milk fat intake, as measured by 15:0,
17:0 and diet history interview data, was not associated with adverse metabolic profiles
and there were some indications of desirable metabolic profiles associated with intake
of milk fat and dairy products in general. These findings are in agreement with a
growing body of literature which suggests that intakes of this food group may be
119

associated with either neutral or favourable effects on a variety of metabolic profiles.
Aslibekyan, Campos & Baylin (2011) reported that milk fat intakes as measured by
15:0, 17:0 and FFQs were not associated with an increased risk of adverse
cardiovascular outcomes. Furthermore plasma phospholipid concentrations of 15:0 and
17:0 may be associated with a reduced risk of stroke (Warensjӧ et al., 2009) or first
myocardial infarction (Warensjö et al., 2010b). Circulating levels of Trans-Palmitoleic
acid (trans-16:1n-7), a fatty acid found in ruminant milk products have also been shown
to be independently associated with a reduced risk of type 2 diabetes mellitus, in a large,
prospective cohort study (Mozaffarian et al., 2010). Unfortunately trans-16:1n-7
concentrations were not able to be analysed in the present study due to technical
limitations of the fatty acid analysis protocol.

The negative association between intake of dairy products and systolic blood pressure
observed in this study mirrors a large body of evidence suggesting a favourable
association between intakes of dairy products and reductions in blood pressure (Jorde &
Bønaa, 2000, Wang et al., 2008, Engberink et al., 2009). Whilst not statistically
significant, a trend towards a reduction in diastolic blood pressure was associated with
dairy product intake in these overweight individuals. As this study was not designed to
evaluate this phenomenon specifically, it is likely that a larger sample size would have
yielded significant results.

The small, negative associations observed between 15:0 concentrations and umbilicus
circumference may be particularly important in this overweight population as central
adiposity is an important predictor of the metabolic syndrome (Lam et al., 2011). A
small clinical trial in obese individuals revealed that yoghurt supplementation during
periods of energy deficit resulted in a significantly greater reduction in waist
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circumference in comparison to an isocaloric control group (Zemel et al., 2005a). Thus
further clinical trial research involving milk fat biomarkers in the overweight
community may be warranted.

Findings from this study support a growing body of literature suggesting there may be a
neutral or small potential health benefit associated with intakes of both milk fat and
dairy products (Warensjö et al., 2009, Aslibekyan, Campos & Baylin, 2011, Fumeron et
al., 2011), however further research involving well designed clinical trials are required
to test this hypothesis conclusively. The concept of food synergy is crucial when
considering the position of dairy products and milk fat on metabolic health. Dairy
products contain bioactive components such as calcium, conjugated linoleic acid,
vitamin D and milk protein derived peptides (Warensjӧ et al., 2010a), which may offset
some of the potential risks associated with consuming fat from dairy products when
eaten as a whole food. In addition the structural composition of milk fat may infer
advantageous metabolic effects in comparison to other saturated fatty acids; this has
been discussed in more detail in Chapter 1 (section 1.10). With an increased
understanding about the complex position of dairy products, and dairy fat in particular,
in the aetiology of the metabolic syndrome, there is a clear need for well controlled
prospective clinical trials to determine whether current public health advice to limit
intakes of dairy fat may require reassessment.

4.5 Study limitations
This study has several limitations which must be considered when interpreting results.
Firstly, this study involved an opportunistic sample of data from individuals
participating in a weight loss trial and thus was not specifically designed and powered
to evaluate associations between dairy product intake and metabolic risk factors.
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Despite this, several significant associations between biomarkers of milk fat and
improved metabolic profiles were evident, even after controlling for potential
confounding. However the observational, cross-sectional nature of this study mean that
a cause and effect relationship between milk fat intake and favourable metabolic
profiles cannot be inferred. Whilst every effort was made to reduce potential sources of
error through the utility of two validated dietary intake tools, it may be that associations
identified were obtained due to chance or residual confounding not accounted for. In
particular, it has been suggested in the literature that 15:0 and 17:0 concentrations may
also reflect intakes of other ruminant products such as beef or lamb (Wolk et al., 1998).
There were no associations between reported intakes of ruminant meat and whole blood
concentrations of 15:0 and 17:0 in the present study (r= -.035, p=.780 for 15:0 and r=
.043, p=.734 for 17:0). Thus it was assumed that the biomarkers were reflecting milk fat
intake primarily.

In addition, the utility of whole blood samples of 15:0 and 17:0 as biomarkers of milk
fat intake may be less accurate than adipose tissue samples, which provide a more stable
reflection of longer term nutritional intake (Aslibekyan, Campos & Baylin, 2011).
However such samples are often costly and invasive for participants, thus the use of
whole blood, which has also been validated to reflect milk fat intakes (Baylin et al.,
2005), was considered preferable from a practical perspective. Despite these limitations
evidence to support a growing body of literature questioning the long held assumption
that milk fat results in adverse metabolic outcomes was established within this small
sample of overweight adults.
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4.6 Conclusion
In this exploratory study, intakes of both milk fat and dairy products, as measured by
both whole blood concentrations of 15:0, 17:0 and self-reported dietary intakes, were
not associated with adverse metabolic profiles in overweight adults. In contrast, there
were indications of some desirable associations between metabolic syndrome disease
risk factors and biomarkers of milk fat intake, which were supportive of a growing body
of literature in this area. Overall this study supports the need for further investigation
into the relationship between milk fat and adverse metabolic profiles in the context of
the dietary management of the metabolic syndrome. Should further research support
these observations, full fat dairy products may have an important dietary position for
overweight individuals seeking to improve their metabolic health.

Findings from this study support the central thesis hypothesis that the position of dairy
foods is a complex one and is defined by health-disease context. It is thus likely, that
dairy fat and full fat dairy products may not infer the same potential health benefit to
individuals with different disease states. This is an important caveat and will be
explored in the proceeding chapters evaluating the position of this core food group in
the CD context.
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Chapter 5. Effects of dairy products on Crohn’s disease symptoms are influenced by
fat content and disease location but not lactose content or disease activity status in a
New Zealand population1

1
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5.1 Introduction
Crohn’s Disease (CD) is a debilitating form of inflammatory bowel disease which can
affect any location of the gastrointestinal tract resulting in considerable morbidity
(Veloso et al., 2001) The incidence of CD in a New Zealand based epidemiological
study was 16.5/100,000 per year, (Gearry et al., 2006), higher than in many Western
Countries and thus affecting a significant proportion of the New Zealand population.
Dairy products have often been perceived as having the potential to cause adverse
effects in individuals with CD and are thus often avoided, potentially increasing the risk
of osteoporosis and related morbidity associated with inadequate dietary calcium intake.
There are several hypotheses proposed to explain this perceived adverse affect. Perhaps
the most frequently reported theory relates to the prevalence of lactose intolerance in
CD patients. A higher prevalence of lactose malabsorption, as diagnosed by hydrogen
breath testing, in individuals with CD has been reported in comparison to controls
(Barrett et al., 2009). Allergy to major milk proteins may be a further reason that a
small number of CD patients report adverse affects from dairy products (Knoflach et al.,
1987). Additionally, individuals with CD may be susceptible to secondary lactose
intolerance. During the periods of acute gastrointestinal inflammation characteristic of
CD, quantities of lactase, the lactose digesting enzyme, may decline in the duodenal
mucosa, resulting in the gastrointestinal discomfort associated with lactose maldigestion
(von Tirpitz et al., 2002). Thus disease state (active or quiescent) may affect response to
dairy products in this clinical population.
Disease location may further influence tolerance to dairy products in individuals with
CD. Barrett et al. (2009) reported a higher proportion of lactose malabsorption in
patients with ileal CD in comparison to colonic CD. As lactase is located within the
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small intestinal villi, this is the primary site of lactose digestion (Vesa, Marteau &
Korpela, 2000) and individuals with inflammation located within this region of the
gastrointestinal tract may have difficulties with lactose intolerance.
The aim of this study was to evaluate the self-reported effects of dairy products on CD
symptoms and to determine whether these perceived effects differed between types of
dairy products consumed, disease state or location. The identification of dairy mediated
effects on CD symptoms may facilitate the provision of more targeted dietary advice
regarding dairy products for this clinical population.
5.2 Methods
This study was based on a secondary analysis of dietary survey and clinical data from
165 adults with CD. All subjects were Caucasian participants in the ‘Genes and Diet in
Inflammatory Bowel Disease’ study, which was an observational study based in
Auckland, New Zealand (Triggs et al., 2010). Subjects were selected on the basis that a
complete set of dietary and clinical data was available.
The original study was approved by the New Zealand Multi-Region Human Ethics
Committee (MEC/04/12/011). Access to the data for this secondary analysis met ethical
approval and all information utilised was coded to protect the anonymity of participants.
5.2.1 Clinical data
Clinical information including age, inflammatory bowel disease diagnosis and latest
Montreal classification illustrating latest CD location (Satsangi et al., 2006) was
provided following evaluation of patient medical notes and secondary patient
investigation by an experienced gastroenterologist as a part of the ‘Genes and Diet in
Inflammatory Bowel Disease’ study. Individuals with a latest Montreal classification of
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L1, indicating ileal involvement, were grouped into the ‘ileal involvement’ group.
While individuals with a classification of L2, indicating isolated colonic involvement,
were classified as the ‘colonic involvement’ group. To ensure that effects observed
could be attributable to either colonic or ileal disease locations, individuals with a
classification of L3 and L4 (indicating ileocolonic and upper gastrointestinal disease in
the presence of classifications of L1-L3 respectively (Silverberg et al., 2005) were
excluded from the part of the analysis seeking to determine whether perceived CD
symptoms from individual dairy products differed between disease locations.
Additional clinical information was sought from the dietary questionnaire whereby
subjects self-reported current disease activity status (active or quiescent).
5.2.2 Dietary data
For the purpose of this study dairy products were categorised to include ruminant milk
(inclusive of sheep, cow and goat varieties), yoghurt, butter, custard, ice cream, cream
and cheese.
The original dietary questionnaire utilised for this study was developed in conjunction
with CD patients and aimed to identify foods that were considered either beneficial or
detrimental to self-reported CD symptoms. Dietary data was reassessed six months
following completion in a subset of CD patients with consistent results indicating good
survey reliability. All data (n=165) was cross checked independently by two researchers
to ensure accuracy. The complete dietary questionnaire is described in more detail
elsewhere (Triggs et al., 2010).
Self-reported data on effects of dairy products were extracted from this dietary
questionnaire, which required participants to nominate whether particular foods items
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made their inflammatory bowel disease condition either: ‘definitely worse’, ‘probably
worse’, ‘had no effect’, ‘probably better’ or ‘definitely better’. Subjects reporting that
particular dairy products made their condition either ‘definitely’ or ‘probably worse’
were categorised as having CD symptom worsening associated with consumption of
that food. Similarly those reporting a ‘definitely’ or ‘probably better’ effect of a
particular dairy product on their CD condition were categorised as having a beneficial
effect on CD symptoms from consuming that food. Several open ended questions within
the questionnaire were also analysed to determine qualitative information regarding
perceived effects on CD condition associated with particular dairy products. These
questions included:


Is there a difference with the type of cheese eaten? If so, please outline:



Is there a difference with the type of yoghurt eaten? If so, please outline:

Both quantitative and qualitative information about the frequency and nature of having
any form of adverse reaction to milk products (such as nausea or bloating), was
extracted from this supplementary questionnaire following an analysis of open ended
questions including:


Have you ever had an adverse reaction to a milk product?



What were your adverse symptoms after consuming milk products?



Have you seen a health professional about your reactions to milk products (if
applicable)?



Have you been formally diagnosed with an intolerance or allergy?
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5.2.3 Data analysis
Qualitative data (including reports on symptoms of adverse reactions to dairy products
and of symptomatic differences from different types of dairy products consumed) was
categorised accordingly and the proportion of individuals responding to each category
was calculated.
Chi Squared analyses were conducted to assess whether significant differences in the
proportions of responses relating to a worsening of CD symptoms from individual dairy
product consumption were evident between individuals with active or quiescent CD, or
ileal or colonic disease locations. Odds ratios with confidence intervals were calculated
to determine whether CD location was associated with a risk of having any type of
adverse reaction to milk products. Results were considered statistically significant at p
<0.05.
For interpretation of data grouped by disease location (ileal vs. colonic), logit scales
were utilised to create a clear visual representation of self-reported CD symptoms
associated with consumption of individual dairy products whilst addressing the issue of
the variance of proportions between the groups.
All analyses were conducted using SPSS (V15.0 1989-2006, SPSS Inc., Chicago II,
USA), R (R Development Core Team (2009). R: A language and environment for
Statistical computing, R Foundation for Statistical Computing, Vienna, Austria. ISBN
3-900051-07-0, URL http://www.R-project.org.ref) and SAS (V9.1 SAS Institute.,
Cary, NC, USA) statistical software packages.

129

5.3 Results
Dietary and clinical data was available for n=165 patients with CD, (mean age
48.8±16.3). The study sample was predominantly female, n=116 (mean age 48.0±15.6)
males n=49, (mean age 50.6±17.8).
5.3.1 Clinical profiles
Of the study sample, n=80 patients (48.5%) reported that their CD was currently active
and n=82 (49.7%) identified their CD as being in the quiescent phase. Three patients did
not answer this survey question. There was no difference between the sexes in the
proportion reporting an active CD period at the time of survey completion (2=0.38, p=
0.54).
Data was available for n=160 patients on the latest Montreal classification indicating
the location of CD. Isolated ileal disease involvement was present for 32.7% of the
study sample, while 27.9% displayed evidence of isolated colonic involvement (Table
5.1). There was no significant difference between males and females in terms of CD
location (2=0.98, p=0.81).
Table 5.1. Latest subject Montreal classifications for location of CD (n=160)
Montreal classification for CD

Group:

Males:

Females:

location

n (%)

n (%)

n (%)

L1 – Ileal

54 (32.7%)

14 (28.6%)

40 (34.5%)

L2 - Colonic

46 (27.9%)

16 (32.7%)

30 (25.9%)

L3 Ileocolonic

51 (30.9%)

15 (30.6%)

36 (31.0%)

L4 – Isolated upper disease

9 (5.5%)

3 (6.1%)

6 (5.2%)
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5.3.2 Effects of all dairy products on self-reported CD symptoms
Forty two participants (25.5%) reported having had an adverse reaction to a product
containing milk, whilst n=111 (67.3%) felt that they had no experience of an adverse
event with milk product consumption. Of patients reporting an adverse reaction
associated with a milk product, n=24 (61.5%) of those reported that the reaction was
persistent, while 7 individuals (4.2%) felt that it was an isolated event.
A formal diagnosis of lactose intolerance was reported for n=11 patients (6.7% of the
study population). A total of n=41 CD patients described adverse symptoms
experienced following consumption of milk products (Figure 5.1).
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Figure 5.1. Adverse symptoms reported by CD patients following consumption of
dairy products (n=41)*
*Some patients reported more than 1 symptom. Other adverse symptoms reported
include: asthma (n=1), reflux (n=1), bowel irritation (n=1) and inflammation (n=1).
Naturopaths were listed as the health practitioner most frequently sought for advice
regarding adverse affects to dairy products (n=9). Specialist consultants including
gastroenterologists and allergy specialists were the next most frequently sought (n=8),
followed by general practitioners (n=7). Only one individual reported seeking advice in
relation to dairy product intolerance from a dietitian.
5.3.3 Associations between individual dairy products and self-reported CD symptoms
No effect on CD symptoms was reported to be associated with the consumption of
butter, standard cow’s milk and reduced fat cow’s milk in 71.5%, 55.2% and 58.2% of
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all patients respectively. Dairy products most frequently reported to worsen CD
symptoms were cream (43.6%), ice cream (37.6%) and cheese (34.5%). Conversely,
yoghurt, the dairy product most frequently perceived as beneficial, was reported by
14.5% of individuals as having favourable effects on CD symptoms. The response to
this question was quite varied (Table 5.2).
Table 5.2. Self-reported effect of individual dairy products on CD symptoms
(n=165)
Food Item

CD Symptoms

No difference

CD Symptoms

Question not

Worse

to CD

better

answered

N (%)

symptoms

N (%)

N (%)

N (%)
51 (30.9%)

91 (55.2% )

2 (1.2%)

21 (12.7%)

30 (18.2%)

96 (58.2%)

10 (6.0%)

29 (17.6%)

Butter

29 (17.6%)

118 (71.5%)

2 (1.2%)

16 (9.7%)

Custard

32 (19.4%)

106 (64.2%)

8 (4.8%)

19 (11.5%)

Goat’s milk

11 (6.7%)

27 (16.4%)

4 (2.4%)

123 (74.5%)

Sheep’s milk

11 (6.7%)

27 (16.4%)

5(3.0%)

122 (73.9%)

Ice cream

62 (37.6%)

94 (57.0%)

3 (1.8%)

6 (3.6%)

Yoghurt

31 (18.8%)

94 (57.0%)

24 (14.5%)

16 (9.7%)

Cheese

57 (34.5%)

95 (57.6%)

5 (3.0%)

8 (4.8%)

Cream

72 (43.6%)

72 (43.6%)

1 (0.6%)

20 (12.1%)

Standard
cow’s milk
Reduced fat
cow’s milk
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5.3.4 Cheese
When asked whether the type of cheese may influence CD symptoms, 26.1% of
participants responded positively. The flavour strength of the cheese was most
frequently reported as influencing tolerance, with n=15 patients reporting that increased
strength cheese decreased tolerance. Richer/soft cheeses were reported to worsen CD
symptoms for 9 patients, with a preference for Feta and Edam cheese varieties reported
by 8 and 7 patients respectively. Cheeses with a lower fat content were reported to
increase tolerance (n= 6) as did hard cheeses (n=5) and plain cheeses without added
herbs (n= 3). Melted cheese was associated with CD symptoms worsening for 4
patients.
5.3.5 Yoghurt
In total 23.0% of respondents reported that the type of yoghurt consumed may also be a
key factor relating to whether it would be tolerated. Patients reported that yoghurts
containing live cultures such as acidophilus were most beneficial to CD symptoms
(n=19), whilst natural yoghurt was preferable to sweetened alternatives for n=11
patients. A preference for reduced fat yoghurt was reported (n=9), with yoghurt lacking
seeds or fruit preferred by a further 4.8% (n=8) of individuals.
5.3.6 Disease activity and self-reported effect of dairy products on CD symptoms
There were no significant differences in the proportion of individuals reporting a
worsening of CD symptoms associated with the consumption of individual dairy
products between patients in the active or quiescent CD state (Table 5.3).
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Table 5.3. Self-reported effect of individual dairy products on worsening CD
symptoms analyzed by disease activity status (n=162)
Food Item

CD Symptoms

No difference to

Worse

CD symptoms

n (%)

n (%)

Active

Quiescent Active

Quiescent Chi Squared Analysis

CD

CD

CD

CD

(n=80) (n= 82)

(n=80)

(n= 82)

21

30

45

43

(2=1.28, p=0.26)

14

15

46

48

(2 =0.004, p=0.95)

Butter

15

9

57

61

(2=1.61, p=0.20)

Custard

17

14

50

54

(2 =0.48, p=0.51)

Goat’s milk

7

4

13

13

(2=0.58, p=0.45)

Sheep’s milk

5

6

13

13

(2 =0.64, p=0.80)

Ice cream

31

30

45

47

(2 =0.053, p=0.82)

Yoghurt

16

14

46

47

(2 =0.14, p=0.71)

Cheese

27

29

46

47

(2=0.02, p=0.883)

Cream

36

36

35

35

(2 = 0.00, p=1.00)

Standard cow’s
milk
Reduced fat
cow’s milk
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5.3.7 Site of disease and self-reported effect of dairy products on CD symptoms
Likewise, no significant differences were detected between self-reported CD symptoms
associated with the consumption of individual dairy products and ileal or colonic
disease location (data not shown). However, significantly less patients with ileal disease
activity reported ever having any type of adverse reaction to dairy products compared to
those with colonic disease involvement (2 =5.90, p=0.015), (OR=0.32, 95% CI (0.130.82), p=0.017)).
Logit scales of self-reported improvement or worsening of CD symptoms associated
with the intake of individual dairy products in individuals with either small intestinal
(ileal) or colonic CD involvement are displayed in figures 5.2(a) and 5.2(b). Only dairy
products with at least one reported beneficial/adverse effect on CD symptoms can be
plotted with the Logit scale. Thus for patients with ileal involvement butter, goat and
sheep milk were not included in the Logit graph. Similarly, cream, ice cream, sheep and
goat milk were not graphed for individuals with colonic involvement.
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Figure 5.2(a). Self-reported effects of individual dairy products on CD symptoms for individuals with ileal disease involvement.
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Figure 5.2(b). Self-reported effects of individual dairy products on CD symptoms for individuals with colonic disease involvement
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5.4 Discussion
This analysis of self-reported effects of dairy products on CD symptoms has clearly
illustrated the extent of variation in perceived tolerance to these items within this
clinical population.
Most importantly, the majority of the study sample reported that consumption of dairy
products made no difference to CD symptoms. This finding reinforces the need to
determine tolerance to dairy products in CD patients prior to encouraging widespread
avoidance of this food group, an idea that may be still encouraged by some physicians
and many alternative health consultants. Whilst it may be pertinent to avoid some dairy
products for CD patients with congenital hypolactasia or during periods of active
disease, unnecessary avoidance of all dairy products by this clinical group without
appropriate nutrition support may have deleterious consequences.
Individuals with CD are more susceptible to osteoporosis (10). Prolonged
corticosteroid utilisation to induce remission of inflammation has been demonstrated to
reduce BMD in CD patients (Yang & Lichtenstein, 2002). CD itself may be an
independent risk factor for osteoporosis (Ghosh et al., 1994) with an increase in proinflammatory cytokines associated with disease pathogenesis mediating excessive bone
resorption (Manolagas & Jilka, 1995). According to the National New Zealand
Nutrition Survey (Russel et al., 1999) milk, cheese and other dairy products were the
highest food contributors of dietary calcium in the New Zealand population,
contributing 37%, 11% and 5% of total calcium consumed respectively. While
evidence is conflicting, Abitbol and colleagues (2002) demonstrated a protective effect
of calcium intake on BMD in individuals with inflammatory bowel disease, and
increased dairy product consumption has been reported to retard bone loss (Baran et al.,
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1990). Thus, eliminating dairy products as the highest contributor of dietary calcium
from the diet may further exacerbate the risk of osteoporosis and related morbidity in
individuals with CD in New Zealand.
Intermittent secondary lactose intolerance may be experienced by some individuals with
CD during periods of active gastrointestinal inflammation (von Tirpitz et al., 2002).
Formally diagnosed lactose intolerance was reported for only a small proportion of the
study sample. However symptoms consistent with lactose maldigestion, including
bloating, diarrhoea and gas (Riitta, 2001), were the most frequently reported adverse
effect associated with milk product consumption. This finding indicates that secondary
lactose intolerance may have influenced the response to dairy products for a greater
number of this CD study sample.
Data from this study supports previous reports that seeking assistance from alternative
health practitioners is a practice frequently observed in individuals suffering from
inflammatory bowel conditions (Joos et al., 2006). Advice of this nature is often sought
as an adjunct to conventional medical therapies in an effort to establish a sense of
control over this debilitating condition (Jamieson, Fletcher & Schneider, 2007). This
practice was evident in this clinical population whereby naturopaths were the most
frequently utilised source of advice regarding issues with dairy product tolerance.
Appropriate dietetic intervention is instrumental to ensuring optimal BMD in patients
with CD (O’Sullivan & O’Morain, 2006). It is therefore important that individuals who
report adverse CD effects associated with the consumption of dairy products receive
dietetic intervention as part of the continuum of care.
In this study sample, individual dairy product tolerance was highly variable. In fact, the
majority of individuals experienced no effect on CD symptoms associated with each of
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the individual dairy products under question. An exception to this finding was evident
for cream, with the highest proportion of individuals in the study sample reporting a
worsening of CD symptoms associated with its consumption. The perceived adverse
affects may relate to the high fat content of this item. High dietary fat intakes decrease
gastric emptying rates (Gentilcore et al., 2006). In addition, disorders in gastrointestinal
motility have been observed in this clinical population, with affected individuals more
likely to experience gastric hypo motility than controls (Annese et al., 1997). This is
particularly pertinent as gastric hypo motility is associated with delayed gastric
emptying (Chen et al., 1996). Thus effects of dietary-fat mediated delays in gastric
emptying following consumption of dairy products rich in fat may be more pronounced
in individuals with CD. Symptoms associated with delayed gastric emptying include
nausea; abdominal pain and bloating (Chen et al., 1996) all of which were frequently
reported as adverse affects following intake of dairy foods in this study.
It should also be noted that cream, like many other foods, is rarely consumed in
isolation and generally forms a component of a meal. Thus there is a possibility that
perceived worsening of CD symptoms assigned to particular foods may relate to the
cuisine context in which these items are consumed rather than the food item itself.
However, other dairy products containing higher amounts of fat including ice cream and
cheese were also associated with a perceived worsening of CD symptoms in a larger
number of patients in comparison to their lower fat dairy counterparts. Furthermore,
reduced fat cheese and yoghurt varieties were perceived as more tolerable. These
findings illustrate that the fat content of dairy products may be a key factor influencing
tolerance in this clinical population.
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Of interest was the finding that butter, a dairy product that contains a very high
proportion of fat, was not reported to worsen self-reported CD symptoms for the
majority of individuals. It may be that butter is not being consumed in quantities great
enough to influence gastric stasis in the study sample. Conversely, butter contains a
relatively high proportion of CLA. CLA has been implicated in the amelioration of
inflammation in experimental models of inflammatory bowel disease, particularly in
relation to colitis (Bassaganya-Riera, Hontecillas & Beitz, 2002). Thus the lack of
perceived worsening of CD symptoms associated with butter intake may be the result of
this CLA mediated anti-inflammatory effect and this area warrants further investigation.
Probiotic–containing yoghurt has been demonstrated to attenuate markers of
inflammation in individuals with inflammatory bowel disease (Lorea Baroja et al.,
2007). The dairy product most frequently associated with having self-reported
beneficial effects on CD symptoms in this study was yoghurt. However, yoghurt was
also found to be associated with a worsening of CD symptoms for a slightly greater
number of individuals than had experienced beneficial effects from it. A limitation of
the survey utilised for analysis was that it failed to distinguish between CD effects
experienced from probiotic yoghurt and non-probiotic varieties. An analysis of
qualitative responses indicated that for individuals experiencing a difference in CD
symptoms dependent on the type of yoghurt consumed, those containing live cultures
and probiotics were most frequently associated with beneficial effects. Thus probiotic
yoghurts appeared to benefit individuals with CD in preference to yoghurt without live
cultures, however this is an area that requires further research and a placebo effect
cannot be ruled out.
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It was expected from previous observations (Triggs et al., 2010) that goat and sheep
milk may result in less perceived worsening of CD symptoms than their bovine
counterparts. Goat milk in particular contains oligosaccharides which have
demonstrated anti-inflammatory effects in rat models of inflammatory bowel disease
(Daddaoua et al., 2006). In addition sheep and goat’s milk contain higher proportions of
medium chain triglycerides than cow’s milk which may enhance digestibility (Russ et
al., 2010). Finally, like butter, sheep milk contains relatively high amounts of CLA
(Park et al., 2007) which may further ameliorate gastrointestinal inflammation
(Bassaganya-Riera, Hontecillas & Beitz, 2002). In this study, only a very small
proportion of individuals reported beneficial effects on CD symptoms associated with
consumption of these milk products, with a slightly greater proportion reporting
symptom worsening. However, because the majority of individuals did not answer this
question, indicating that they did not consume these items, it was not possible to
determine the true effect of goat and sheep milk on CD symptoms. Given emerging
evidence to suggest a potentially beneficial role for sheep and goat milks in relation to
CD symptoms, evaluating the true effects of these products may be an important area
for future research.
The lactose content of the individual dairy products did not seem to influence selfreported CD symptoms in this study sample. Cow’s milk, which contains a significantly
greater amount of lactose per serve than cream, ice cream or cheese (Riitta, 2001) was
associated with comparatively less perceived symptom worsening. Additionally,
lactose tolerance may be influenced by gastrointestinal transit time, with higher fat milk
products travelling less rapidly throughout the small intestine, affording lactase a
greater opportunity for lactose digestion (Riitta, 2001). Thus, if lactose was a key factor
relating to CD symptoms in this study sample, reduced fat cow’s milk would have been
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associated with less favourable CD symptoms than its standard counterpart. As this was
not the case it appears that the lactose content of individual dairy products does not have
a major impact on CD symptoms. In contrast, qualitative responses regarding the types
of cheese and yoghurt consumed that may influence tolerance, indicate a lactose effect
in a small proportion of the study sample. The preference for yoghurt containing live
bacteria previously outlined may be associated with tolerance to lactose for some
individuals, given that these organisms perform the activity of lactase (Adolfsson,
Meydani & Russell, 2004), enhancing digestibility. Similarly, several individuals
reported a preference for hard cheeses such as cheddar in comparison to soft cheeses.
Hard cheeses contain slightly less lactose than soft varieties such as cream cheese
(Riitta, 2001) and may thus be better tolerated by individuals with lactose maldigestion.
In this study disease activity (active vs. quiescent) did not appear to influence perceived
effects of dairy products on CD symptoms, with a similar proportion of individuals
reporting either adverse or beneficial dairy mediated effects on CD symptoms
irrespective of disease activity. This finding challenges the necessity of dairy avoidance
during active CD. However, as disease activity was subjectively reported, these
findings should be interpreted with caution.
Reference to the logit scales developed in this analysis illustrate that individuals with
isolated colonic inflammation appeared to have an increase in perceived adverse CD
symptoms associated with the consumption of reduced fat cow’s milk, custard, sheep’s
milk and yoghurt in comparison to those with isolated small intestinal (ileal)
involvement. This was an unexpected finding as it was anticipated that individuals with
small intestinal inflammation would be more likely to have issues with lactose and thus
dairy product tolerance, given that lactase lines the small intestinal mucosa (Vesa,
144

Marteau & Korpela, 2000). Furthermore Annese et al. (1997) reported that most severe
gastrointestinal motility disorders occur in Crohn’s ileitis. This unexpected finding
warrants further investigation and may relate to functional differences in gut microbiota
amongst individuals with CD affecting varied locations throughout the gastrointestinal
tract.
A possible explanation for the unexpected outcomes observed in relation to dairy
product tolerance in this study may be attributable to individual genetic variation.
Although clear genomic loci such as NOD2 and IL23R have been repeatedly associated
with CD in genome wide association studies (Van Limbergen, Wilson & Satsangi,
2009) there is a paucity of evidence in relation to genetic factors that may influence
tolerance to dairy products in individuals with this inflammatory condition. Future
research efforts should consider the impact of genetic interactions on dairy product
tolerance in CD to conclusively address the research question.
5.5 Study limitations
This study was limited by the subjective nature of the dietary questionnaire utilised, and
the relatively small size of the CD sample that make it difficult to extrapolate findings
to the wider Crohn’s disease community. Additionally, information relating to the
specific macronutrient composition or processing methods utilised for each of the dairy
products included within this study was not acquired. Thus results obtained may only
be applicable to this study sample and may not apply to individuals consuming dairy
products that differ greatly from the generic food composition of New Zealand dairy
products. Furthermore information about the quantity of dairy food items required to
elicit effects on self-reported CD symptoms was not collected in the dietary
questionnaire. Quantification of such items may provide a further insight into the factors
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that may influence tolerance to dairy products in this clinical population, in particular
whether there is a threshold of consumption that must be achieved in order to influence
perceived symptoms. Despite these limitations, this is the first study to assess the
perceived affects of dairy products on CD symptoms taking into account both clinical
and qualitative data, and provides some important insights for both future research and
dietetic practice within this clinical population.
5.6 Conclusion
Within this study sample of CD patients in Auckland, New Zealand, dairy products in
general had no effect on self-reported CD symptoms for most people. When analysed
according to type of dairy product, items with a high fat content were most frequently
reported to worsen perceived CD symptoms. The lactose content of individual dairy
products did not influence self-reported CD symptoms for the majority of patients.
Clinically, CD activity status did not influence responses to dairy products; however site
of disease appeared to have an effect. Colonic inflammation was more frequently
associated with an increase in reported adverse CD effects from dairy product
consumption in comparison to ileal CD involvement.
Results from this study reinforce the idea that that ‘one size does not fit all’ when it
comes to making dietary recommendations relating to dairy product consumption for
individuals with Crohn’s disease. The observation that dairy products with a higher fat
content were most detrimental to self-reported CD symptoms is in contrast to the
previous study (chapter 4) suggesting an intrinsic metabolic benefit associated with
intake of milk fat in overweight individuals. Thus, this study supports the central thesis
hypothesis that the position of dairy products is defined by health-disease context and
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suggests that a distinction between an individual’s disease states must be made when
translating new evidence relating to dairy products to practice.
In as much as it is defined by health disease context, the positioning of core foods
within the diet may also be influenced by genetic factors. Thus to gain a comprehensive
understanding of the role of dairy products in CD, additional research that considers
genetic variants associated with exposure to this food group will be informative.
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Chapter 6. Genetic adult lactase persistence is associated with risk of Crohn’s disease
in a New Zealand population1
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6.1 Introduction
Crohn’s Disease (CD) involves both genetic and environmental aetiological factors. As
discussed in more detail in chapter 1, Mycobacterium avium subsp. Paratuberculosis
(MAP) exposure has resurfaced within the literature as a potential environmental variant
that may be implicated in the development of CD (Chamberlin et al., 2001). To
reiterate, MAP is an infective agent frequently found in ruminants such as cows and
sheep that results in Johne’s disease, an inflammatory bowel condition similar to that
experienced by humans with CD (Greenstein, 2003). MAP is secreted into the milk of
infected ruminants (Sweeney, Whitlock & Rosenberger, 1992) and is delivered to
humans via the consumption of milk products (Ayele et al., 2005) due to its reported
resistance to commercial pasteurisation methods (Grant, Ball & Rowe, 2002).

One of the most important factors that may influence the amount of milk consumed, and
hence exposure to MAP in humans relates to the presence of Lactase-Phlorizin
Hydrolase (lactase) in the small intestinal mucosa. Lactase is the enzyme required to
hydrolyse lactose, the sugar found in milk products, into its constituent galactose and
glucose (Vesa, Marteau & Korpela, 2000). Infants are born with the ability to digest
lactose, but for the majority of the world’s population this declines with age, a
phenomenon known as lactase non persistence. However, lactase persistence is highly
prevalent in descendants from populations with a rich pastoralist heritage (Tishkoff et
al., 2007) Greater than 70% of individuals of white European heritage are reportedly
lactose persistent compared to less than 40% throughout individuals from Asian
countries (Sahi, 1994).

Enattah et al. (2002) identified a DNA variant, rs4988235 (c.1993+327 C>T, previously
termed C/T-13910); 14kb upstream from the LCT locus that demonstrated complete
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agreement with clinically identified lactase non persistence in a Finnish population.
LCT is a gene which encodes Lactase Phlorizin Hydrolase for the hydrolysis of lactose.
Homozygotes for the C allele of rs4988235 were found to be lactase-non persistent,
whilst those heterozygous or homozygous for the T allele were determined to be lactase
persistent. This finding has been replicated in several other European populations
(Kerber et al., 2007, Ridefelt & Håkansson, 2005) and support for the functionality of
this DNA variant has been demonstrated in vitro (Lewinsky et al., 2005) Thus the C/C
genotype for rs4988235 is now a widely accepted marker of adult-type hypolactasia in
Europeans.

Evaluating the association of lactase persistence with CD as a key factor influencing
exposure to MAP via the consumption of milk products is particularly important in New
Zealand, a country with one of the highest incidences of CD in the Western world at
16.5/100,000 per year (Gearry et al., 2006) coupled with the highest herd prevalence
estimate of Johne’s disease at 60% (Grant, 2005).

The aim of this study was to determine whether lactase persistence, as evident by the
presence of the T allele of rs4988235, is associated with CD in a New Zealand
population.

6.2 Methods

6.2.1 Samples
The Auckland CD Project is a population-based study of genetic and environmental
determinants of CD aetiology. CD patients were recruited between May 2005 and April
2007 through local doctors and medical surgeries in Auckland, New Zealand, and also
other North Island centres, by media campaigns, e.g. local newspaper and television.
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Control participants were recruited by the same means, and also recruited from nonaffected family members and friends of CD patients.
A total of n=945 subjects (n=333 CD patients and n=612 controls) consented to take
part. The cases in this study are a subset of the Caucasian participants of the Auckland
CD Project. Their gastroenterologists were approached, clinical records scrutinised to
confirm diagnosis, and CD was defined using standard diagnostic criteria (LennardJones, 1989). Cases were phenotyped according to the Montreal Classification systems,
allowing genotype-phenotype analysis to be performed. Phenotypic information was
available for 323 CD patients. All participants included in this study were of selfreported European ancestry (subjects who self-reported having any Maori or other nonCaucasian ancestry were not included in the dataset to increase the likelihood of genetic
homogeneity within the study sample).
The study was conducted under ethical protocol MEC/04/12/011, authorised through the
New Zealand Multi-Region Human Ethics Committee. All study participants gave
written informed consent to participate in the study and the collection of peripheral
blood for DNA extraction and genotyping.
DNA was extracted from blood samples or buccal swabs using Qiagen’s DNA
extraction kit (Qiagen, Valencia, CA, USA) and following the manufacturer’s
instructions.
6.2.2 Genotyping
Genotyping of rs4988235 was performed using the ABI TaqMan MGB diallelic
discrimination system with forward and reverse primer sequences 5’-CTG CGC TGG
CAA TAC AGA TAA G-3’ and 5’AAA TGC AAC CTA AGG AGG AGA GTT C-3’
respectively and VIC-- ATA ATG TAG TCC CTG GCC T and FAM--ATA ATG TAG
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CCC CTG GC probes (Applied Biosystems, Melbourne, Australia). The reactions were
prepared using 2x TaqMan Universal Master Mix, 40x SNP Genotyping Assay Mix,
DNase-free water, and 10 ng genomic DNA in a final volume of 5ul per reaction. The
PCR amplification was performed using the ABI Prism 7900 HT sequence-detector
machine under the following conditions:

50°C for two minutes, 95°C enzyme

activation for ten minutes followed by 40 cycles at 95°C for 15 sec and 60°C for one
minute (annealing/extension).
To reduce the possibility of genotyping error, genotyping was repeated utilising
different primers (5’-CTC TGC GCT GGC AAT ACA G

and 5’-AAA TGC AAC

CTA AGG AGG AGA) and probes (VIC-ATA AGA TAA TGT AGC CCC TGG C and
FAM- ATA AGA TAA TGT AGT CCC TGG C) (Applied Biosystems, Melbourne,
Australia) under the following conditions: 60°C for one minute, 95°C for ten minutes,
followed by 55 cycles of 92°C for 15 seconds and 60°C for one minute and 60°C for
one minute. The allelic discrimination results for both sets of genotyping were
determined after the amplification by performing an endpoint read.
Assays were optimized in n=24 samples consisting of 20 reference Centre d’Etude du
Polymorphisme Humain (CEPH) samples and four blanks. All sample plates contained
cases, controls, blanks, CEPH and duplicate samples. Quality control measures included
independent double genotyping, blind to sample identity and blind to the other caller,
and comparison of our CEPH genotypes to those in the HapMap database
(www.hapmap.org) to test for accuracy of genotyping results.
6.2.3 Statistical analyses
The allelic trend test (Sasieni, 1997) was used to compare frequencies between case and
control alleles. An exact test was used to test for departures from Hardy-Weinberg
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equilibrium (HWE) in the case and the control samples (Wigginton & Abecasis, 2005).
Lactase persistence was defined as having genotypes C/T and T/T of rs4988325 whilst
C/C was defined as lactase non-persistence.
Genotypic analysis was carried out and the allelic odds ratio with confidence interval
was calculated to test the effect of the T allele on CD risk. SAS (V9.1 SAS Institute.,
Cary, NC, USA) and R (Ihaka & Gentleman, 1996) were used for statistical analyses.

6.3 Results

The genotypes did not meet HWE for both the cases and controls. However, as
genotyping was repeated using an alternative primer and probe set, the genotypes were
confirmed to be correct. Also, the minor allele frequency was 0.273 which is similar to
the HapMap CEU population frequency of 0.274. Deviations from HWE may have
resulted by chance, as a result of population admixture or perhaps the rs4988235 SNP is
associated with a currently unknown factor in controls.
For rs4988235, the T/T genotype showed a significantly increased risk of having CD as
compared with the C/C genotype (OR=1.61, 95% CI=1.03-2.51) however, no
significant difference was found between C/T and C/C. Additionally, a significant
increase in the frequency of the T allele was observed in CD patients (OR=1.30, 95%
CI=1.05-1.61, p=0.013), indicating that the T allele encoding lactase persistence was
associated with risk of CD (Table 6.1).
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Table 6.1. Genotype and allele count frequencies for rs4988235 in CD participants
and in control participants

Genotype

CD

Control
OR (95%CI)

Allele

C/C

N (%)

N (%)

32 (9.6)

82 (13.4)

p

1.00

118
C/T

238 (38.9) 1.27 (0.80-2.02)
(35.4)

0.065

183
T/T
(55.0)

292 (47.7) 1.61 (1.03-2.51)

Z= 2.34, p < Z 0.009*
484
T

822 (67.2) 1.30 (1.05-1.61)
(72.7)
0.013
182

C

402 (32.8)

1.00

(27.3)

*Cochran-Armitage Trend Test
Genotype-phenotype analysis: of n=323 cases, n=88 (28.4%) had relatives with IBD,
n=98 (31.6%) had undergone a bowel resection, n=44 (14.2%) had extra-intestinal
manifestations of CD occurring and n=112 (46.9%) smoked at diagnosis (Table 6.2).
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Table 6.2. Summary of clinical data in subgroups of CD participants with a T
allele for rs4988235
N (%)

OR (95% CI)

p

Age at first diagnosis
0-16 years

30 (10.6)

0.98 (0.55-1.75)

1.00

17-40 years

203 (71.5)

1.36 (1.05-1.76)

0.021

>40 years

51 (18.0)

1.56 (0.96-2.53)

0.087

Ileal

97 (36.5)

1.50 (1.05-2.15)

0.032

Colonic

86 (32.3)

1.26 (0.88-1.81)

0.245

Ileocolonic

83 (31.2)

1.25 (0.86-1.81)

0.273

Inflammatory

152 (57.6)

1.36 (1.02-1.82)

0.039

Stricturing

81 (30.7)

1.27 (0.87-1.85)

0.233

Penetrating

31 (11.7)

1.41 (0.77-2.57)

0.315

Relative with IBD

88 (28.4)

1.71 (1.17-2.51)

0.006

Bowel resection

98 (31.6)

1.47 (1.03-2.10)

0.033

Extra Intestinal

44 (14.2)

1.38 (0.84-2.28)

0.228

CD: 112 (46.9)

1.04 (0.69-1.56)

0.918

CD location

CD Behaviour

Manifestations
Smoker at diagnosis

Control: 130 (31.7)
*IBD – Inflammatory Bowel Disease
* Bold text indicates statistically significant at p<0.05
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The results from this study indicated that individuals carrying the T allele of rs4988235
had an increased probability of developing CD that was diagnosed between 17 and 40
years (OR=1.36, 95% CI=1.05-1.76, p=0.021); and a significantly increased risk of
developing ileal CD (OR=1.50, 95% CI=1.05-1.76, p=0.032) or CD of an inflammatory
nature (OR=1.36, 95% CI=1.02-1.82, p=0.039). In addition, a significantly increased
risk of having other relatives with IBD and of undergoing bowel resection was observed
in individuals with the T allele of rs4988235 (OR=1.71, 95% CI=1.17-2.51, p=0.006
and OR=1.47, 95% CI=1.03-2.10, p=0.033 respectively).

6.4 Discussion

Results from this study suggest that genetic adult-type lactase persistence as evident by
the T allele of rs4988235 may increase the risk of developing CD in this New Zealand
population. These findings are in agreement with Juste et al. (2009), who reported an
increased frequency of the T allele of rs4988235 in CD patients (61.9%) compared with
controls (47.1%, p=0.0275). Similarly, a highly significant correlation between
incidence of CD and lactase persistence (r= -0.655, p=0.0017) was reported in an
observational study encompassing data from 20 countries (Juste, 2010), whilst Shrier,
Szilagyi & Correa (2008) reported a reduction in CD risk with increasing prevalence of
lactase non-persistence in a review of global population data.
Conversely, Büning et al. (2003) failed to find an association between the C/C genotype
of rs4988235 and the pathogenesis of CD in a German case-control study of n=166 CD
patients and n=187 healthy controls. This discrepancy may relate to the smaller sample
size of this study; however, evaluation of this phenomenon on a regional basis, taking
into consideration adult lactase status, dairy food consumption, and degree and
management of MAP infection within ruminant populations may provide evidence to
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ensure that a consensus can be reached regarding the role of lactase persistence and
MAP exposure in the aetiology of CD.
The finding that lactase persistence was associated with an increased risk of having a
relative with inflammatory bowel disease may reflect the autosomal dominant nature of
lactase persistence, whilst the increased risk of CD diagnosis between 17-40 years of
age may correspond with the onset of hypolactasia that typically occurs in adulthood in
susceptible individuals. The T allele for rs4988235 was also associated with an
increased risk of inflammation, having an ileal CD location and bowel resection
amongst CD cases. This was an unexpected finding and warrants further investigation to
conclusively determine whether lactase persistence may influence the phenotypic
expression of CD.
As associations between MAP and inflammatory bowel disease have largely been
limited to individuals with CD, this study did not evaluate lactase persistence in the
ulcerative colitis context. However, the inclusion of this clinical population in future
research may provide further insights into the potential association between lactase
persistence and inflammatory bowel disease.
Whether lactase persistence is an independent risk factor for CD or merely a marker of
the likelihood of exposure to the MAP pathogen, found predominantly in milk products,
is beyond the scope of this particular study. However epidemiological evidence is
conflicting, indicating an urgent need for further, well controlled dietary and genetic
case-control studies to distinguish between these two hypotheses.
In Japan, Shoda et al. (1996) reported that incidence of CD was strongly correlated
with consumption of milk protein, whilst Shrier, Szilagyi & Correa (2008) identified a
trend with estimated yearly per capita dairy food consumption and increased risk of CD.
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In contrast Abubakar et al. (2007) reported that consumption of pasteurised milk was
associated with a decreased risk of CD in a case-control study of n=218 individuals with
CD in England.
Recent advances in technology have ensured that the presence of MAP in vivo is more
accurately detected (Bull et al., 2003). These advances have contributed to the
resurgence of the MAP and CD hypothesis. Viable MAP was recently identified in the
peripheral blood of a high proportion of individuals with CD, with only MAP DNA
isolated in a small proportion of controls (Naser et al., 2004). This may reflect different
physiological responses to the pathogen between cases and controls. These findings
were supported locally in a New Zealand study, utilising a larger cohort of n=361 CD
patients and n=200 controls. In this study, MAP DNA in peripheral blood was found to
be over-represented in CD patients in comparison to controls (Bentley et al., 2008).
The Zoonotic potential of MAP was discussed in a review by Grant (2005), who
reported that hypotheses suggesting a causal role for MAP in the pathogenesis of CD
were plausible, however, insufficient available evidence is available to either prove or
disprove this idea at present.
Results from this exploratory study do not prove that MAP exposure is responsible for
the development of CD; or that milk products increase the risk of the development of
CD. However, the findings presented indicate that there may be a complex interaction
between exposure to this infectious agent as a consequence of an evolutionary
adaptation to ensure tolerance to the milk products that may serve as the medium for its
delivery to humans. As the worldwide incidence of CD is rapidly increasing,
(Munkholm et al., 1992, Phavichitr, Cameron & Catto-Smith, 2003, Leong, Lau &
Sung, 2004), there is an urgent need to determine whether the presented findings can be
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replicated in larger populations. If so, efforts to eradicate MAP through animal
vaccination and greater prevention of its contamination into the food supply should
become key public health priorities.
6.5 Conclusion
Following a case-control evaluation of rs4988235 in a New Zealand CD population, it
was determined that lactase persistence as evident by the presence of a T allele was
associated with increased CD risk. This finding may relate to the increased exposure to
dairy products in individuals with lactase persistence, a food group that has been
implicated in the aetiology of CD due to the presence of MAP species in milk. Further
research is required to substantiate these findings and to conclusively determine the
nature of the observed association between lactase persistence and CD.
This research contributes to a greater understanding of the complexity of dairy products
in the CD context. Whilst this food group per se may not result in adverse clinical
outcomes for CD patients, foods are inextricably linked to the environment in which
they were created. In the case of dairy products, contamination with an infective agent
from the environment may mitigate some of the health benefits that may be inferred for
CD patients. This area of research is controversial and the subject of much scientific
conjecture, however it is an important issue that warrants further investigation. Should
future research substantiate the associations identified in this study, it will be difficult to
translate this complex new information to practice.
In a broader sense, the translation of emerging dairy-related research to practice is a
critical component in the development of evidence based nutrition surrounding core
foods. Thus social research seeking to understand consumer behaviour relating to dairy
product intake and the impact of nutrition education on attitudes towards dairy foods is
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extremely important. Such research will help to identify the best approach for nutrition
professionals seeking translate new research surrounding dairy products into practice.
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Chapter 7. Consumers’ salient beliefs regarding dairy products in the functional food
era: a qualitative study using concepts from the theory of planned behaviour1

1

This study was funded by the School of Health Sciences, University of Wollongong, Australia and drew
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Australia (#514631). The preliminary outcomes of this study were presented at an International
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of functional dairy products using concepts from the theory of planned behaviour’ International
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7.1 Introduction
Dairy products represent an important core food group within many Western diets,
provide an important source of protein and calcium to the diet (McLennan & Podger,
1998a) and have been associated with a decreased risk of developing osteoporosis
(Heaney, 2000) and the metabolic syndrome (Elwood, Pickering & Fehily, 2007).
Current public health recommendations suggest that Australian adults consume a
minimum of two to three serves of dairy products per day for optimal health (Kellet,
Smith & Schmerlaib, 1998). However, up to four serves of dairy foods per day may be
recommended for particular population groups to ensure optimal calcium intake of a
minimum of 1000mg/day according to Australian Nutrient Reference Values
(Department of Health and Ageing/National Health and Medical Research Council,
2005). In a large longitudinal study of Australian women aged 50-55 years, only 32%
were found to be consuming a minimum of two serves of yoghurt, milk or cheese per
day (Ball et al., 2004). The latest available National Nutrition Survey indicates that
Australian adults on average are not meeting recommended dietary intakes for calcium
(McLennan & Podger, 1998b) potentially increasing the risk of developing osteoporosis
in these individuals .
Social research enables exposure of the factors that may impede compliance with
dietary recommendations. Within this research paradigm, the technique of focus groups
provides a means for generating hypotheses relating to consumer behaviour (Fern,
1982). For example, research on dairy product consumption in elderly and young
women in New Zealand found that a fear of weight gain, perceptions of adverse health
effects and inappropriate medical advice were important barriers to increasing
consumption (Horwath et al., 1995). Whether this is also the case in the current
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Australian context is not known. It is an area worthwhile pursuing, particularly with the
introduction of functional dairy products. Whilst a universally agreed upon definition
of functional foods is lacking, in general, functional foods may include those that have
been formulated to provide additional health benefits beyond the provision of nutrients
(Tapsell, 2008). Functional dairy foods may include calcium enriched or plant sterol
and omega 3 fortified products. These products also represent a key area of growth for
the national dairy industry.
In order to interpret consumer opinions in a sound theoretical framework, it is necessary
to articulate the analytical reference points. Such positions are provided by the theory of
planned behaviour (TPB) (Ajzen, 1991) and will form the basis from which to interpret
opinions in relation to dairy products.
One of the challenges for public health professionals is to demonstrate the efficacy of
nutrition education in improving attitudes toward nutrient rich foods. In particular,
there is a lack of evidence evaluating the role that nutrition education may have on
shaping attitudes towards dairy foods. It is important to evaluate these attitudes in
Australian adults, as this group have reported inadequate calcium (McLennan & Podger,
1998b) and dairy product intake (Ball et al., 2004). In this study we explore the uptake
of nutritional advice to participants in a weight loss trial where the dietary guidance was
based on the Australian Guide to Healthy Eating (Kellet, Smith & Schmerlaib, 1998) in
which dairy foods were a key component. A comparative group of similar non trial
participants from the same study population was recruited identify differences of
opinion which could be attributed to trial participation and exposure to nutrition
education. It was hypothesized that trial participants would express more positive
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attitudes and beliefs towards traditional dairy foods and new functional dairy products
in comparison to non trial participants.
The aim of the study was to explore the salient beliefs underlying attitudes towards
traditional and functional dairy products.
7.2 Methods
Focus group interviews were conducted to ascertain salient attitudes and beliefs of
participants regarding dairy products in general, current dairy product consumption
recommendations and functional dairy products.
7.2.1 Participants
Participants consisted of individuals who had received intensive nutrition education
following participation in a weight loss trial inclusive of 6 dietary counselling sessions
with qualified dietitians. Education relating to traditional dairy products was provided
over a twelve month period (Tapsell, Batterham & Charlton, 2011). In particular,
participants were advised to consume reduced fat dairy products or an appropriate
dietary alternative in quantities consistent with the Australian Guide to Healthy Eating
(Kellet, Smith & Schmerlaib, 1998) as part of a whole of diet approach to facilitate
weight loss. In addition, many of the study participants that were randomised to
consume a dietary prescription rich in omega 3 polyunsaturated fatty acids as part of the
weight loss trial, were provided with specific advice relating to functional (omega 3
enriched) dairy products. Further details on the clinical trial from which the participants
were drawn from can be found at www.anzctr.org.au, (ACTRN12608000425392).
A convenience sample of university employees drawn from the same region and
matched for sex was recruited to act as a comparative group representative of
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individuals that had not received formal nutrition information. All trial participants who
had completed the trial as of November 2009 (n=34) were invited to participate in the
study via an email and follow up phone call. University staff members were recruited
via an email that was sent to all general non-academic staff, with interested parties
receiving follow up phone calls to arrange session times.
All participants were provided with an information form outlining the study procedure
and food of interest to be discussed and parking vouchers were provided. The study was
approved by the University of Wollongong Human Research Ethics Committee and
signed informed consent was provided by all participants prior to the commencement of
the study. Data on demographic and anthropometric characteristics of participants
including age range, highest level of education and estimated height and weight were
collected on entry to the study.
7.2.2 Focus group procedure
Six semi-structured focus group interviews were conducted at the University of
Wollongong in November 2009, within two months of participants completing the
weight loss trial. All questions relating to dairy products were conducted by a trained
moderator in the presence of an observer. The same moderator and observer facilitated
each of the interviews to reduce any potential ambiguity in the results obtained.
Interview questions were developed in accordance with general guidelines provided by
Krueger & Casey (2000) and influenced by themes identified throughout the literature.
Interview questions were reviewed by members of the research team (DNC, EN and
LT) to ensure appropriateness to the topic of interest. Participants were encouraged to
openly discuss their responses until no further views were expressed. Probing questions
were utilised where required to encourage participants to clarify or expand on views
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expressed (Figure 7.1). University staff and trial participants attended separate focus
groups to ensure that beliefs expressed could be attributed to the study group.
Figure 7.1. Focus group questions to determine consumer perceptions of
traditional and functional dairy products
What are some of the things that come to mind when you think about dairy products?
Probe, types, brands, immediate reactions
What do you consider to be the main benefits, if any that can be attributable to including dairy
products as part of your diet?
What do you consider to be the adverse effects if any that can be attributable to including dairy
products as part of your diet?
What are your thought about the current dairy food dietary recommendations to consume 2-3
serves of dairy products a day?
How do you feel about the achievability of this target? Probe – knowledge of serve sizes
What are some of the barriers, if any, to consuming dairy products?
What factors, if any, would motivate you to consume dairy products?
What are your thoughts and experiences with regard to functional dairy products?
What factors, if any, might influence your decision with regard to the consumption of functional
dairy products in the future?

7.2.3 Data analysis
All focus groups were recorded using two digital tape recorders and transcribed
verbatim by the moderator (DNC), with codes replacing participant names to ensure
anonymity. Transcribed data were coded using the qualitative software package NVivo
7.0 (QSR International Pty Ltd, Melbourne, Australia, 2007). Coding was based on a
method previously utilised by Patch, Tapsell & Williams (2005) to describe consumer’s
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salient beliefs on omega-3 enriched functional food products. This meant data were
coded according to the TPB model into three distinct categories that constitute an
individual’s behavioural intention with regard to dairy product consumption. Categories
of analysis consisted of behavioural beliefs, those beliefs which pertained to influence
an individual’s attitude towards dairy products, normative beliefs, an individual’s
consideration of the social pressure to consume/not consume dairy products based on
the influences of peers and control beliefs, an individual’s perceived efficacy in their
ability to consume dairy products. Identified themes were discussed with several
members of the research team (DNC, EN and LT) until a consensus was reached
regarding key thematic findings. All data outcomes were checked by the focus group
observer (EN) to ensure accuracy.
An independent t-test was utilised to determine whether any between group differences
existed for BMI. All statistical analysis was performed using SPSS for Windows
(version 17.0, SPSS Chicago, IL, 2008).
7.3 Results and discussion
Eighteen trial participants expressed an interest in attending one of the three focus group
interviews (53% response rate). Three trial participants failed to attend their allocated
focus group interview, citing time constraints as the reason for their absence, leaving a
total of 15 trial participants. Fourteen non trial participants were recruited and all
participated in one of the focus groups, resulting in a sample size of 29. Saturation of
key themes was achieved throughout both study groups. A total of six focus groups of
approximately 60-80 minutes duration were conducted. The study sample was
predominantly female in both the trial participants and the non trial participants (Table
7.1). The trial participants were overweight on average with a mean BMI of 29.0±4.0
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kg/m². This was significantly higher than the non trial participants with a mean BMI of
24.9±5.0kg/m² (p=0.023).
Table 7.1. Focus group participant characteristics
Trial Participants

Non-trial Participants

(n=15)

(n=14)

Females

12

11

Males

3

3

< 40 years

0

4

>40 years

15

10

29.0±4.0

24.9±5.0

Year 10-12

4

2

Technical and Further Education

6

4

5

8

Gender frequency:

Age frequency:

Mean BMI (kg/m2)
Education level Frequency:

(TAFE)
University degree

7.3.1 Salient behavioural beliefs
Overall, non-trial participants reported that they believed that calcium and bone health
were the key health benefits attributable to the consumption of dairy foods, with few
other health benefits identified.
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“Your calcium comes to mind, yeah, it’s drummed into you, your growing bones and I
think for women like later on in life osteoporosis and those kinds of things…”
(Group 1, F, non trial participant)
This perception mirrors previous focus group outcomes reported by Hagy, Brochetti &
Duncan (2000), whereby women attributed the health benefits of dairy foods to their
calcium content and potential for osteoporosis prevention, and failed to identify other
nutrients such as protein or specific vitamins and minerals present within dairy
products. In contrast, the trial participants identified health benefits attributable to dairy
products beyond bone health. Dairy foods were seen as a significant source of protein,
vitamins and minerals. This may reflect the extent of nutrition education received by
this group.
Beliefs relating to adverse health effects of dairy products were identified by several
members of the non trial group who reported that they felt that these foods were
fattening and mucous producing. The perception of dairy products as fattening
throughout the control group is consistent with focus group findings by Hagy, Brochetti
& Duncan (2000) and Eddy, Brochetti & Duncan (1999) and represents a challenge for
nutrition professionals, particularly with current public health recommendations to
consume a reduced fat diet (Kellet, Smith & Schmerlaib, 1998). This finding does not
reflect literature in the nutrition science domain which suggests a potential weight loss
effect associated with the consumption of dairy products (Zemel et al., 2009).
Furthermore dairy fat has been associated with favourable metabolic profiles in large
population studies (Mozaffarian et al., 2010, Warensjö et al., 2010b, Bonthuis et al.,
2010).
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Overall trial participants did not report perceiving dairy products to be weight inducing,
with one participant discussing literature which indicated that dairy products may assist
with weight loss. Most trial participants did not feel that the fat from full cream dairy
products was cause for concern, discussing negligible differences between the fat
content of full cream dairy products and their reduced fat counterparts. Another
participant expressed the belief that reduced fat dairy products were high in sodium;
however this view was not shared by the group. Persistent belief of fallacies
surrounding dairy products, despite intensive nutrition education illustrates the difficult
and challenging nature of communicating nutrition concepts related to food.
The idea that dairy products have been recently positioned in a negative way was
discussed by both groups of participants. However, unlike the non trial participants that
felt this ‘demonisation’ was due to the high fat content of dairy products, trial
participants felt that dairy products were an easy target for this negative image for many
individuals trying to distract themselves from other unhealthy dietary behaviours.
“..It’s a scapegoat , because we eat too much, don’t exercise enough and there’s too
many fast food options, something had to be modified in this incredible way to make us
all feel better…” (Group 4, F, trial participant)
Discussions relating to functional dairy products by non trial participants indicated that
most were highly resistant to these products. A high degree of scepticism with regards
to their efficacy in producing beneficial health effects and the removal of the product
from its natural state were cited as key factors which would impede consumption of
these items for this group. The perception that dairy products have deviated
significantly from their natural state over the years was also shared by trial participants,
with a preference for ‘natural’ products shared by the group. However, trial participants
170

expressed a more open attitude to consuming functional dairy products such as calcium
enriched milk and dairy products containing plant sterols than non trial participants.
This observation may reflect the exposure to what would be termed functional products
by many participants throughout the clinical trial. Despite being more open to
functional products than non trial participants, some degree of scepticism of their
efficacy was also expressed by trial participants and a preference for food sources from
which to derive additional health benefits naturally was discussed. Preferences for food
products with minimal processing have been reported throughout the literature (Grunert,
2005). The perceived healthfulness of food products is an important factor influencing
their acceptance by consumers and a food’s health value is hypothesised to decrease in
proportion with processing technologies it may have undergone (Grunert, 2005). Thus,
despite an overall improvement in attitude towards functional foods evident within the
trial participants, preferences for natural food products with minimal processing was
overriding in both groups.
7.3.2 Salient control beliefs
Trial participants overall had considerably less perceived control barriers than non trial
participants in relation to dairy product intake, with participants expressing an
understanding of both dairy food serve sizing and recommended intakes of dairy
products. Most trial participants practised label reading and could clearly articulate how
they would incorporate the recommended amount of dairy foods into their diet. In
contrast, non trial participants expressed a lack of knowledge about what constitutes a
serve of dairy food and how many serves per day were recommended.
“I have no idea what a serve really is” (Group 3, M, non trial participant)
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A lack of time and ability to decipher dairy food labels and health claims was also
discussed by most group members that had not participated in the trial. Access to dairy
products was not perceived to be a barrier for their consumption by both groups as most
participants felt they were freely available and readily accessible. However the
relatively short shelf life of dairy foods was a concern for three non trial participants.
Despite these differences, several salient control beliefs remained consistent between
both groups. Taste was an important factor influencing consumption of dairy foods,
with preferences for full cream or reduced fat varieties expressed throughout both
groups. Health issues including lactose intolerance, high cholesterol and lactose
intolerance were discussed in relation to restricting dairy food intake by group
members.
The high cost to perceived benefit of functional dairy products was a key belief
expressed by non trial participants that may impede consumption of these items. A lack
of trust in the efficacy of products available was discussed with reference to functional
dairy items. Non trial participants were not convinced that these items actually
contained the additional ingredients advertised or that addition of such ingredients
would have any influence on their health status. The high cost of functional dairy
products remained another consistent topic of discussion for trial participants,
particularly given participants’ lack of knowledge about the dosage of functional
ingredients required to elicit a health benefit.
“I’m very sceptical cos in the end say like you pay two dollars for the normal milk, the
added calcium will cost you another dollar and is it really worth it?” (Group 5, M, trial
participant)
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In a study in Northern Ireland, the cost of functional or health enhancing dairy products
was also identified as an issue for consumers, with only 35% of questionnaire
respondents reporting feeling satisfied with the price of such products (Armstrong et al.,
2005).
Perceived behavioural control has been reported in the literature to be most predictive of
intention to consume dairy products and correlated significantly (r=.48, p<.001) with
dairy product consumption in a sample of older adults (Kim, Reicks & Sjoberg, 2003).
Similarly, Park & Ureda (1999) reported that pregnant women’s perceived level of
control was related to eventual milk consumption. Thus improvements in perceived
efficacy regarding one’s ability to consume dairy products or functional dairy foods
may be the most important aspect of the TPB in terms of generating the desired
behaviour. Overall trial participants discussed considerably less control barriers that
may restrict dairy food consumption in comparison to non trial participants, indicating
that nutrition education may have improved the beliefs surrounding dairy foods that are
most likely to facilitate an increase in their eventual consumption.
7.3.3 Salient normative beliefs
Family purchasing habits and preferences for dairy products were an important factor
for both groups in terms of influencing dairy product consumption. Lactose intolerance
within the family initiated the replacement of dairy foods with soy products for one
participant, whilst a family history of osteoporosis was a key motivating factor for
others to consume dairy foods. Several individuals discussed adding dairy products such
as cheese and milk to evening meals in an effort to ensure that children were meeting
calcium recommendations.

173

Government initiated school milk programs were also discussed as a normative
influence that had either positively or negatively influenced milk consumption
throughout both groups depending on the freshness of the milk provided. Trial
participants in particular discussed feeling coerced to drink milk past its shelf life during
the program.
“They used to make you drink it hot and I haven’t liked milk since” (Group 5, F, trial
participant)
This school milk program was introduced in 1951 as the Commonwealth’s milk for
school children Act and provided children under 13 with daily milk during school hours
(Queensland Government Department of Education & Training, 2011). The scheme was
introduced to improve the nutritional adequacy of children’s diets, however it appears
this scheme may have had some deleterious consequences in terms of milk acceptance
in later years.
Several participants reported that health professionals such as general practitioners had
discouraged consumption of items such as cheese due to its perceived high fat content
and the replacement of full cream dairy products with their reduced fat counterpart.
“..that was the first thing my doctor said when she looked at my body mass index, she
said oh you must eat a lot of cheese, so that’s from a GP” (Group 2, F, non trial
participant)
The normative influence of general practitioners in terms of identifying particular dairy
products, such as cheese, as weight inducing or cholesterol raising was identified by
both groups. Older women reported that physicians were the strongest normative
influence regarding dairy foods with many avoiding particular items solely as a result of
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advice received from their doctor (Eddy, Brochetti & Duncan, 1999). General
practitioners are a key source of nutrition information for many individuals (Hiddink et
al., 1997), thus any advice given should reflect the current body of evidence to limit
unnecessary avoidance of key food groups. As expected, trial participants discussed that
dietitians encouraged dairy product consumption or appropriate alternatives for
individuals not willing to consume dairy foods.
In relation to functional dairy products, both groups reported feeling highly sceptical of
the food industry and unlikely to purchase functional dairy foods based on advertising
messages or their own initiative. Generally however, non trial participants would try
these items if recommended by health professionals, whilst trial participants were
sceptical of health practitioners recommending functional foods and wanted
independent scientific research regarding the efficacy of these products to make their
own judgements. Previous consumer research regarding perceptions of functional dairy
products indicates that physicians and health professionals were regarded as being the
most credible source of information regarding functional dairy foods (Grunert, 2005).
Trial participant’s desire to seek independent scientific research may reflect their
exposure to evidence based nutrition education that has fostered confidence in their
ability to decipher nutrition messages autonomously. Alternatively, this contrast may
reflect personality differences between the groups. The willingness of the trial group to
volunteer for this study following completion of an intensive twelve month clinical trial
suggests that these individuals were highly motivated with a desire to learn healthier
eating practices.
Overall salient normative beliefs did not differ greatly between trial and control
participants, potentially indicating that these influences are more static than attitudes
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and perceived behavioural control in relation to dairy foods. This is an interesting
observation given that a study by Kim, Reicks & Sjoberg (2003) found that behavioural
and control beliefs in relation to dairy foods contributed to a predictive model of
intention to consume dairy products, whilst normative beliefs did not influence this
behavioural intention. Thus nutrition education appears to have been most efficacious in
improving the belief types which have been demonstrated throughout the literature to
result in increased dairy food intake. A more comprehensive list of key quotations for
both groups is included as Appendix II.
7.4 Limitations
Findings from this exploratory study should be interpreted with care due to the
relatively small sample size of participants interviewed and the motivated nature of the
trial participants. Thus, results may not reflect views of the general population. The two
groups were not matched for weight status, with trial participants having an increased
BMI in comparison to non trial participants. This discrepancy may have influenced the
outcomes observed. In addition it is likely that trial participants agreeing to take part in
this study were those that had been successful with implementing the dietary changes
suggested by trial dietitians. Thus the impact of nutrition education in this context for
individuals that may not have completed the trial or did not achieve desired results was
not able to be examined. However, the trial participants who took part in the present
study were found to match closely with the broader clinical trial population, in terms of
BMI and age and could thus be considered to be a representative sample of the
population of interest.
Despite these limitations, the important role of nutrition education in shaping consumers
salient beliefs with regard to dairy product consumption is clearly visible. This is
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particularly the case with regard to the favourable influences on control and behavioural
beliefs which have been reported to most influentially predict dairy product
consumption Kim, Reicks & Sjoberg (2003).
Future research should quantify the impact of nutrition education with regard to
influencing intent to consume both dairy products and functional dairy products using
the TPB theoretical framework. Quantification of the role of nutrition education by
appropriately qualified health professionals in predicting dairy product consumption
may highlight the need to involve such individuals in the development and
implementation of public health campaigns aimed at increasing dairy product
consumption.
7.5 Conclusions
Overall, key differences in salient control and behavioural beliefs in relation to dairy
products were evident between weight loss trial participants and a comparative group
that had not received nutrition education. Individuals that had received prolonged
exposure to nutrition education appeared more confident in their ability to incorporate
dairy foods into their diet and to utilise label reading to identify appropriate products. A
more favourable attitude towards dairy products in terms of their contribution to the diet
and health effects was also observed in comparison to non trial participants.
Normative beliefs regarding dairy products were similar between the groups, indicating
that these may be less amenable to change through nutrition education, and should
possibly be a lower public health education priority when seeking to elicit change in
dairy food consumption behaviour. Despite more favourable attitudes towards
functional dairy products expressed by trial participants in comparison to non-trial
participants, the degree of scepticism regarding these products retained by both groups
177

suggests that nutrition education was not effective in overcoming control barriers such
as the high cost of these functional products in this sample. Whilst limited by its sample
size, restricting generalisation, this exploratory study has provided a proof of concept
demonstration that nutrition education that focuses on improving attitudes and self
efficacy regarding the consumption of dairy products, will favourably influence salient
beliefs that may translate to an improvement in eventual consumption of this core food
group.
In the context of the body of work presented throughout this thesis, this study
highlights important nutrition education targets for clinicians seeking to translate
complex and emerging information relating to dairy products into practice.
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Chapter 8. Conclusion
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8.1 Introduction
The research presented throughout this thesis and accompanying review of the literature
endeavoured to address the central hypothesis that the position of dairy foods in the diet
is complex, defined by health-disease context and subject to consumer behaviour.
In order to test this hypothesis, a number of studies were performed to address the
following research questions:
1. What happens when people are advised to consume reduced fat dairy foods?
2. Does dairy fat intake lead to adverse metabolic parameters?
3. Does intake of dairy products result in self reported perceptions of adverse CD
symptoms?
4. Can a genetic factor mediating dairy product intake increase CD risk?
5. What do consumers think about dairy foods? Can nutrition education influence
these perceptions?
The position of dairy products in the obesity context was explored using dietary data
from a clinical nutrition trial, dietary biomarkers and qualitative consumer research,
whilst the position of dairy products in the CD context was evaluated following
analyses of dietary and related CD symptom survey data and a nutrigenomic case
control study. The utility of a range of studies to address the central hypothesis has
provided a broad range of insights that may have implications for both clinical practice
and in terms of the stimulation of further research endeavouring to evaluate the position
of core foods on chronic diseases.
8.2 Key thesis outcomes, significance and implications for clinical practice
1. What happens when people are advised to consume reduced fat dairy foods?
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Chapter 3 outlined some of the potential dietary adaptations that individuals make in the
weight loss context when given advice to consume low fat dairy foods. In this case
males reduced the total amount of dairy products consumed and females selected
dairy products with higher carbohydrate content such that a net reduction in
kilojoules contributed from this food group was not seen.
Observations from this study raise important questions when considering the potential
dietary impact of public health nutrition campaigns recommending replacing whole
dairy products with reduced fat varieties. This is particularly of interest given the body
of evidence presented in the literature review of this thesis suggesting that full fat dairy
products may be beneficial in terms of metabolic health (Warensjö et al., 2010a),
(Elwood et al., 2008). From a clinical perspective, outcomes from this study inform
dietetics professionals of the need to consider the background diet when recommending
reduced fat dairy products to overweight individuals to ensure these foods are not being
inadvertently removed from the diet once low fat diet advice is provided. This study
also supports literature which suggests that gender may have an important influence on
dietary choices in this context (Collins et al., 2011) and thus must be considered in the
clinical setting.
Thus when given advice to consume low fat dairy foods, some individuals may avoid
dairy products in preference to selecting reduced fat alternatives, but is this necessary
for effects on metabolic parameters in overweight individuals?
2. Does dairy fat intake lead to adverse metabolic parameters?
Results of the study reported in chapter 4 showed that intakes of both milk fat and
dairy products as measured by diet history interview data and validated milk fat
biomarkers (15:0 and 17:0), were not associated with adverse metabolic profiles in
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overweight adults. Conversely, there were desirable associations between habitual
intakes of milk fat and reduced umbilicus circumference, hip circumference and
BMI after controlling for potential confounders. Acknowledging the limitations of
this study, we can be confident in the results given the utility of both self-reported
dietary intake information and objective biomarkers of milk fat intake reduced potential
biases associated with reliance on a single method of estimating milk fat consumption.
The outcomes from this study contribute to a growing body of evidence that suggests
that milk fat may infer some metabolic advantages (Warensjö et al., 2009). This finding
also raises some interesting questions, particularly when considering current health
advice to reduce the intake of fat from dairy products and the potential behavioural
consequences of this advice. Challenges to currently held beliefs relating to dairy
products could also be seen in another disease context.
3. Does intake of dairy products result in self reported perceptions of adverse CD
symptoms?
Analysis of dietary survey and clinical data from CD patients revealed that dairy
products had no effect on self-reported CD symptoms for the majority of the study
sample. However, for those experiencing a perceived CD symptom worsening that
they attributed to an individual dairy product, those with a higher fat content were
most frequently reported to worsen perceived symptoms. In contrast to expectations,
CD activity status and the lactose content of dairy products was not associated
with perceived CD symptom worsening. Thus we may need to question the advice
surrounding widespread dairy product avoidance within this clinical population, even
during periods of active disease. There is also a need to consider each dairy product and
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its potential to influence CD symptoms on an individual product basis, rather than
assuming that all items fitting within this food category will have equivalent effects.
To add to this complexity, nutrigenomic factors may also influence exposure effects of
dairy foods and indeed CD risk.
4. Can a genetic factor mediating dairy product intake increase CD risk?
The large nutrigenomic case-control study presented in this thesis suggests that genetic
lactase persistence appears to be associated with a significantly increased CD risk.
In this study, one of the first studies to explore genotype-phenotype associations in this
context, it was also observed that genetic lactase persistence was associated with an
increased risk of developing CD of an inflammatory nature. A plausible explanation
for this observation based on current literature may be that lactase persistent individuals
have an increased intake of milk products and thus an increased exposure to the
infective agent MAP. This infective agent causes a debilitating gastrointestinal
inflammatory disease in ruminants similar to CD in humans and has been detected in
commercial dairy products. This study highlights the need for future research to explore
the true relationship between MAP and the pathogenesis of CD. Should milk products
be implicated in the aetiology of CD as a result of their contamination with MAP,
efforts to remove it from the food supply via animal vaccination and improved
pasteurisation methods may be imperative from a public health perspective. Should
these events transpire, there will be a critical role for nutrition educators to ensure that
consumers are able to understand that the relationship between CD and dairy products
does not come from the milk per se, rather from contamination with an infective agent.
Combined, the studies presented in this thesis, reflect the complexity of factors involved
when seeking to explore the position of dairy products within the diet. The studies
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discrete to both the obesity and CD contexts, suggest that this positioning is conditional
on one’s disease state and may be influenced by a range of factors including gender,
genetics, and personal preferences. Should ongoing research further support these
findings, nutrition educators will have a critical role in translating this knowledge to
new messages relating to dairy products.
5. What do consumers think about dairy foods? Can nutrition education influence these
perceptions?
The consumer research in this thesis identified that nutrition education, inclusive of
advice relating to dairy products, favourably influenced attitudes towards these
foods. In particular, individuals receiving nutrition education expressed more
favourable behavioural and control beliefs regarding dairy products in contrast to
individuals that had not received this nutrition education using the theory of planned
behaviour theoretical framework.
Outcomes from this study provide a proof of concept illustration that nutrition education
may favourably influence the belief types that have been demonstrated to be most
important in predicting dairy product intake behaviour (Kim, Reicks & Sjoberg, 2003).
This study also identified that nutrition education did not influence normative beliefs in
relation to this food group. Practical implications for this observation may be that
education programs seeking to change attitudes toward dairy products that target
behavioural and control beliefs will be more successful than those aiming to influence
normative beliefs as these relate largely to an individual’s external peer environment
(Ajzen, 1991) and may be less amenable to change. From a clinical practice perspective,
targeting behavioural and control beliefs surrounding this core food group may be an
effective strategy for nutrition professionals seeking to translate the complex, new
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scientific observations surrounding dairy products that were uncovered within this body
of work into practice.
8.3 Limitations and future directions
Each of the studies presented throughout this thesis has several inherent limitations and
recommendations for further research. These individual limitations and
recommendations as they relate to each study have been discussed in detail within the
relevant chapters. More generally, however, many of the studies included within this
thesis were derived from secondary analyses of data available from other larger studies.
These studies were not designed to evaluate the effect of dairy products on chronic
disease specifically. Nevertheless the body of evidence produced combined with the
review of the literature suggests the following types of studies could be conducted to
extend the arguments presented here:


A large randomised controlled trial exploring the impact of 3-4 servings/day of
either reduced fat or whole dairy products (depending on dietary preferences) for
one year on:

1. Body weight
2. Markers of inflammation
3.

Serum lipids (including VLDL)

4. Waist circumference
5. Body composition
6. Faecal fat/energy excretion
7. Energy expenditure
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This study should consider individual preferences for dairy products, utilise
dietary modelling to match background diets according to macronutrient
contributions and calcium content, and rely on both self-reported diet history
interview data and biomarkers of milk fat intake to strengthen dietary intake
data.


Acute meal tests in CD patients, providing a dairy based meal to assess the
impact of this food on markers of inflammation and self perceived CD
symptoms in individuals with both active and quiescent CD and utilising a
variety of dairy product types



Evaluation of the level of contamination of milk with MAP within the
Australian context (previously unexplored)



Further nutrigenomic case-control studies to identify genetic factors that may
account for different host responses to viable MAP to ascertain whether it is a
causative factor in the aetiology of CD or simply a trigger for an exaggerated
immune response in those with a genetic predisposition.



Surveys of a large representative sample of Australian adults to explore their
opinions on both reduced fat and whole dairy products, inclusive of both genders
to drive strategic directions for future nutrition education campaigns involving
dairy products

8.4 Recommendations for dietetic practice
The body of work presented throughout this thesis has identified key insights that may
have implications for dietetic practice. Whilst several recommendations for practice
have been discussed within each relevant chapter, overall recommendations are as
follows:
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Consider the implications of recommending reduced fat dairy products to all
overweight individuals, taking into consideration an individual’s personal food
preferences, gender, likely dietary adaptations and the nutritional consequences
of such adaptations.



Utilise skills in dietary modeling to negotiate instances where full fat dairy
products may be included as part of a whole of diet approach to weight loss in
situations where individuals may be unwilling to consume reduced fat dairy
products.



Make dietary recommendations surrounding dairy products to CD patients on an
individual basis, taking into consideration an individual’s personal preferences,
tolerance and symptom history. Such recommendations should also differentiate
between the many different varieties of dairy products so that consumption of
each may be negotiated based on CD symptoms, tolerance and personal
preferences. Appropriate alternatives to dairy products should be recommended
in instances where such foods are not tolerated by this patient group.



When seeking to translate complex new findings relating to dairy food into
practice focus nutrition education on improving both behavioural and control
beliefs surrounding dairy products to improve attitudes toward this core food
group.

8.5. Summary
Findings from this thesis have raised many questions regarding currently held beliefs
surrounding the position of dairy products in the context of obesity, the metabolic
syndrome and CD. Overall, the studies presented within this thesis support the central
hypothesis that the position of this core food group within the diet is indeed complex,
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defined by health-disease context and subject to consumer behaviour. It is anticipated
that outcomes from this thesis will be valuable in terms of influencing clinical dietetic
practice and highlighting important areas for further research to ensure that the
positioning of dairy products, as a core food within the context of the total diet, reflects
the best available evidence.
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Appendix 1. Participant information sheet for ‘Smart’ study, University of
Wollongong, Australia
PARTICIPANT INFORMATION SHEET

THE ‘SMART’ DIET

Who are we?

This study is funded by the National Health and Medical Research Council and is being
conducted by a group of researchers from the Smart Foods Centre at the University of
Wollongong. Professor Linda Tapsell, the study leader, is Director of the National
Centre of Excellence in Functional Foods. Dr Marijka Batterham, Dr Karen Charlton
and Dr Yasmine Probst are academic staff members of the Smart Foods Centre in the
School of Health Sciences, Ms Jane O’Shea is study co-ordinator, Ms Rebecca Thorne
is a research dietitian while Ms Anne McMahon is a PhD student and academic within
the Smart Foods Centre.

Study investigators


Professor Linda Tapsell



Dr Marijka Batterham



Dr Karen Charlton



Dr Yasmine Probst



Ms Jane O’Shea (ph 02 4221 5124)



Ms Rebecca Thorne (ph 02 4221 5992)



Ms Anne McMahon (ph 02 4221 4829)

230

Study Mobile: 0458 203 701

Why are we doing this?

The project aims to assess the benefits and achievability of different dietary
approaches in the management of overweight. The results of this research will
contribute to better understanding of the role of food components in diets for weight
loss and healthy weight maintenance and thereby more effective treatment.

What will we ask you to do?

This research is a 12-month dietary intervention study in which you will receive dietary
advice from a qualified dietitian. Your diet will be assessed and then you will be
prescribed a weight loss dietary plan to follow for 12 months, with monthly follow up
with a dietitian for the first three months, followed by three-monthly visits thereafter.
You will also be required to take one capsule every day for the 12 month period, which
may contain either fish oil or an inactive ingredient.

The study also involves the use of a facility known as the Wollongong Room
Calorimeter, before, during and after the dietary intervention, to assess your energy
balance and ability to burn fat. The facility is a closed room which measures oxygen
consumed and carbon dioxide produced by the person staying inside. From these
measurements we are able to calculate energy expenditure, which is important in
understanding how body weight is controlled.

If you decide to participate in the study, we will require you to attend for a total of 1517 separate visits for various measurements and procedures. At the start of the study and
at months three and 12, you will be required to attend the research facility three times:
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(1) once for dietary assessment, anthropometry (weight, height, body fat) and to be
fitted with a 24-hour blood pressure (BP) monitor; (2) once for the 24-hr calorimeter
visit and blood sampling; and (3) once for a dual energy x-ray absorptiometry (DEXA)
scan (to be performed at Wollongong Nuclear Medicine) A DEXA scan tells us how
much fatty tissue is in your whole body. Dietary assessments and anthropometrical
measurements will also be performed at months 1, 2, 6, 9 (i.e. four visits). You will also
be invited to participate in two interviews. The first will take approximately ½ - one
hour in the first three months and the second similarly take ½ - one hour in the last three
months of the trial. Anne McMahon will try to co-ordinate this interview with one of
your required visits. If time constraints are an issue for you Anne McMahon will contact
you to arrange another suitable time and meeting place.

Blood pressure (BP) will be measured for a continuous 24-hr period at baseline and at
three and 12 months of follow-up using a Spacelabs monitor. The monitor will be
programmed to take readings every 20 minutes during awake time (06h00-22h00) and
every 30 minutes during asleep time (22h00-06h00). The information will be
downloaded to a computer software programme for analysis.

Fasting blood samples taken at the beginning of the study and at three and 12 months
will be analysed for fatty acids, cholesterol and other blood lipids, insulin, glucose and
leptin (a hormone) concentrations. Additional blood samples for fatty acid analyses will
be taken at six and nine months. DNA material will be extracted from baseline blood
samples in order to assess the prevalence genetic markers associated with energy
expenditure and different response to the weight loss diets.

The study also involves questionnaires to be completed at home and to be returned to
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the university in a timely manner. Participants are asked to fill in a food diary, complete
a physical activity questionnaire and to wear an activity monitor at home over three
days at the start and the end of the study.

A flow chart of your commitments is outlined on the following page.
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Interested in the study

Call us
Screening questionnaire completed and eligibility
assessed

Pre study assessment (<2 hours)







Visit to calorimeter facility
Weight and height
Body composition
Diet history interview
Activity and health questionnaires
3 day food records to be taken and filled out at home
and returned prior to calorimeter visit
 Activity monitors to be worn for 3 days and returned
with food records.

DEXA scan

t = 3 months*

(Wollongong Nuclear Medicine, Piccadilly Centre)
t=0
Calorimeter visit (overnight
stay; Room 41. 302)
+ blood collection
+ BP monitor to be worn for
24 hours

Calorimeter visit

Start of diet
Dietmonth
counselling

t = 1 month*

t = 2 months*

Diet support

Diet support

(1 hour).

(½ hour)

(½ hour)

+ blood collection

Capsules
provided.

Weight, body
fat, 3-day food
records.

Weight, body
fat, 3-day food
records.

+ BP monitor to be
worn for 24 hours

Weight, body fat.

(overnight stay;
Room 41. 302)

DEXA scan
(Wollongong Nuclear
Medicine, Piccadilly
Centre)

t = 12 months

t = 12 months**

t = 9 months**

t = 6 months

Post-study assessment (1 hour)

Calorimeter visit

Diet support

Diet support







(overnight stay

(½ hour)

(½ hour)

(½ hour)

Room 41. 302)

+ Blood
collection

+ Blood
collection

(fatty acids) +
3-day food
records

(fatty acids) +
3-day food
records

Weight, body fat,
3-day food
records.

Weight
Body composition
Diet history interview
Activity, health questionnaires,
3 day food records to be filled
in and returned within 1-2
weeks

+ blood collection
+ BP monitor to be
worn for 24 hours

t=0
Diet support

DEXA scan
(WNM, Piccadilly Centre)
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Pre study assessment (Visit 1)

This involves providing us with background information and will take around two
hours. You will also be shown the Wollongong room calorimeter during this visit and
be orientated to protocols used in the calorimeter. You will be given a number of
questionnaires on activity levels and food intake. You will be asked to wear an activity
monitor (the size of a pager) on your waist for a three day period (two weekdays and
one weekend day). It is taken off when you shower and go to bed. You will also be
asked to complete a three-day food diary on these same three days.

At this visit we will measure:
a)

Weight, height and waist circumference measures.

b)

Body composition using bioelectrical impedance analysis using Tanita scales.

c)

An Accredited Practising Dietitian will conduct a diet history interview to assess
usual dietary intake.

We will also show you examples of menus for your stay in the calorimeter to ensure
that you are willing to consume those foods in the amounts provided.

Calorimeter Stays (Baseline, three months, 12 months)
At baseline and at three and 12 months of follow-up, you will be required to stay in the
calorimeter for a 24-hour period. The calorimeters are enclosed spaces (3.0 x 2.1 x
2.4m) which may cause discomfort to some people. A computer with internet access is
provided in the room, as well as a TV with a number of DVDs for your viewing
enjoyment. The room contains a desk and chair, fold-away bed, toilet, sink and is airconditioned. There is also a window providing an ocean view. You will be shown the
calorimeter when you attend for your pre-study assessment (see Figure on previous
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page) and will have the opportunity to ask questions about the facility at that visit.

The procedure for the calorimeter stay is as follows:

You should arrive at 8:00am after following an organised meal plan for the 24 hours
beforehand and having fasted for at least ten hours.

At these visits we will measure:
a)

Your resting energy expenditure where you will need to lie down in a supine
position rest for 30 minutes without falling asleep.

b)

Your weight and body composition.

c)

Your urine output which helps us determine your energy expenditure. We will
need to collect all urine during your 24 hour calorimeter stays.

Bloods: Blood pressure and a blood sample will be taken the morning you leave the
calorimeter for analyses of glucose, insulin, lipids levels, fatty acids and DNA markers
associated with energy expenditure and different response to the weight loss diets.

Meals: You will be asked to eat all of the food provided by us and only the foods
provided by us during your stays in the calorimeter. All meals will be prepared using
normal foods, and will be designed to contain recommended amounts of vitamins and
other essential nutrients. Meal times will be set to replicate your usual meal pattern.

Physical activity: During your stays in the calorimeter your physical movements will be
monitored using a digital Doppler motion sensor. These units operate in the same way
as common burglar alarms. You will also wear the activity monitor while you are
awake. You will be asked to do certain activities (e.g. walking around the chamber,
stepping on wooden block) at set intervals to replicate the activities you perform outside
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the chamber.

DietAdvice website: During your stay in the calorimeter we request that you use an
automated dietary assessment website developed by the University of Wollongong to
help to pass the time. The website has been developed to ensure your privacy is upheld
and information will not be accessible by anyone other than the researchers on the
study. The website will ask you about your usual food intake similar to your pre-study
visit and your dietary counselling sessions. The information will be used to validate the
accuracy of the information reported on the website. The website is managed by Dr
Yasmine Probst who will be available by telephone and on email if you have any
difficulties with using the website. You will be able to withdraw at any time from using
the website without any penalty or prevention from participating in the trial.

Dietary Counselling
4th Visit:
At this visit you will receive dietary counselling and a dietary plan for the twelve
month intervention period and be supplied with a six-month supply of capsules.

1, 2, 3, 6, 9 and 12 month visits:
At these visits, the dietitian will go through your dietary plan and determine if you have
any questions or problems with your program. At the six and nine month visits, blood
samples will be drawn in addition to dietary counselling.

Interviews
First Interview
At one of your visits in the first three months you will be asked to participate in a ½one hour interview on general health and wellbeing issues and about what might have
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attracted you to participate in the trial.

Second interview
The last interview will be scheduled to occur within the last three months of the trial
and will be similarly on your thoughts and understanding of general health and
wellbeing and your views on the trial itself. It is expected that the interview will again
be approximately ½-one hour.

Anne McMahon will contact you to confirm a time for both interviews. There is no
preparation necessary for these interviews as Anne McMahon is looking to hear your
views. The interviews will be recorded so your thoughts are transcribed exactly. Anne
McMahon is a PhD student and will be utilising this information for her doctoral study.
Any individual comments will not be identifiable in any reports or publications
developed from these interviews. The recordings and transcribed documents of the
interviews will be kept in a locked secure cabinet. You will be able to withdraw at any
time from the interview/s without any penalty or prevention from participating in the
trial.

Three and twelve month visits
This is a repeat of your initial assessment. At this visit we will again measure:
a)

Weight and waist circumference measures

b)

Body composition

c)

Conduct a diet history interview

d)

Questionnaires and activity monitors will be provided for return within one-two
weeks

e)

DEXA scan

f)

24-hr calorimeter stay, including blood analyses
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g)

24-hr blood pressure monitoring

Who can participate?

We are looking for healthy male and female participants aged 18 - 60 years who are
overweight. It is important that you are willing to consume only the types and
amounts of foods provided to you during your stays in the calorimeter.
You should not participate in this study if you:


Know or suspect that you are pregnant
Your energy requirements will be increased during pregnancy and this will
compromise some of the calculations



Are breast feeding
Your energy requirements will be increased during breastfeeding and this will
compromise some of the calculations



Suffer from diseases that may alter the energy expenditure pattern e.g. cancer,
endocrine disorders, diabetes, AIDS



Wear a pacemaker



Smoke cigarettes regularly



Are taking regular medication (except the oral contraceptive pill)



Suffer from any food allergies



Be unwilling to consume fish



Have lost or gained more than approximately 3kg over the past six months, or are
on a weight-reducing diet



Regularly take fish oil supplements and are unwilling to stop taking them during
the study
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Cannot understand English

What are the possible disadvantages and risks of taking part?

The taking of blood samples may produce some temporary discomfort and may result in
mild bruising at the site of sampling. Any bruising would be expected to resolve in a
few days. The DEXA scan which will be conducted at Wollongong Nuclear Medicine is
associated with an extremely small radiation dose which is 700 times less than a chest
x-ray and 100 times less than a coast to coast plane flight. We do not foresee any other
risks or any disadvantages (except for the time commitment required of you) in taking
part in this study.
If you feel too uncomfortable, for example whilst in the calorimeter, you may stop the
study at any time. You may if you wish also withdraw your consent for the use of your
data in the study.

What will we do with the information and samples we obtain?

All information will be kept secure and identified by a code rather than by your actual
name. Nothing which identifies individual participants will be published. Standards of
medical confidentiality will apply. As a result of the study you will be able to gain some
information about your body fat percentage, how many calories you are using in a day
and your dietary intake. Blood samples will be stored for no less than five years on site
at the University of Wollongong.

If at any time you have any questions, please do not hesitate to ask. Your
involvement in the research is entirely voluntary. You are free to withdraw from
the research at anytime without penalty. If you have any enquiries regarding the
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conduct of the research please contact the Secretary of the University of
Wollongong Human Research Ethics Committee on (02) 42214457.
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Appendix II
Table II (a). Salient behavioural beliefs related to dairy product consumption expressed by non trial participants
Theme
Sample Quotation
Provide benefits in relation to “Your calcium comes to mind, yeah, it’s drummed into you, your
bone heath
growing bones and I think for women like later on in life osteoporosis
and those kinds of things…” (Group 1, F )
Produce adverse health
“Fat is a major issue, yeah” (Group 3, M)
effects
“It’s the mucous, I think it just encourages the mucous” (Group 2, F)
Demonization of dairy foods There’s some sort of push pull with dairy, you know, you’re meant to
have the calcium for defending osteoporosis but too much dairy is seen
as bad when you’ve got a cold or high in fat, or there’s all these other
kind of messages about dairy, not having too much dairy but actually
getting enough calcium, so it’s hard to know what the balance is”
(Group 2, F)
Current dairy product
“Well ideally if they’d asked me how many servings I should have or
recommendations
my children should have I would have just guessed I wouldn’t have a
unfamiliar/unachievable
clue to be honest, whereas I could tell you they should have five
vegetables with their evening meal and they get that every night”
(Group 1, F)
“There’s no way I would meet that minimum requirement, no” (Group
3, F)
Sceptical of efficacy of
“Yeah I’m sceptical” (Group 1, F)
functional dairy products
“…It’s all a selling thing, that’s my view” (Group 2, M)
Removal of dairy products
“Its messing with nature a bit too much” (Group 2, F)
from natural state
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Table II (b). Salient normative beliefs related to dairy product consumption expressed by non trial participants

Theme
Family Members

Sample Quotation
“Yeah so we have milk every morning and sometimes um if my son doesn’t fancy
yoghurt I’ll take one yoghurt for me…” (Group 3, F)
“My grandmother was bent right over with osteoporosis so that’s a big thing for me”
(Group 1, F)
“..Our youngest daughter was lactose intolerant, so we sort of did try and keep the dairy
products out of the fridge as much as possible…” (Group 1,M)

Government Initiated School
Milk program

“That was such a fantastic thing for the government to do cos you know, we all grew
up drinking just plain milk” (Group 2, F)
“When I was a young kid at primary school we used to get the bottled milk, remember
that for recess, ah sometimes it was icy cold and sometimes it would be filthy if it had
been sitting there it was warm and horrible..” (Group 1, F)

Health Professionals

“..that was the first thing my doctor said when she looked at my body mass index, she
said oh you must eat a lot of cheese, so that’s from a GP” (Group 2,F)
“I would if it was going to affect my health, if the doctor said to me well look you’re
not getting enough calcium so I recommend you take these and see how you go, and if
it was improving this I probably would yeah but I wouldn’t worry about it at this stage
unless the doctor said to” (Group 2,M)

Food Industry

“I am a bit sceptical I think their conning me, educated savvy shopper I am probably
not but I just think, yeah go away” (Group 1, F)
“Yeah I think they’re just taking advantage of the fact that we’re all trying to be health
conscious and they’re bombarding us with, with nonsense” (Group 1,F)
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Table II (c). Salient behavioural beliefs related to dairy product consumption expressed by weight loss trial participants
Theme
Provide a variety of health
benefits
Unconcerned of fat content
of dairy products

Open to functional dairy
products
Sceptical of efficacy of
functional dairy products

Sample Quotation
“protein, good source of protein” (Group 4, F)
“calcium for your bones” (Group 4, F)
“I mean most dairy things that you get, even if its full cream its only four
percent fat and that is still low percentage fat and most of its low fat
yoghurt and things there’s not that much fat” (Group 5, F)
“Yeah and comparing the fat content of dairy to something else that people
eat on a regular basis and showing that, you know, it’s not too bad actually”
(Group 4, F)
‘Yeah since the study finished I just switched to cholesterol lowering
milk…. And yeah I can’t taste anything different about it” (Group 4, F)
“I’d want like a combination of things in there” (Group 6, F)
“There obviously is something that they’ve done but to what extent I’d like
to know that before I.. I don’t know I just feel sceptical” (Group 5, F)

Demonization of dairy
products

“It’s a bit of a shock to have cheese identified as such a baddie that’s, I
don’t agree with that” (Group 5, F)
“..It’s a scapegoat , because we eat too much, don’t exercise enough and
there’s too many fast food options, something had to be modified in this
incredible way to make us all feel better…” (Group 4, F)

Removal of dairy products
from natural state

“See I’m a natural person I like things that are natural, you know, like milk
that’s natural, butters natural, I wouldn’t eat margarine” (Group 5, F)
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Table II (d). Salient normative beliefs related to dairy product consumption expressed by weight loss trial participants

Theme
Family Members

Government Initiated
School Milk program
SMART Clinical trial
dietitians

Health Professionals

Food Industry

Sample Quotation
“We get both kinds of milk, cos he won’t drink skim or low fat” (Group 4, F)
“…My husband has pointed it out quite a lot over the years, you know the difference
between lite white and the full cream you know.. and says there’s not a great deal of
um difference, but certainly taste wise there is” (Group 6, F)
“They used to make you drink it hot and I haven’t liked milk since” (Group 5, F)
“Its ruined a generation of milk drinkers” (Group 4, M)
“I didn’t have any dairy so they said to ramp up your soy milk and make sure its
calcium enriched…” (Group 4, M)
“I know sometimes cups are classified as two hundred (mls) but they said 250 (mls)
was a serve of milk” (Group 5, F)
“.. my mum’s in her seventies, my mother uses that Proactive margarine even though
its mega expensive and she can’t always afford it cos the doctors tell them to” (Group
5, F)
“Yeah, they’ve got shares in the company” (Group 5, F)
“yeah written on the packet doesn’t convince me like I’d have to find a research paper
and have a bit of a read to see whats going on in there” (Group 4, F)
“The trouble with those sort of those sort of things you know the calcium or whatever
fortified things, is that they, you know the manufacturer is controlling how much
they are putting in there, you know so how much your getting. I would prefer to see a
better education process so they are educating people as to what they can eat that is as
natural as possible to get those things .. so you know turn the control over to the
individual rather than the manufacturers of something controlling it” (Group 5, F)
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Table II (e). Salient control beliefs related to dairy product consumption expressed by non trial participants
Theme
Sample Quotation
Shelf life issues
“In the summer my milk never lasts as long as the label on the bottle” (Group 3,
M)
Taste/Texture
“Yeah after a few months on skim milk you can’t drink full cream milk cos its too
rich, it’s way too rich” (Group 3, M)
“I think its hard too like if you don’t drink milk it’s hard to get those serves in,
because I might have a slice of cheese at lunch but that might be the whole dairy I
have all day…” (Group 2, F)
High cost of functional
“… those things are usually a higher cost and a markedly higher cost” (Group 3,
dairy products
F)
“The price is really a concern”(Group 2, F)
“..(The cost is)… a lot more than you’d expect from just the extra processed
involved cos anything that is a health food tends to get a mark up” (Group 3, F)
Lack of understanding of
“I think people in general they know they should have some dairy products but
current dairy product
they just don’t know how much” (Group 1, F)
intake recommendations
Lack of understanding of
“I have no idea what a serve really is” (Group 3, M)
dairy product serve sizes
“It would be good on the packaging if it said equivalent to six or ten serves of
dairy so there’s some standardisation cos I don’t think I can judge that at all from
what I’ve seen” (Group 2, M)
Lack of time to read food
“Unfortunately I don’t have that much time to go shopping and look at every
labels
label..” (Group 1, M)
“..I sort of go to that section and you just go oh too much choice, haven’t got time,
couldn’t be bothered I’ll just stick to the devil I know, sort of the milk that I like..”
(Group 1,F)
Lack of control/trust of
“Can you trust the bottle?” (Group 2, F)
functional dairy products
“When you go to the yoghurt section or whatever and it’s the same brand but one
for your heart or one for your bones..I mean do they actually put different things in
to support all these claims?” (Group 3, F)
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Table II (f). Salient control beliefs related to dairy product consumption expressed by weight loss trial participants
Theme
Taste/Texture

Health issues
High cost of functional dairy
products

Lack of knowledge regarding
dosage/effects of functional
dairy foods

Sample Quotation
“…Dairy has that fatty taste, and I don’t like that taste”
(Group 4, F)
“ I’d rather not have it than have a low fat one (dairy
product)” (Group 5, F)
“I’ve got irritable bowel syndrome so I haven’t eaten
anything whole fat for over twenty years” (Group 5, F)
“If you’re feeding a family it just gets too expensive”
(Group 6, F)
“I’m very sceptical cos in the end say like you pay two
dollars for the normal milk, the added calcium will cost
you another dollar and is it really worth it?” (Group 5, M)
“…well how much do you have to actually eat before it
does have an effect?” (Group 4, F)
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